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Abstract 
 
People with epilepsy have a 16 to 24 fold higher risk of sudden death than the general 
population. Autonomic dysfunction, cardiac electrical abnormalities, and use of potentially 
arrhythmic antiepileptic drugs (AEDs) have all been reported in epilepsy and suggest that the 
heart may be involved. Peri-ictal ventricular arrhythmia has been described in video-EEG 
recordings of people with severe epilepsy i.e. individuals at high risk of sudden unexpected 
death in epilepsy (SUDEP): a predominantly seizure-related type of sudden death without 
known anatomical or toxicological cause. Ventricular tachycardia/ventricular fibrillation 
(VT/VF) in epilepsy and its association with SUDEP have not yet been investigated in people 
with less severe epilepsy in the community.  
 
Postictal generalized EEG suppression (PGES)>20s after convulsive seizures (CSs) has been 
proposed as a new SUDEP risk marker, but these results have not been confirmed in a second 
study. Conflicting findings regarding the value of PGES>20s as a SUDEP risk marker may be 
explained by high intraindividual variability.  
 
I have undertaken three studies to obtain a better understanding of the pathophysiology of 
sudden death in epilepsy, directly by analysing a potential underlying cardiac mechanism 
(VT/VF in epilepsy) and evaluating whether this mechanism could be one of the causes of 
SUDEP in the community. Indirectly, the pathophysiology of sudden death in epilepsy was 
approached by analysing the intraindividual consistency and the facilitating co-factors of the 
recently proposed SUDEP risk marker PGES. 
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Study 1 
I compared the proportions of people with active epilepsy in 1019 cases with ECG-
documented VT/VF from the prospective community-based ARREST-database of out-of-
hospital resuscitations in the Dutch region of Noord-Holland and 2834 controls matched by 
age, gender, and index date from the HAG-net-AMC-database containing the general 
practitioner’s medical files of ≥60000 people in the same study area. I calculated whether 
people with active epilepsy had a higher risk of VT/VF than the general population after 
correction for cardiac risk factors. Active epilepsy was confirmed in 12 (1.2%) people among 
cases and 12 (0.4%) among controls, and was an independent risk factor for VT/VF: adjusted 
OR 2.9; 95% CI 1.1-8.0.  
Study 2 
I analysed whether 18 cases with active epilepsy and ECG-confirmed VT/VF fulfilled 
SUDEP criteria. These 18 cases were compared with 470 VT/VF controls without epilepsy 
from ARREST and 54 epilepsy controls without VT/VF matched by age and gender from the 
OPPEC pharmacy-based out-patient cohort with epilepsy. In most cases of VT/VF in 
epilepsy, there was an obvious (10/18) or presumed cardiovascular cause (5/18) in view of 
pre-existent heart disease. In two of the three remaining persons, VT/VF remained 
unexplained and a diagnosis of near-SUDEP was established after successful resuscitation. 
People with epilepsy and VT/VF were younger and more likely to have congenital heart 
disease than VT/VF controls without epilepsy. The onset of VT/VF in epilepsy was more 
likely to be unwitnessed and occur at/near home. Clinically relevant heart disease (adjusted 
OR 6.9; 95% CI 1.3-36.6) and intellectual disability (adjusted OR 41.3; 1.4-1264.8) were 
independent risk factors for VT/VF in epilepsy. 
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Study 3  
I collected data on 59 people with multiple recorded CSs (154 seizures in total) from the EEG 
database of two tertiary epilepsy referral centres (Heemstede and Bonn) and assessed the 
intraindividual variability of PGES>20s and its facilitating co-factors. PGES>20s was found 
in 37 (63%) of individuals and 57 (37%) of seizures. The number of people with consistent 
presence/absence of PGES>20s decreased as the number of recorded CSs increased. Sleep 
(adjusted OR 2.5, 95% CI 1.3-5.0) or AED reduction before a CS (adjusted OR 3.7, 95% CI 
1.4-9.7) were independent risk factors for PGES>20s. 
 
People with active epilepsy are at higher risk of VT/VF, which mostly occurs in the context of 
acute or pre-existing heart disease. VT/VF in epilepsy and SUDEP partially overlap 
suggesting that ventricular arrhythmia may be an underlying mechanism of SUDEP in the 
community. PGES>20s after a CS is unlikely to be a reliable predictor of SUDEP due to its 
high intraindividual variability. Sleep and AED reduction before the onset of a CS appear to 
facilitate PGES>20s, which may provide more insight into the process underlying this EEG 
characteristic. 
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Introduction 
Epilepsy is a chronic neurological condition affecting an estimated over 65 million people 
worldwide (Ngugi et al., 2010). Overall, the risk of premature mortality in people with 
epilepsy is 2 to 3 times as high as in the general population (Cockerell et al., 1997; Neligan et 
al., 2011). Causes of death in people with epilepsy can be subdivided into three main 
categories: unrelated to epilepsy (e.g. pancreatitis); the underlying aetiology of epilepsy (e.g. 
stroke, brain tumour); and directly epilepsy-related causes such as sudden unexpected death in 
epilepsy (SUDEP), seizure-related accidents, and status epilepticus (Hitiris et al., 2007 a). The 
term SUDEP has been coined to describe sudden deaths in people with epilepsy that remain 
unexplained even after detailed postmortem investigations (Annegers, 1997; Nashef, 1997). 
SUDEP was believed to be a rare phenomenon until a nationwide audit of epilepsy-related 
deaths demonstrated that SUDEP frequently went unrecognized (Hanna et al., 2002). Since 
then, it has become increasingly clear that SUDEP is a considerable public health burden: 
victims are most frequently between 20 and 40 years of age and in the prime of their lives 
(Ficker et al., 1998). Correspondingly, people with epilepsy in this age group have a 16 to 24-
times higher risk of sudden death than the general population (Ficker et al., 1998; Holst et al., 
2013). In a recent nationwide study of deaths in the young (1 to 35 years of age), SUDEP was 
shown to be responsible for 7% of deaths in those with epilepsy and almost 1% of deaths in 
the entire population (Holst et al., 2013). When compared with selected neurological diseases 
(stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease, Parkinson’s 
disease, bacterial meningitis), SUDEP ranked second only to stroke in potential years of life 
lost (Thurman et al., 2014).  
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To reduce the considerable societal burden of SUDEP, it is important to gain a better 
understanding of its pathophysiology. Several lines of evidence suggest that the heart, or more 
specifically cardiac arrhythmias, may play a role in SUDEP: In those with chronic focal 
epilepsy progressive autonomic dysfunction and changes in cardiac electrical properties have 
been documented (Tomson et al., 2008), which may lower the threshold for ventricular 
arrhythmia. In addition, sudden cardiac death may present as SUDEP, as in a subset of SCA 
cases no clear cause of death is found at autopsy (van der Werf et al., 2010). In an analysis of 
25 cases of SUDEP or near-SUDEP that occurred under video-EEG monitoring sudden 
cardiac arrest (SCA) due to seizure-related ventricular arrhythmia (VT/VF) was the reported 
underlying mechanism in one case (Ryvlin et al., 2013 a). This study may, however, not 
directly apply to out-of-hospital SUDEP cases in the general population with epilepsy: most 
video-EEG-recordings were performed in a selected group of people with severe refractory 
epilepsy for the purpose of presurgical evaluation. In addition, rapid AED tapering schedules 
may have been used to increase the odds of recording at least one seizure. This procedure can, 
however, lead to more severe seizures than those seen in everyday life (Rajakulendran & 
Nashef, 2015). To study SCA due to VT/VF, this potential underlying cardiac mechanism of 
sudden death, in a non-selected cohort more representative of the general population with 
epilepsy, I could make use of a prospective community-based registry of out-of-hospital 
resuscitations with ECG-confirmed VT/VF. My aim was to determine whether having 
epilepsy was a risk factor for SCA in the general population after accounting for cardiac risk 
factors and to assess the underlying causes, characteristics, and risk factors of SCA in 
epilepsy. 
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Apart from an analysis of potential underlying mechanisms, the pathophysiology of sudden 
death in epilepsy and SUDEP may also be approached indirectly by studying its potential risk 
factors such as postictal generalized EEG-suppression (PGES).  
 
PGES occurs in the majority of fatal CSs, where it appears to be an EEG hallmark of SUDEP 
starting off a chain of postictal events culminating in death (Ryvlin et al., 2013 a). Elucidation 
of the process underlying PGES may therefore shed more light on the pathophysiology of 
SUDEP. PGES can also occur after non-fatal CSs and has been proposed as a risk factor for 
future SUDEP (Lhatoo et al., 2010), but findings as to the value of this EEG-characteristic 
have been conflicting (Surges et al., 2011). To find an explanation for these divergent results, 
my goal was to determine the level of intraindividual variability of prolonged PGES in people 
with multiple recorded CSs. 
 
In recent years, SUDEP has steadily gained attention in both lay and medical circles (Brigo et 
al., 2014), which is hopeful news. The example of sudden infant death syndrome (SIDS), a 
better-known cause of sudden death, shows that the continuing concerted efforts of laymen 
and professionals can yield valuable results; in the last couple of decades the incidence of 
SIDS has plummeted in developed countries after the implementation of large-scale 
educational campaigns (Hauck & Tanabe, 2008). 
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1. A critical review of the literature  
 
1.1 History of SUDEP 
The first proposals to define SUDEP were made in 1997, but the phenomenon it describes has 
been documented for much longer. The first description of SUDEP was probably provided by 
George Washington, first president of the United States of America (Doherty, 2004). In 1773, 
Patsy Custis, his 17-year old stepdaughter, who had intractable epilepsy died in the aftermath 
of one of her seizures. In 1868, George MacKenzie Bacon, medical superintendent of the 
Cambridge County Asylum, described the phenomenon of SUDEP for the first time in 
medical literature as “sudden deaths in a fit” (MacKenzie Bacon, 1868). During the 19th 
century, having epilepsy was the second most common reason for committal to an asylum in 
Europe and the United States, as people with epilepsy (particularly those with intractable 
seizures) could not usually earn a living and were thought to display erratic behaviour 
(Spurzheim et al., 1835; Lannon, 2002). Unlike their colleagues in the regular medical 
establishment, the physicians working in these asylums were able to monitor a large 
population with epilepsy continuously and, therefore, were in a much better position to 
recognize that those with epilepsy would regularly succumb to sudden death. As George 
MacKenzie Bacon notes: “of the causes enumerated, that of suffocation in bed is far from 
uncommon in asylums (five cases having occurred in a large asylum in one year); but this 
does not seem to be recognized as such in the outside world” (MacKenzie Bacon, 1868). In 
the late 19th century epilepsy was increasingly being viewed in the medical community as a 
brain disorder rather than the result of “spiritual punishment or feeble-mindedness”.  
Due to continuing stigma, however, people with epilepsy were still ostracized from their 
families and communities. 
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Philanthropists in Europe and the USA then started to establish isolated, self-financing 
agricultural “colonies”, where “sane epileptics” could work, providing them with “healthy 
occupation” (Sander et al., 1993; Lannon, 2002; Novy et al., 2013). The ‘colonies’ included 
Stichting Epilepsie Instellingen Nederland (SEIN) in the Netherlands, the Epilepsy Centre 
Bethel in Germany, the Chalfont Centre near London and the Craig Colony in New York 
State. The physicians in these “colonies” continued to recognize and describe the 
phenomenon of sudden death in epilepsy without apparent cause. Spratling, one of the 
founders of the Craig Colony, described epilepsy as “a disease which destroys life suddenly 
and without warning through a single brief attack, unaided by an accident to the patient at the 
moment, such as suffocation, or fracture to the skull from falling, and does so in 3 to 4 per 
cent of all who suffer from it” (Spratling, 1904). Munson, another founder who conducted a 
study on 582 deaths in the Craig Colony described “a definite and fairly large group where 
neither accident of any kind nor suffocation can be assigned as the cause of death” (Munson, 
1910). In a later section he added: “each patient must be seen every few minutes, for as has 
been noted these deaths occur very rapidly at times” (Munson, 1910). These physicians, 
therefore, considered SUDEP to be a rather common phenomenon that might be preventable 
with good quality care. In the years after the world wars, however, this view completely 
changed and earlier research on the subject was largely ignored. In later years, therefore, it 
became common belief that epilepsy was not a fatal condition. In 1954 it was stated in a 
review of 77 deaths in people with epilepsy that “the epileptic under adequate medical control 
with patient and critical guidance and understanding of his problem, is substantially a 
mortality risk no greater than the average normal person” (Schwade & Otto, 1954). 
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A lonely opposing view was espoused by Rodin: “it appears to be quite obvious that the life 
expectancy of the epileptic individual does not reach that of the average person. It is also quite 
impressive that the figures have not shown a dramatic improvement during the past five 
decades. Although death from a seizure is relatively rare, it does occur on occasion and is not 
preventable under all the circumstances at the present time” (Rodin, 1968). Livingston, the 
author of a key textbook in this period stated: “As far as longevity is concerned, the patient 
should definitely understand that epilepsy per se rarely causes death and that there is no 
reason why an epileptic should not live as long as he would if he did not have epilepsy” 
(Livingston, 1963). Paradoxically, the advent of better treatment options in the field of 
epilepsy including the introduction of new AEDs and the deinstitutionalization of people with 
epilepsy may have been responsible for this reduced awareness of SUDEP (Nashef, 1995 a). 
The expansion of treatment options may have given rise to the false belief that complete 
seizure control and, thereby, a normalization of the prognosis of epilepsy was now finally 
within reach. In addition, the closure of asylums limited the opportunities for long-term 
observation of people with severe epilepsy, those at highest risk of SUDEP. SUDEP did not 
become the focus of attention again until the autopsy studies by Leestma et al., in the 1980s 
(Leestma et al., 1984; Leestma et al., 1985; Leestma et al., 1989). Since then, interest in 
SUDEP has steadily risen culminating in the proposal of two SUDEP definitions in 1997 
(Annegers, 1997; Nashef, 1997). In addition, the National Sentinel Clinical Audit of Epilepsy-
related Deaths was performed in the UK in 2002, providing a detailed assessment of SUDEP 
incidence while highlighting the inadequate recognition of this phenomenon by medical 
professionals (Hanna et al., 2002).  
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When looking back at the evolution of SUDEP research in these past 150 years, it is a 
sobering realization that aspects discussed more than a hundred years ago (incidence, the 
tendency to occur after a single brief seizure, and the potential benefit of supervision), had to 
be relearned in the last two decades. The greater should be the determination of the general 
and scientific community to keep SUDEP on the agenda and continue research efforts in this 
area. 
1.2 Definition of SUDEP 
In 1997 two separate but similar definitions of SUDEP were adopted (Annegers, 1997; 
Nashef, 1997). While Nashef’s main criteria are now most widely used, the additional 
classification of diagnostic certainty by Annegers has also been adopted (Annegers, 1997; 
Nashef, 1997). SUDEP is the “sudden, unexpected, witnessed or unwitnessed, non-traumatic 
and non-drowning death in patients with epilepsy, with or without evidence for a seizure and 
excluding documented status epilepticus, in which postmortem examination does not reveal a 
toxicologic or anatomic cause of death”(Nashef, 1997). Three categories of diagnostic 
certainty have also been specified: definite, probable, and possible (Annegers, 1997). Definite 
SUDEP meets all criteria including a negative post-mortem examination, whereas in probable 
SUDEP no post-mortem examination has been performed. In possible SUDEP there is either a 
competing cause of death or insufficient information regarding the circumstances of death. In 
this case, the diagnosis can neither be confirmed nor ruled out (Annegers, 1997). Recently, 
the amendment of these criteria has been proposed, as the potential contribution of somatic 
comorbidity to SUDEP may not have been addressed adequately thus far (Nashef et al., 
2012).  
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The authors of these new unified SUDEP criteria proposed the following changes: the 
establishment of a “SUDEP plus” category to designate those cases with a (non-lethal) 
concomitant condition discovered before or after a death which would fulfil all the original 
criteria of SUDEP (Nashef et al., 2012). “Possible SUDEP” will only be used for those in 
whom a competing cause of death is present, whereas a case will remain unclassified if 
insufficient information is available. The timeframe in which death should occur after a 
witnessed terminal event (e.g. seizure) has been set to within one hour to minimize the 
possibility that other causes of death are involved. The term “near-SUDEP” pertains to those 
cases that satisfy all criteria, but who are successfully resuscitated after the life-threatening 
event. 
1.3 Incidence of SUDEP 
The incidence of SUDEP varies considerably depending on which population is studied.  The 
lowest numbers are found in unselected, community-based cohorts of people with incident 
epilepsy: 0.09 to 0.41/1,000 person years: table 1. Other study methodologies may 
approximate SUDEP incidence in a population with prevalent epilepsy: (1) cases are found by 
reviewing postmortem records and incidence is calculated using the assumed prevalence of 
epilepsy in the catchment area (0.9-2.3/1000 person years) or (2) people with epilepsy with 
and without SUDEP are identified through AED prescription databases (0.54-1.3/1000 person 
years). In addition, SUDEP incidence has been analysed in cohorts from a hospital discharge 
registry (1.5/1000 person years) or epilepsy clinics (1.1-5.9/1000 person years): table 2. 
Similar numbers are found in selected groups who cannot live independently: long term 
residents at a tertiary epilepsy referral centre (2.1/1000 person years), pupils with epilepsy and 
a learning disability at a special residential school (3.4/1000 person years), and people with 
epilepsy and mental retardation (1.97-3.6/1000 person years). 
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SUDEP incidence has also been reported in populations with presumably refractory epilepsy: 
those on AED polytherapy (2.2/1000 person years), participants in AED trials (2.52-3.8/1000 
person years), and people with an implanted vagal nerve stimulator (VNS) device (3.3-
4.1/person years): table 3.  
 
Table 1: Community-based studies of SUDEP incidence in adults 
Study Country Population Cases (n) Total person 
years 
SUDEP incidence  
(per 1000 person years)  
Lhatoo et al., 2001 UK Community 
(age 1-90 years) 
1 11400 0.09 
Ficker et al., 1998 USA Community 9 25940 0.35 
Holst et al., 2013 Denmark Community 
(age 1-35 years) 
50 120096 0.41 
Terrence et al., 1975 USA Community 
(autopsy records) 
37 Not mentioned 0.9# 
Opeskin & Berkovic, 2003 Australia Community 
(autopsy records)  
50 Not mentioned 1.3# 
Langan et al., 1998 Ireland Community 
(autopsy records) 
15 Not mentioned 1.5# 
Leestma et al., 1984 USA Community 
(autopsy records) 
66 Not mentioned 1.9# 
Leestma et al., 1989 USA Community 
(autopsy records) 
60 Not mentioned 2.3# 
Tennis et al., 1995 USA AED prescription database 
(age 15-49 years) 
18 33299 0.54 
Jick et al., 1992 USA AED prescription database 
(age 15-49 years) 
11 8460 1.3 
#The number of person years is calculated based on an assumed prevalence of epilepsy in the coroner’s 
catchment area.  
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Table 2: Studies of SUDEP incidence in selected populations with epilepsy 
Study Country Population Cases (n) Total person 
years 
SUDEP incidence  
(per 1000 person years)  
Nilsson et al., 1999 Sweden Epilepsy cohort from 
hospital discharge centre 
(age 15-70 years) 
62 40508 1.5 
Mohanraj et al., 2006 UK Epilepsy clinic  
(newly diagnosed)  
7 6482 1.1 
Vlooswijk et al., 2007 Netherlands Tertiary referral centre 29 Not mentioned 1.2¶ 
Walckzak et al., 2001 USA Three epilepsy centres  20 16463 1.2 
Timmings, 1993 UK Epilepsy clinic  14 7000 2 
Mohanraj et al., 2006 UK Epilepsy clinic 
(chronic patients) 
55 22935 2.5 
Nashef et al., 1995 b UK Tertiary referral centre 11 1849 5.9 
Klenerman et al., 1993 UK Residential care, epilepsy 7 3392 2.1 
Nashef et al., 1995 c UK Residential care, epilepsy 
and learning disability 
14 4135 3.4 
Kiani et al., 2014 UK Residential care or 
supported living, epilepsy 
and mental retardation 
(age ≥20 years) 
26 13201 1.97 
McKee & Bodfish, 2000 USA Residential care, epilepsy 
and mental retardation 
11 3012 3.6 
¶The number of person years is calculated based on an assumed mean number of people with epilepsy treated 
per year at the tertiary referral centre.  
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Table 3: Studies of SUDEP incidence in cohorts with presumably chronic, refractory epilepsy 
Study Country Population Cases (n) Total person 
years 
SUDEP incidence 
(per 1000 person years) 
Derby et al., 1996 UK AED prescription database 
(patients on >2 AEDs; age 
<50 years) 
15 6784 2.2 
Tomson et al., 2013 USA/UK Lamotrigine add-on trials 8 3168 2.52 
Leestma et al., 1997 USA/UK Lamotrigine add-on trials 20 6721 2.98 
Ryvlin et al., 2011 International AED add-on trials 
(entire cohort) 
20 5589 3.58 
Ryvlin et al., 2011 International AED add-on trials  
(efficacious AED dose) 
14 2022 6.9 
Ryvlin et al., 2011 International AED add-on trials  
(add-on placebo)  
3 3297 0.9 
Racoosin et al., 2001 USA AED add-on trials 52 13617.1 3.8 
Racoosin et al., 2001 USA AED monotherapy trials 0 982.5 0 
Granbichler et al., 2015 International VNS cohort 10 2993.8 3.3 
Annegers et al., 2000 International VNS cohort 13 3176.3 4.1 
 
SUDEP occurs most frequently in candidates or former candidates for epilepsy surgery (e.g. 
those who were rejected for surgery or who declined surgery): 5.94-9.3/1000 person years.  
The incidence of SUDEP, therefore, increases in tandem with epilepsy severity. This trend is 
also reflected in the estimated individual life-time risk of SUDEP, which was recently 
calculated based on pooled data from higher quality population-based studies of SUDEP 
incidence (Thurman et al., 2014): the individual life-time risk of SUDEP was calculated as 
8% for the entire population with epilepsy, and 35% for those with refractory epilepsy 
(Thurman, 2013). 
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Interestingly, in people with drug-resistant epilepsy who participated in randomized 
controlled trials comparing add-on AED treatment to placebo, those receiving an efficacious 
add-on dose had a much lower incidence of SUDEP (0.9/1,000 person years) than those 
allocated to placebo: 6.9/1,000 person years (Ryvlin et al., 2011). People who received a 
temporal lobectomy, the most successful type of epilepsy surgery, appeared to have a lower 
incidence of SUDEP (0.51-3.99/1000 person years) than those who were evaluated for 
epilepsy surgery: table 4. In addition, SUDEP occurred less frequently in those who became 
seizure free after surgery than in people with persistent seizures: 7.49 vs. 0/1000 person years. 
This suggests that measures to achieve seizure control, such as AED optimization and 
epilepsy surgery, may prevent SUDEP (at least in some individuals). It should be stressed, 
however, that firm evidence that epilepsy surgery itself reduces SUDEP incidence is lacking. 
In children, SUDEP appears to occur less frequently than in adults with a similar epilepsy 
severity: unselected, community-based cohorts of children with incident epilepsy (0.176-
0.26/1000), cases found by reviewing postmortem records while using an assumed prevalence 
of epilepsy in the catchment area to calculate an incidence (0.2/1000 person years), children 
identified through an AED prescription database (0.33/1000 person years), cases who were 
treated at a children’s hospital (0.43/1000), and a cohort from an epilepsy clinic (0.8/1000): 
table 5. In children as in adults, however, SUDEP incidence appears to be higher in those with 
more severe epilepsy 
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Table 4: Studies of SUDEP incidence in (former) epilepsy surgery candidates, and cohorts after surgery 
Study Country Population Cases (n) Total person 
years 
SUDEP incidence  
(per 1000 person years)  
Bell et al., 2010 UK After epilepsy surgery  2 3905 0.51 
Seymour et al., 2012 UK After epilepsy surgery 6 3569 1.68 
Salanova et al., 2002 USA After epilepsy surgery 3 1514 1.98 
Nilsson et al., 2003 Sweden After epilepsy surgery 6 2455 2.4 
Sperling et al., 2005 USA After epilepsy surgery 
(entire cohort)  
6 1502.6 3.99 
Sperling et al., 2005 USA After epilepsy surgery 
(seizure free) 
0 701.1 0 
Sperling et al., 2005 USA After epilepsy surgery 
(persistent seizures) 
6 801.5 7.49 
Bell et al., 2010 UK Surgery candidates, no 
surgery performed  
20 3365 5.94 
Nilsson et al., 2003 Sweden Surgery candidates, no 
surgery performed 
4 635 6.3 
Ryvlin et al., 2013 a International During presurgical video-
EEG monitoring 
10 1334 7.5 
Dasheiff, 1991 USA Surgery candidates, no 
operation 
7 _ 9.3 
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Table 5: Studies of SUDEP incidence in children  
Study Country Population Cases 
(n) 
Total person 
years 
SUDEP incidence  
(per 1000 person years)  
Holst et al., 2013 Denmark Community 
(age 1-17 years) 
10 57703 0.176 
Berg et al., 2013 USA/UK/Canada/ 
Netherlands 
Community 
(pooled analysis of four 
studies) 
8 30284 0.26 
Donner et al., 2001 Canada Community 
(autopsy records) 
27 _ 0.2 
Ackers et al., 2011 UK AED prescription database 
(age 0-18 years) 
9 26890 0.33 
Weber et al., 2005 Switzerland Epilepsy cohort from 
children’s hospital  
4 9295 0.43 
Grønborg & Uldall, 2014 Denmark Tertiary referral centre 9 11309 0.8 
 
1.4 Descriptive and risk factor studies 
 
Case series 
It is estimated that >60% of SUDEP cases are unwitnessed (Nashef et al., 1998; Kloster & 
Engelskjøn, 1999; Langan et al., 2000; Langan et al., 2005). Most victims are found in or next 
to their bed, which suggests that they died during sleep (Nashef et al., 1998; Langan et al., 
2005). Signs of a recent seizure such as a lateral tongue bite, urinary incontinence, posturing, 
and secretions/blood are frequently found: 64-88% (Nashef et al., 1998; Kloster & 
Engelskjøn, 1999; Langan et al., 2005). 
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Most victims (70-73%) are discovered in the prone position, although body position at time of 
death is not always accurately recorded (Kloster & Engelskjøn, 1999; Liebenthal et al., 2015). 
If witnessed, most witnesses confirm that victims had experienced a seizure shortly before 
death (Langan et al., 2000). This was usually a convulsive seizure (CS). Most witnesses 
reported seeing respiratory problems (cyanosis, laboured breathing), although one should be 
cautious when interpreting testimony from non-medical individuals (Langan et al., 2000). 
Autopsy studies 
Autopsy plays an important role in establishing the diagnosis of SUDEP and may be 
indispensable for a correct classification: in 14/35 (40%) people who would have been 
diagnosed clinically as probable SUDEP, an alternative cause of death was found after 
postmortem investigations (Novy et al., 2013). A structural cause of death is, by definition, 
not found in SUDEP victims, but (non-lethal) abnormalities such as pulmonary oedema (30 to 
100%) and cerebral oedema (25 to 55%) have been frequently reported (Terrence et al., 1981; 
Leestma et al., 1984; Leestma et al., 1989; Earnest et al., 1992; Antoniuk et al., 2001; Salmo 
& Connolly, 2002, Zhuo et al., 2012). The pulmonary findings may suggest neurogenic 
pulmonary oedema, a condition thought to be triggered by the surge in central sympathetic 
activity accompanying CSs (Swallow et al., 2002). Alternatively, it may be the result of 
premortem congestive or “backward” cardiac failure (Thom, 1997). Various cardiac 
pathologies have also been reported in SUDEP victims: myocardial fibrosis (14 to 57%) 
(Earnest et al., 1992; Natelson et al., 1998; Zhuo et al., 2012), mild to moderate coronary 
atherosclerosis (4 to 16%) (Leestma et al., 1989; Zhuo et al., 2012), moderate left ventricular 
hypertrophy 10% (Zhuo et al., 2012), old myocardial infarction 4% (Leestma et al., 1989). 
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Myocardial fibrosis was more frequently found in SUDEP victims (71%) than in controls 
without epilepsy who died suddenly (4%), which may suggest that these lesions play a role in 
their deaths (Natelson et al., 1998). Autopsy findings support the notion that SUDEP deaths 
may be seizure-related: tongue biting is described in 23 to 28% of cases (Coyle et al., 1994; 
Salmo & Connolly, 2002; Pollanen & Kodikara, 2012). In addition, markers of acute cerebral 
injury such as HSP-70 and c-jun were more frequently found in SUDEP victims than in 
controls with and without epilepsy, thus also favouring a seizure-related cause (Thom, 2003). 
Case-control studies (SUDEP vs. deceased controls with epilepsy) 
Risk factors for SUDEP can be analysed by comparing SUDEP victims (cases) with 1) those 
with epilepsy who died of other causes (controls) or with 2) living people with epilepsy 
(controls) (Tomson et al., 2008). The first design appears to be most suitable for elucidating 
SUDEP circumstances. In these studies, the most consistent risk factor associated with 
SUDEP is evidence of a recent seizure and a younger age at time of death (Téllez-Zenteno et 
al., 2005 a). In addition, the AED concentration variability measured in scalp hair was higher 
in SUDEP victims than in controls with epilepsy who died of other causes or living controls 
with epilepsy, suggesting that AED non-compliance may increase SUDEP risk (Williams et 
al., 2006). 
Case-control studies (SUDEP vs. living controls with epilepsy) 
Comparing SUDEP victims with living controls may be more clinically relevant, because it 
can help to determine which people with epilepsy have the highest risk of SUDEP. In a 
combined analysis pooling data from four large case-control studies (Nilsson et al., 1999; 
Walczak et al., 2001; Langan et al., 2005; Hitiris et al., 2007 b), a high frequency of CSs was 
found to be the strongest risk factor for SUDEP after adjustment for data source, gender, 
duration of epilepsy, and age at death (Hesdorffer et al., 2011).  
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To a lesser degree, the variables male gender, structural/metabolic epilepsy, young age of 
onset, long duration of epilepsy, polytherapy (≥2 AEDs), and lamotrigine use were also 
associated with increased SUDEP risk (Hesdorffer et al., 2011). In addition, lamotrigine use 
among individuals with idiopathic generalized epilepsy (IGE) was found to be a risk factor for 
SUDEP in univariable analysis. Previously, four SUDEP cases involving young women with 
IGE who were on lamotrigine monotherapy had been reported (Aurlien et al., 2009). In 
addition, female SUDEP victims were taking lamotrigine more frequently than living controls 
with epilepsy matched by age and gender in a subsequent case-control study (Aurlien et al., 
2012). There are several possible explanations for the association between lamotrigine use 
and SUDEP, particularly in those with IGE and young women: lamotrigine may not be as 
effective as valproic acid in achieving seizure control in people with IGE (Bauer et al., 2008). 
In addition, young women with IGE may be more likely to switch from valproate to 
lamotrigine monotherapy, because use of lamotrigine carries a smaller risk of foetal 
congenital malformation (Tomson et al., 2011). Women exposed to lamotrigine monotherapy 
in pregnancy were less likely to be seizure free than those using other AEDs as monotherapy 
(Battino et al., 2013). 
 
Recently, it was shown that lamotrigine use and AED polytherapy were no longer significant 
risk factors for SUDEP after correction for CS frequency (Hesdorffer et al., 2012). In a meta-
analysis of 42 lamotrigine randomized controlled trials, this drug was not associated with a 
higher risk of SUDEP (Tomson et al., 2013). All together, these data suggest that lamotrigine 
use in IGE and AED polytherapy appear to be surrogate markers for poor seizure control 
rather than independent risk factors for SUDEP. Achieving seizure freedom, therefore, 
appears to be of greater importance than limiting the number of AEDs. 
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In the largest of the four case-control studies the effect of possible preventive measures was 
evaluated (Langan et al., 2005). The presence of an individual of normal intelligence and ≥10 
years of age in the same bedroom was found to reduce the risk of SUDEP by 2.5 times. The 
use of special precautions (regular checks throughout the night or the use of a listening 
device) was even associated with a 10 times lower risk of SUDEP. It is still unclear, however, 
how these measures also known as nocturnal supervision may be protective and which 
patients would benefit most. 
1.5 Ictal recordings of (near-)SUDEP  
In total, twenty-two cases of people who (almost) died of SUDEP while under (video)/EEG 
monitoring have been reported (Dasheiff & Dickinson, 1986; Purves et al., 1992; Thomas et 
al., 1996; Bird et al., 1997; Lee, 1998; So et al., 2000; Tavee & Morris III, 2008; Espinosa et 
al., 2009; Lhatoo et al., 2010; Bateman et al., 2010 a; Tao et al., 2010; Lanz et al., 2011; 
Ryvlin et al., 2013 a; Jeppesen et al., 2014). At first glance, this appears to be in contrast with 
the reported high incidence of SUDEP in those with refractory epilepsy. This finding, 
however, emphasizes the notion that SUDEP most readily occurs when there is least 
supervision: at home rather than in the hospital, and unwitnessed rather than witnessed. 
 
Ictal recordings of (near-)SUDEP appear to confirm the findings of descriptive studies: all 
(near) deaths were seizure-related and occurred in the first 30 minutes after seizure end 
(Ryvlin et al., 2013 a). In most cases the (near-)fatal seizure was a CS (82%; 18/22), whereas 
focal seizures with alteration of awareness were seen less frequently (18%; 4/22). Despite the 
high level of supervision in an epilepsy monitoring unit (EMU), a surprising number of events 
were unwitnessed (32%; 7/22); another 32% (7/22) of cases were witnessed, while in the 
remaining case reports (36%; 8/22) this issue was not mentioned.  
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Seizures started during sleep in 50% (11/22) of events, during wakefulness in 41% (9/22), and 
seizure timing was not mentioned in 9% (2/22). In a recent retrospective survey of EMUs that 
incorporated most of the 22 previously mentioned (near-)SUDEP cases, 14/16 (88%) of 
individuals in whom body positions could be evaluated were lying in the prone position at 
seizure end (Ryvlin et al., 2013 a). In spite of the similar clinical presentation of all (near)-
SUDEP cases, three peri-ictal pathomechanisms were observed that preceded (near)-SUDEP: 
1. The sequence of pronounced post-ictal generalized attenuation of EEG activity 
followed by respiratory and cardiac arrest  
2. Central and/or obstructive peri-ictal apnoea  
3. Peri-ictal cardiac arrhythmias including VT/VF or asystole  
1.6 Peri-ictal pathomechanisms of SUDEP 
Postictal generalized EEG suppression 
In earlier studies postictal attenuation of EEG activity or the “flat EEG” was described as 
“abruptly attenuated termination pattern” or “electrocerebral shutdown” (Kim et al., 2006; 
Bird et al., 1997), but in recent years the term “postictal generalized EEG suppression” 
(PGES) has been coined (Lhatoo et al., 2010). PGES has been defined as “the immediate 
postictal (within 30 seconds) generalized absence of electroencephalographic activity <10μV 
in amplitude, allowing for muscle, movement, breathing, and electrode artifacts” (Lhatoo et 
al., 2010). In subsequent studies additional criteria have occasionally been used such as a 
minimum PGES duration of 1s (Surges et al., 2011; Tao et al., 2013) or 2s (Seyal et al., 2012). 
In most ictal recordings of SUDEP, PGES is the first discernible abnormality before 
cardiorespiratory deterioration and cessation, suggesting that this EEG characteristic may 
reflect an underlying SUDEP mechanism.  
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PGES: facilitating co-factors 
PGES does not occur exclusively in (near)-SUDEP cases, but can also be found after non-
lethal seizures (Lhatoo et al., 2010; Surges et al., 2011). This has made the search for clinical 
determinants of this EEG characteristic much more achievable. PGES appears to be more 
prevalent in adults than in children (Freitas et al., 2013; Pavlova et al., 2013). Seizure type 
appears to be the most important determinant of PGES, as this EEG phenomenon is found 
more frequently after CSs than focal seizures with alteration of awareness (Lhatoo et al., 
2010; Surges et al., 2011). In addition, PGES duration was significantly longer in focal 
seizures evolving into a bilateral convulsive seizure with tonic and/or clonic components than 
in GTCSs (Freitas et al., 2013). Seizure duration was not associated with PGES (Lhatoo et al., 
2010; Surges et al., 2011; Poh et al., 2012; Semmelroch et al., 2012; Seyal et al., 2012; Freitas 
et al., 2013; Lee et al., 2013; Moseley et al., 2013; Pavlova et al., 2013; Tao et al., 2013), but 
a longer duration of the tonic phase may promote PGES (Freitas et al., 2013; Tao et al., 2013). 
PGES has also been associated with more severe peri-ictal hypoxaemia and postictal coma 
(Semmelroch et al., 2012; Seyal et al., 2012). AED changes may facilitate PGES; after the 
withdrawal of AED therapy, the introduction of levetiracetam decreased the severity of 
postictal EEG suppression and coma (Tilz et al., 2006).   
PGES: aetiology 
Three hypotheses regarding the origin of PGES have been proposed based on the 
aforementioned facilitating co-factors. PGES was suggested as being the result of a “passive” 
process such as seizure-related neuronal fatigue or neurotransmitter depletion (Lhatoo et al., 
2010; Surges et al., 2011). This appears unlikely, however, given the sudden onset of this 
EEG phenomenon and the lack of correlation between PGES and seizure duration. 
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The second theory proposes that PGES may be due to the activation of inhibitory neuronal 
networks triggered by ongoing seizure activity. In an intracranial video-EEG-recording, EEG 
flattening originated in the right hemisphere ipsilateral to the seizure onset zone before 
spreading to the rest of the brain and evolving into PGES (Bird et al., 1997). The association 
between PGES and the severity of postictal coma further suggests that it reflects an 
endogenous seizure termination process that may not only suppress ongoing seizure activity 
but also modalities such as consciousness.  
 
It is important to realize that the exact sequence of (post)ictal events in SUDEP remains 
incompletely understood. Even in video-EEG recordings of SUDEP critical physiological 
parameters such as BP or O2 saturation were not assessed. In a study where O2 saturation was 
continuously analysed, PGES following non-fatal CSs was found to be associated with 
preceding hypoxaemia (Seyal et al., 2012). In addition, early peri-ictal nursing interventions 
including oxygen administration were reported to reduce the duration of PGES (Seyal et al., 
2013). In a recent case report, prolonged PGES after a non-fatal GTCS coincided with 
profound postictal hypotension, the end of PGES correlating closely with blood pressure 
normalization (Bozorgi et al., 2013). The third hypothesis regarding the origin of PGES, 
therefore, suggests that this EEG pattern is, at least in some cases, secondary to preceding 
hypoxia, hypotension, or asystole as seen in ictal recordings of (near-)SUDEP and vasovagal 
syncope.  
PGES: SUDEP risk marker? 
It has been hypothesized that PGES following non-fatal CSs may predict SUDEP risk. In a 
retrospective electroclinical case-control study (SUDEP cases (n=10, living epilepsy controls 
(n=30), recorded seizures (n=122)), those individuals who exhibited prolonged PGES of >20s 
after a CS were 13 times more likely later to die of SUDEP (Lhatoo et al., 2010). 
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These findings, however, could not be replicated in a second case-control study (Surges et al., 
2011): SUDEP cases (n=17), living epilepsy controls (n=17), recorded seizures (n=80). The 
value of PGES >20s after non-lethal CSs as a risk marker for SUDEP, therefore, remains 
unclear. 
Peri-ictal respiratory disturbances 
Ictal respiratory abnormalities such as apnoea or hypoxaemia are not uncommon. In a 
landmark study, evidence of central apnoea was found in 44% of 100 seizures for which nasal 
airflow and abdominal excursion data were available (Bateman et al., 2008). In addition, 
mixed apnoea (with central and obstructive components) was reported in 7% of seizures and 
obstructive apnoea in 2% of seizures. Hypoxaemia (i.e. oxygen saturation <90%) was found 
in 33% of all seizures (Bateman et al., 2008). Apnoea and hypoxaemia were also frequently 
encountered in other studies with apnoea in 30 to 50% and hypoxaemia in 25-87% of seizures 
(Walker & Fish., 1997; O’Regan & Brown, 2005; Seyal & Bateman, 2009; Seyal et al., 2010; 
Moseley et al., 2010; Moseley et al., 2011; Moseley et al., 2013; Singh et al., 2013; Pavlova et 
al., 2013; Moseley & Britton, 2014). Ictal apnoea appears to be more common in children 
than adults, possibly because children have a lower apnoeic threshold (Rowley et al., 2006). 
Ictal hypoxaemia, however, was found to be more prevalent in adults (Moseley et al., 2011). 
Mechanisms other than apnoea such as diffusion-perfusion mismatch due to pulmonary 
oedema may, therefore, also contribute to seizure-related respiratory dysfunction (Seyal et al., 
2010). In a recent study where consecutive chest X-rays were performed following a CS, 
pulmonary oedema was found in 29% of individuals and pulmonary oedema was most likely 
to occur after seizures with a longer duration (Kennedy & Seyal, 2015).  
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Both central apnoea and hypoxaemia were mostly related to temporal lobe seizures, to the 
contralateral spread of ictal activity, and longer seizure duration (Bateman et al., 2008; Seyal 
& Bateman, 2009; Singh et al., 2013). In fact, brief apnoeic responses could be reproduced 
after electrical stimulation of sections of the limbic system such as the cingulate gyrus in 
humans (Penfield & Jasper, 1954). This suggests that the spread of seizure activity to the 
limbic system, which modulates autonomous cardiac and respiratory control, can trigger ictal 
respiratory changes.  
 
Mixed/obstructive ictal apnoea is far less common than the central type, but is described at 
least equally frequently as the underlying pathophysiological mechanism in ictal recordings of 
(near-)SUDEP (Thomas et al., 1996; So et al., 2000; Tavee & Morris III, 2008). Postictal 
laryngospasm due to inhalation of stomach contents during a CS and the frequent assumption 
of a prone position after seizure end may both aggravate upper airway obstruction (Tavee & 
Morris III, 2008; Blum, 2009). On a cellular level, dysfunction of the 5-hydroxytryptamine 
(5-HT) neurotransmitter system or release of the endogenous anticonvulsant adenosine may 
partially explain the link between ictal respiratory changes and SUDEP. 5-HT is found in the 
raphe and other related brain stem nuclei in control of a variety of functions including 
stimulation of autonomous breathing control (Ptak et al., 2009). Mice with defects in the 5-HT 
system exhibited postictal respiratory arrests (Tecott et al., 1995; Tupall & Faingold, 2006; 
Uteshev et al., 2010). Stimulation of breathing by the 5-HT system is likely to be particularly 
relevant in the aftermath of a CS when an individual with epilepsy may be prone, hypoxic and 
incapacitated. At this point, failure of the autonomic respiratory drive may eventually lead to 
SUDEP. Interestingly, defects of the 5-HT system have been reported in SIDS, another 
condition characterized by unwitnessed nocturnal sudden death (Richerson & Buchanan, 
2011). 
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The incidence of SIDS decreased dramatically after advising parents to position their children 
in a supine rather than a prone sleeping position (Kinney & Thach, 2009). This further 
underscores the need to determine the effectiveness of similar measures (nocturnal 
supervision, body repositioning after seizure end) in preventing SUDEP. 
 
Adenosine is an inhibitor of neuronal activity and is released in elevated levels during 
seizures (During & Spencer, 1992).The activation of adenosine receptors in the brainstem 
triggered severe respiratory depression in rats (Barraco et al., 1990). In another animal model, 
seizures were induced with kainic acid in mice while inhibiting adenosine clearance in some, 
thus leading to a build-up of adenosine (Shen et al., 2010). All animals with impaired 
adenosine clearance died within 20 minutes after the onset of seizures, whereas controls with 
normal adenosine clearance survived their seizures. The authors, therefore, suggested that 
excessive adenosine build-up plays a role in the pathophysiology of SUDEP. It should be 
noted, however, that sudden death in this study occurred during prolonged induced CSs, a 
model of status epilepticus rather than SUDEP. Caution should, therefore, be used when 
extending these results to SUDEP (Massey et al., 2014). 
Peri-ictal cardiac arrhythmias 
Various seizure-related cardiac arrhythmias have been described, but only two types have 
been reported in ictal recordings of (near-)SUDEP: cardiac asystole (Lanz et al., 2011) and 
ventricular tachycardia/fibrillation (VT/VF) (Dasheiff & Dickinson, 1986; Espinosa et al., 
2009). The cross-sectional prevalence of ictal asystole was found to be relatively low when 
databases of video-EEG-recordings were retrospectively analysed: 0.3 to 0.4% of people with 
epilepsy (Rocamora et al., 2003; Schuele et al., 2007; Lanz et al., 2011). 
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A much higher prevalence was found when heart rhythm was measured continuously for 18 
months using implantable cardiac loop recorders: 21% (4/19) of participants had clinically 
relevant ictal bradycardia or asystole necessitating pacemaker implantation (Rugg-Gunn et al., 
2004). In a second study, (ictal) asystole was found in 6% (1/19) of participants (Nei et al., 
2012). The discrepancy in prevalence between long-term ECG registries and video-EEG-
databases may suggest that many ictal periods of asystole (of potential clinical relevance) go 
unnoticed in regular clinical practice. Ictal asystole occurs predominantly in people with 
temporal lobe epilepsy during focal seizures with alteration of awareness; the side of seizure 
onset does not appear to be of consequence (Rocamora et al., 2003; Schuele et al., 2007; Lanz 
et al., 2011). The aetiology of ictal asystole is incompletely understood. Electrical stimulation 
of parts of the limbic system such as the insula and cingulate gyrus was found to reproduce 
this arrhythmia analogous to the brief apnoeic responses described earlier (Oppenheimer et 
al., 1992; Altenmüller et al., 2004). The spreading of seizure activity to the limbic system 
may, therefore, trigger both asystole and ictal respiratory changes. Alternatively, this 
arrhythmia may be mediated by a transient increase in vagal tone after seizure onset, since 
ictal asystole has similar characteristics to those seen in cardioinhibitory vasovagal syncope 
(Schuele et al., 2008). It has further been suggested that ictal asystole may function as a 
seizure termination mechanism by causing cerebral ischaemia, which then both ends the 
seizure and the ictal asystole itself (Schuele et al., 2010). Ictal asystole may, therefore, be a 
benign self-limiting condition.  
 
Seizure-related VT/VF has been described far less extensively than ictal asystole: only three 
cases have been reported (Dasheiff & Dickinson, 1986; Espinosa et al., 2009; Ferlisi et al., 
2013). VT/VF appears to be triggered by CSs thus suggesting a different aetiology than 
asystole.  
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CSs have a number of proarrhythmic effects: a sympathetic surge activity triggers dramatic 
increases in the level of circulating catecholamines (Simon et al., 1984) and pronounced peri-
ictal HR acceleration (Surges et al., 2010 a). Catecholamines affect cardiac repolarization 
resulting in prolongation of the QTc-interval (Magnano et al., 2006). Accordingly, abnormal 
peri-ictal QTc-lengthening has been described in several studies (Brotherstone et al., 2010; 
Surges et al., 2010 a; Surges et al., 2010 b). QTc-prolongation has been associated with an 
increased risk of cardiac arrhythmia, specifically torsade de pointe VT (Straus et al., 2006; 
Feldman & Gidal, 2013). Seizure-related QTc-shortening has also been described, but the 
clinical implications of this finding are less clear (Surges et al., 2010 a; Surges et al., 2010 b). 
Transient myocardial ischaemia reflected by ST-segment depression was seen in 40% of 
seizures in one study, predominantly in CSs and those with a higher maximum HR (Tigaran et 
al., 2003).Together, these seizure-related changes may lower the threshold for VT/VF, thus 
explaining why CSs can trigger this arrhythmia. In conclusion, ictal asystole appears to be 
more common than VT/VF, but its lethality and, therefore, its role in SUDEP 
pathophysiology remain unclear. There is stronger evidence for a link between VT/VF and 
SUDEP, as this arrhythmia was reported in three cases of (near-)SUDEP and is less likely to 
be self-limiting. 
1.7 Predisposing interictal factors 
In addition to potential peri-ictal pathomechanisms of SUDEP, various interictal 
abnormalities that may lower the threshold for (seizure-related) cardiac arrhythmias and thus 
contribute to SUDEP have been described. These predisposing interictal factors may be 
subdivided into intrinsic susceptibility (genetic modifiers of cardiac arrhythmias) and 
acquired susceptibility (autonomic alterations, cardiac electrical changes, effects of AED 
therapy). 
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Genetic modifiers of cardiac arrhythmias  
With the advent of population genotyping, certain IGE syndromes have been associated with 
inherited sodium channelopathies (Hirose et al., 2005). In addition, the importance of sodium 
and potassium channel mutations in various cardiac arrhythmias has been established 
(Antzelevitch et al., 2005; Brenyo et al., 2012): KCNQ1, KCNH2, and SCN5A variants in the 
long-QT-syndrome and the Brugada syndrome. While these inherited syndromes are 
relatively rare, other mutations causing mild ion channel dysfunction may be more common 
and might enhance the susceptibility to arrhythmia. It is conceivable, therefore, that some 
patients with epilepsy may be genetically susceptible to arrhythmias due to expression of the 
same mutation in the heart and the brain. In a retrospective study of 343 individuals with 
long-QT-syndrome, those with subtype 2 (due to mutations in the KCNH2 gene) were much 
more likely to have a personal history of seizures than other subtypes (Johnson et al., 2009). 
In addition, a missense SCN5A mutation was recently described in three different family 
members who exhibited both epilepsy and the Brugada syndrome (Parisi et al., 2013). 
 
Several ion channel gene mutations have been found in either SUDEP victims or their 
immediate family; in a family with a mutation in the sodium channel SCN1A and generalized 
epilepsy with febrile seizures plus (GEFS+) syndrome two cases of SUDEP were reported 
(Hindocha et al., 2008). An SCN1A mutation was also described in a young boy who died of 
SUDEP (Le Gal et al., 2010). An SCN5A mutation was found at post-mortem in a SUDEP 
victim (Aurlien et al., 2009). In a third sodium channel gene, SCN8A, a de novo pathogenic 
mutation was found in an individual with infantile epileptic encephalopathy who died of 
SUDEP (Veeramah et al., 2012).  
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After genetic analysis of postmortem DNA samples of 68 SUDEP victims, two variants in the 
KCNH2 and SCN5A genes were found, which were absent in control alleles and therefore 
potentially pathogenic (Tu et al., 2011 a). In postmortem DNA samples from 48 SUDEP 
victims, two non-synonymous variants in HCN2 and one non-synonymous variant in HCN4 
(all absent in control alleles) were reported (Tu et al., 2011 b). The HCN genes encode for a 
mixed sodium potassium channel that is involved in generating spontaneous rhythmic activity 
in cardiac pacemaker and neuronal cells (Tu et al., 2011 b). The finding of these variants of 
neuro-cardiac ion channel genes (SCN1A, SCN5A, SCN8A, KCNH2,  HCN2, and HCN4) in 
SUDEP victims further supports the notion of a pathogenic link between heart and brain, 
which may be involved in SUDEP (Tu et al., 2011 b). SCN1A mutations are found in up to 
80% of individuals with clinical signs of Dravet syndrome, a severe epileptic encephalopathy 
with onset in infancy characterized by refractory seizures (Marini et al., 2011). The rate of 
SUDEP, particularly in older children and young adults with Dravet syndrome, appears to be 
extremely high (12.5% before age 50), even when compared with other childhood-onset 
epileptic encephalopathies with a similar seizure burden (Genton et al., 2011). The evidence, 
therefore, for a link between SCN1A mutations and SUDEP is stronger than for other ion 
channels. 
Autonomic alterations 
In people with epilepsy the prevalence of interictal cardiac arrhythmias appears to be similar 
to that of the general population (Blumhardt et al., 1986; Massetani et al., 1997). In those with 
epilepsy, however, interictal HR was faster, thus suggesting a changed autonomic balance 
(Evrengül et al., 2005; Shobha et al., 2007; Harnod et al., 2008; Harnod et al., 2009). The 
measure most commonly used to study changes in the autonomous nervous system is heart 
rate variability (HRV): the beat-to-beat change in heart rate (HR) thought to be regulated by 
sympathetic and parasympathetic activity (Stein & Kleiger, 1999).  
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HRV decrease has been associated with a higher risk of cardiac mortality and sudden cardiac 
death in healthy people and in individuals with cardiac disease (Tsuji et al., 1996; Stein & 
Kleiger 1999). In a recent meta-analysis, people with epilepsy were found to have lower HRV 
measures than healthy controls, with increased sympathetic and/or decreased parasympathetic 
tone (Lotufo et al., 2012). People with chronic temporal lobe epilepsy had significantly lower 
HRV measures than healthy controls, especially during the night (Tomson et al., 1998; 
Ronkainen et al., 2005). In addition, HRV changes appear to be progressive in refractory 
epilepsy, but not in well-controlled epilepsy; in a cross-sectional study comparing children 
with refractory and well-controlled epilepsy and normal controls, HRV measures were 
significantly lower in the first group (Raju et al., 2012). It was found that HRV measures 
progressively decreased during a period of six years in people with refractory, but not in those 
with well-controlled, temporal lobe epilepsy (Suorsa et al., 2011). These findings may have 
relevance for SUDEP pathophysiology: most SUDEP cases occur at night and individuals 
with refractory epilepsy have a higher SUDEP risk. In fact, in an individual with refractory 
temporal lobe epilepsy, progressive HRV deterioration was measured over the course of nine 
months after which he died from SUDEP (Rauscher et al., 2011). 
 
Baseline HRV measures were not found to be predictive of SUDEP risk (Surges et al., 2009; 
Surges et al., 2010 b). The association between long-term HRV progression and SUDEP risk 
has, to my knowledge, not yet been systematically investigated. Other autonomic functions 
tests also appear to be abnormal in people with epilepsy, confirming the results found in HRV 
studies. In people with focal epilepsy, blood pressure variability differed significantly when 
compared with healthy controls, reflecting an impairment of baroreceptor function (Devinsky 
et al., 1994). In addition, decreased baroreceptor sensitivity was documented in people with 
epilepsy (Dütsch et al., 2006).  
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Cardiac electrical changes & the effects of AED therapy 
Several interictal cardiac electrical changes have been documented in people with epilepsy. In 
seven studies the QTc-interval in people with and without epilepsy was compared: in three 
studies those with epilepsy had a slightly longer QTc-interval (Drake et al., 1993; Neufeld et 
al., 2009; Dogan et al., 2010), in two studies QTc-durations were found to be similar in both 
groups (Akalın et al., 2003; Krishnan & Krishnamurthy, 2013), and in two other studies those 
with epilepsy had a shorter QTc-interval (Teh et al., 2007; Ramadan et al., 2013). The co-
incidence of a prolonged baseline QTc-interval and peri-ictal QTc-lengthening may increase 
the risk of ventricular arrhythmia further than either of those conditions separately. Neither 
baseline QTc-duration nor the level of peri-ictal QTc-prolongation differed, however, 
between later SUDEP victims and living controls with epilepsy (Surges et al., 2010 b). AED 
use may contribute to the QTc-abnormalities found in people with epilepsy. Widely-used 
AEDs such as carbamazepine and phenytoin have sodium channel blocking or QTc-
prolonging effects (Smits et al., 2008; Feldman & Gidal, 2013). These drugs may, therefore, 
adversely affect the cardiac depolarization and repolarization process.  
 
AEDs that induce the CYP450 enzyme system (again carbamazepine and phenytoin) may also 
have other negative effects on the heart. Use of enzyme-inducing AEDs has been associated 
with elevated levels of serological vascular risk markers (total cholesterol, LDL), and may, 
thus, lead to accelerated atherosclerosis and cardiac disease (Mintzer & Mattson, 2009; 
Mintzer, 2010). In addition, abrupt AED reduction or withdrawal may carry negative effects. 
Abrupt withdrawal of carbamazepine can increase sympathetic tone, especially during sleep, 
and may facilitate the occurrence of cardiac arrhythmias (Kennebäck et al., 1997; Hennessy et 
al., 2001). In addition, AED cessation/reduction may worsen seizure control leading to a 
higher risk of SUDEP. 
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As stated earlier, no individual AED has unequivocally been associated with an increased risk 
of SUDEP .In a meta-analysis of randomized controlled AED trials SUDEP incidence was 
found to be lower in those subjects with add-on treatment than in those receiving add-on 
placebo. The positive effects of AED use on seizure control, therefore, seem to outweigh the 
negative effects with respect to SUDEP. 
1.8 Comorbidity and SUDEP 
 The new category of SUDEP plus has been defined to include cases where comorbidity may 
in part contribute to SUDEP (Nashef et al., 2012). Comorbidity has come to be defined as a 
greater than co-incidental association of two conditions in the same individual (Téllez-
Zenteno et al., 2005 b; Ng et al., 2012). Major epidemiological studies have consistently 
shown that people with epilepsy have a higher prevalence of somatic comorbidity than those 
without epilepsy (Li et al., 1997; Gaitatzis et al., 2004; Strine et al., 2005; Téllez-Zenteno et 
al., 2005 b; Nuyen et al., 2006; Kobau et al., 2008; Elliott et al., 2009; Hinnell et al., 2010; 
Ivanova et al., 2010 a; Ivanova et al., 2010 b; Ottman et al., 2011; Eccher et al., 2012; 
Kaiboriboon et al., 2012; Kessler et al., 2012; Kadima et al., 2013; Selassie et al., 2014). 
 
In a recent nationwide study of sudden, unexpected death in the young, people with epilepsy 
had a significantly higher prevalence of comorbidity (23%) than the non-epilepsy population 
(5%) (Holst et al., 2013): p<0.001. Specifically, those with epilepsy had an increased risk of 
neurological disease (13 vs. 0.9%), psychiatric disease (2.7 vs. 0.1%), mental retardation (2 
vs. 0.1%), cerebral palsy (5 vs. 0.2%), and congenital disease (8 vs. 1%) (Holst et al., 2013). 
The increased burden of comorbidity, therefore, appears to be distributed across the entire 
spectrum of disease in the population with epilepsy without predilection for a specific 
condition or group of conditions.  
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Several biases have to be taken into account when addressing the association between 
epilepsy and comorbidity: people with epilepsy are consistently found to have a significantly 
lower socio-economic status, an important determinant of overall health and mortality, than 
the general population (Mackenbach et al., 1997; Mackenbach et al., 2000). In addition, 
people with epilepsy may be more likely to receive and report an additional diagnosis (i.e. 
comorbidity) due to their more intensive use of medical care services (“medical diagnosis 
bias”) (Ottman et al., 2011). Epilepsy may be associated with specific comorbid conditions, 
because these diseases (such as stroke or brain tumours) are the cause of the epilepsy (causal 
bias). Other conditions may be more prevalent in epilepsy because they result from the effects 
of epilepsy or its treatment (resultant bias) (Gaitatzis et al., 2004; Gaitatzis et al., 2012). 
Evidence suggests, however, that people with epilepsy have a significantly higher prevalence 
of somatic comorbidity even when taking these biases into account (Strine et al., 2005; 
Ottman et al., 2011; Neligan et al., 2011).  
 
Cardiovascular comorbidity is the most likely group of conditions to play a contributory role 
in SUDEP considering that it is the most prevalent cause of sudden death in the general 
population; in clinicopathological series, approximately 70% of all sudden deaths under 40 
years of age were ascribed to an anatomical cardiac cause, 20% to non-cardiac causes, and in 
10% the underlying cause could not be determined (sudden unexplained death) (Van der Werf 
et al., 2010). A further analysis of this last category (autopsy-negative sudden unexplained 
death victims) through non-targeted screening of genes associated with primary arrhythmia 
syndromes established a putative cardiac cause in over a third of individuals (Tester & 
Ackerman, 2007). Postmortem investigations may be negative, therefore, in a considerable 
number of SCAs in the general population (Puranik et al., 2005), and a negative postmortem 
is also the hallmark of SUDEP. 
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As stated before, non-lethal cardiac pathology was found in a considerable number of SUDEP 
victims at autopsy. Analogous to the predisposing factors discussed earlier, (occult) 
cardiovascular comorbidity may lower the threshold for ventricular arrhythmia in people with 
epilepsy, so that peri-ictal changes can trigger SUDEP.  
1.9 Model of SUDEP pathophysiology 
SUDEP is presumably the result of a complex interplay of various predisposing and peri-ictal 
factors: figure 1. Predisposing factors may increase the vulnerability of an individual with 
epilepsy to the (cardiovascular) effects triggered by CSs or rarely focal seizures with 
alteration of awareness. Risk factors generally reflect how many potentially lethal CSs an 
individual with epilepsy is likely to experience. When CSs occur they may set off three 
distinct pathophysiological cascades that may end in SUDEP if left unchecked. External 
circumstances may further aggravate peri-ictal (respiratory) distress, further contributing to 
SUDEP.  
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Figure 1: Pathophysiological model of SUDEP. 
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1.10 Preventive measures 
The fact that SUDEP usually occurs unwitnessed suggests that the (immediate) presence of a 
caregiver at the scene may be preventive. Timely medical intervention may save lives. The 
MORTEMUS study demonstrated that cardiopulmonary resuscitation was always started 
within 3 minutes after seizure end in those with non-fatal near-SUDEP and delayed for >10 
minutes or not performed in all SUDEP cases. Laypersons may also be able to prevent 
SUDEP; in a cohort with severe epilepsy and learning disabilities at a special residential 
school, all deaths were unwitnessed and occurred when the students were not under the close 
supervision of the school (Nashef et al., 1995 c). In addition, nocturnal supervision at home 
was found to be protective (Langan et al., 2005). Why untrained witnesses may be capable in 
part of preventing SUDEP is unclear; postictal attempts at arousal and body repositioning 
might be effective. For caregivers, the most crucial time to check-up on their family members 
with epilepsy is at night, as SUDEP predominantly occurs at night. There has, therefore, been 
increasing interest in developing new types of seizure-surveillance systems that may facilitate 
the recognition of nocturnal seizures. Seizures can be detected by registering changes in 
environmental noise, body and limb movements, HR, breathing pattern, blood oxygenation 
level, electrodermal activity or a combination of some of these modalities (van de Vel et al., 
2013). Most devices are capable of detecting CSs at rather high sensitivity; other seizure types 
are missed far more frequently (Poppel et al., 2013). Unfortunately, none of the current 
devices are fit for long-term monitoring of high-risk individuals in the home environment; the 
rate of false-positive alerts remains too high and most systems are too uncomfortable if worn 
continuously in everyday life (Carlson et al., 2009; Beniczky et al., 2013; Narechania et al., 
2013; van de Vel et al., 2013).   
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1.11 Improving AED treatment adherence  
An important goal of SUDEP counselling is treatment adherence. It is estimated that 
approximately 40% of those with epilepsy take fewer antiepileptic medications than 
prescribed (Davis et al., 2008). Non-compliance has been shown to be associated with a three-
fold higher mortality rate in people with epilepsy (Faught et al., 2008). It may lead to a higher 
CS frequency and thus increase the risk of SUDEP. The higher AED concentration variability 
found in the scalp hair of SUDEP victims provides further evidence for a link between 
treatment non-adherence and SUDEP. In other studies, however, no differences in AED 
treatment adherence were found between SUDEP victims and living controls with epilepsy 
(Nilsson et al., 2001; Walczak et al., 2001). There are, broadly speaking, two schools of 
thought about which people with epilepsy should receive SUDEP counselling, which is nicely 
illustrated in a paper contrasting the views of a Scottish and an American epileptologist 
(Brodie & Holmes, 2008). The Scottish physician provides each of his patients with both 
written and oral information preferably shortly after diagnosis, while the American physician 
favours a more individualized approach. He communicates SUDEP risk at a later stage only to 
those who ask about epilepsy-related death or are estimated to be at high-risk. This contrast is 
also evident in national epilepsy guidelines: the UK and Scottish epilepsy guidelines espouse 
“routine disclosure”, whereas the recently published Dutch guideline appears to favour 
“tailored disclosure” (NICE clinical guideline 137, NVN Richtlijn Epilepsie). When asked, 
the majority of patients and family members prefer to be told about SUDEP at the time of 
diagnosis (Gayatri et al., 2010; Ramachandrannair et al., 2013). In some individuals, however, 
this may inadvertently cause stress culminating in a higher seizure frequency (Lathers & 
Schraeder, 2006; Yuen et al., 2007; Brodie & Holmes, 2008).  
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Most healthcare professionals appear to favour tailored disclosure: in surveys the majority of 
neurologists (82 to 90%) informs only specific individuals of SUDEP, while approximately 5 
to 10% of doctors routinely mention SUDEP, and 7 to 10% never discuss the subject at all 
(Morton et al., 2006; Vegni et al., 2011; Abdalla et al., 2013; Friedman et al., 2014). In a 
survey among US neurologists (Friedman et al., 2014), important reasons not to discuss 
SUDEP were the estimated small risk of SUDEP in a particular individual (53.6%), fear of 
negatively affecting mood or quality of life of people with epilepsy (32.8%), and lack of 
proven prevention (33.8%). A clear disadvantage of tailored disclosure is that it may come too 
late for a significant number of people, since SUDEP may also affect those with a recent 
diagnosis or those with infrequent seizures (Hanna, 1997). Detailed data are not available to 
the best of my knowledge, but the collection of stories by bereaved relatives at least gives the 
impression that it is not rare: 11/37 (30%) of SUDEP cases had a similar presentation 
(SUDEP: continuing the global conversation, 4
rd
 edition). In addition, many people with 
epilepsy may, by this stage, have already absorbed information on the internet that may not 
always be accurate: the interest in SUDEP as measured by Google search terms has increased 
enormously in recent years (Brigo et al., 2014).  
1.12 Summary  
SUDEP is the most common seizure-related cause of death. To establish the diagnosis no 
anatomical or toxicological cause of death should be found at autopsy. Most deaths are 
unwitnessed and occur at night. SUDEP predominantly affects people with refractory epilepsy 
in the aftermath of a CS. The strongest SUDEP risk factors are associated with poor seizure 
control. Achieving seizure freedom is, therefore, the best strategy to prevent SUDEP.  
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Ictal recordings have demonstrated three potential seizure-related pathomechanisms of 
SUDEP: the sequence of PGES followed by cardiorespiratory arrest; central/obstructive 
apnoea; cardiac arrhythmias. Predisposing factors may increase the vulnerability for seizure-
related (cardiac) effects. Comorbidity (especially occult cardiovascular disease) may play a 
contributory role. Specific preventive strategies are not yet available: nocturnal supervision is 
a promising measure if stronger scientific evidence of its effectiveness is produced. An 
important goal of SUDEP counselling is to promote treatment adherence. Disagreement 
remains on the most optimal counselling strategy: routine vs. tailored disclosure.   
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2. Aims of the studies 
 
3.1 Prospective, community-based, case-control study of epilepsy as a risk factor for sudden 
cardiac arrest due to ECG-confirmed VT/VF  
 
a) To assess whether having active epilepsy is a risk factor for sudden cardiac arrest due to ECG-
confirmed VT/VF in the general population 
 
3.2 Prospective, community-based case-control study of the circumstances and risk factors of 
sudden cardiac arrest due to ECG-confirmed VT/VF in epilepsy  
 
a) To describe the causes, circumstances, and characteristics of SCA due to VT/VF in epilepsy and review 
them against (near)-SUDEP criteria 
b) To compare patient and event characteristics in people with SCA due to VT/VF with and without 
epilepsy and determine whether the aetiology of SCA differs between these two groups  
c) To search for determinants of SCA due to VT/VF risk in epilepsy 
 
3.3 Retrospective assessment of PGES >20s in people with multiple CSs recorded on video-
EEG in two epilepsy referral centres  
 
a) To assess the intraindividual consistency of PGES >20s in people with multiple CSs and reconcile 
previous conflicting studies on the clinical value of this EEG-characteristic as a predictor of SUDEP  
b) To analyse co-factors that facilitate the occurrence of PGES >20s and gain a better understanding of its 
underlying cause  
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3. Methods 
 
3.1 Prospective, community-based case-control study of epilepsy as a risk factor for sudden 
cardiac arrest due to ECG-confirmed VT/VF    
Study design 
This investigation was conducted in a community-based study in the Netherlands: the 
Amsterdam Resuscitation Studies (ARREST). ARREST was designed to study the 
determinants of SCA in the general community (Bardai et al., 2011; Bezzina et al., 2010; 
Arking et al., 2011; Blom et al., 2014). Data were retrieved in the study period July 2005 to 
January 2010. This study was conducted according to the principles expressed in the 
Declaration of Helsinki. Written informed consent was obtained from all participants who 
survived the SCA. The Medical Ethics Committee of the Academic Medical Centre in 
Amsterdam approved the use of data from patients who did not survive the SCA, and 
approved this study (Appendix 1). 
Design of ARREST 
ARREST is a prospective, community-based study aimed at establishing the genetic and 
clinical determinants of SCA in the general community in a contiguous region (urban and 
rural communities, ~2.4 million inhabitants) of the Netherlands. The ARREST research 
group, in collaboration with all Emergency Medical Services (EMS) in the study region, 
prospectively collects data of all cardiopulmonary resuscitation efforts using a mandatory 
multiple-source notification system (involving personnel of dispatch centres, ambulance 
services and all 14 area hospitals). This ensures a complete coverage of the study region and 
inclusion of >95% of all patients with out-of-hospital SCA (Bardai et al., 2011). 
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The data collection infrastructure used records all out-of-hospital SCA parameters, from 
ambulance dispatch to discharge from the hospital or to death. Cases are included as follows. 
After each suspected out-of-hospital SCA, the dispatch centre notifies the study centre 
(providing information on the place and circumstances of SCA). Ambulance personnel are 
obliged by protocol to send the ECGs by modem to the study centre directly after 
resuscitation, and to call the study centre to provide extra information (e.g., whether SCA 
onset was witnessed, whether basic life support was provided before arrival of ambulance 
personnel, whether the patient died at the resuscitation site or was transported to a hospital). If 
an automated external defibrillator was used, the study centre is notified by the dispatch 
centre, ambulance personnel and/or the user of this device (most automated external 
defibrillators in the study region carry a label requesting that the study centre is notified after 
the device has been used). ARREST personnel visit the resuscitation site upon notification to 
collect the ECG recording from the device. The electrocardiograms are stored and analysed 
with dedicated software (Code Stat Reviewer 7.0, Physio Control, Redmond, Washington). 
Rhythms are categorized as shockable (VT/VF) or non-shockable (asystole or pulseless 
electrical activity). Data items concerning the cardiopulmonary resuscitation procedure are 
stored according to the Utstein recommendations (Jacobs et al., 2004). ECG recordings from 
the ambulance monitor/defibrillator or automated external defibrillator are used to determine 
whether VT/VF had occurred. SCA cases are defined as patients with cardiac arrest in an out-
of-hospital setting with ECG-documented VT/VF. Patients with an obvious non-cardiac cause 
of VT/VF (e.g., trauma, intoxication, drowning, suicide) or those in whom no ECG-
documented evidence of VT/VF was available (these patients typically had asystole or 
pulseless electrical activity) are excluded. Medical histories are obtained from the general 
practitioner (GP) and/or hospital (Appendix 2). 
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In the Netherlands, every individual has a GP who acts as gatekeeper for all medical care. 
Thus GPs have a full overview of all diagnoses made by medical specialists. Complete 
medication histories of the year preceding VT/VF are obtained from the community 
pharmacies. Controls who had never experienced VT/VF were randomly drawn from the 
same source community as cases, using the HAG-net-AMC database of GPs. HAG-net-AMC 
contains the complete medical records of ~60,000 patients from a large group of GPs in the 
study area (van Doormaal et al., 2010).
 
Each case was matched with up to 5 controls by age (± 
5 years), gender, and index date (date of VT/VF in cases; in the accompanying controls data 
acquired after this index date was excluded from analysis). 
Definition of active epilepsy and risk factors  
We ascertained which cases and controls had a diagnosis of epilepsy; all GP records with the 
terms “epilepsy” or “epileptic seizure” in the diagnosis list were reviewed by two 
epileptologists (RD Thijs, JW Sander). Epilepsy was confirmed if the diagnosis was 
established by a neurologist in accordance with national guidelines (NVN Richtlijn 
Epilepsie). Additional information was requested from the attending neurologist if needed. 
Only people with a diagnosis of active epilepsy were included in the analysis as having 
epilepsy. Active epilepsy was defined as current treatment with AEDs or seizures within the 
previous 2 years (Fisher et al., 2005). For all cases and controls, we also assessed the 
following established risk factors for VT/VF: ischaemic cardiovascular disease, heart failure, 
hypertension, diabetes mellitus and hypercholesterolaemia. This was established from GP 
records based on a formal diagnosis, or by use of medication. 
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Statistical analysis 
A conditional logistic regression model was used to estimate the association of various 
cofactors, including epilepsy, with VT/VF. Univariable analysis (matched for age, gender, 
and index date) was employed, as well as two models: multivariable analysis including all 
variables for which p <0.1 in the univariable analysis; multivariable analysis including all 
variables (other than epilepsy) which had p<0.1 in univariable analysis, and which changed 
the point estimate of the univariable association between epilepsy and VT/VF by >5%; the 
only such covariates were ischaemic cardiovascular disease, diabetes, and heart failure. 
Subanalyses were performed using multivariable logistic regression, adjusting for age, gender 
and risk factors. 
 
3.2 Prospective, community-based case-control study of the circumstances and risk factors of 
sudden cardiac arrest due to ECG-confirmed VT/VF in epilepsy   
Design & setting 
Two case-control studies were conducted using one case group and two control groups of 
individuals ≥12 years of age who were drawn from two community-based databases: cases 
were defined as people with epilepsy who suffered VT/VF. They were compared to those 
without epilepsy who experienced VT/VF (VT/VF controls) and to individuals with epilepsy 
who had not suffered VT/VF (epilepsy controls). Cases and VT/VF controls were drawn from 
the Amsterdam Resuscitation Studies (ARREST) registry, while epilepsy controls were drawn 
from the Out-Patient Population-based Epilepsy Cohort (OPPEC). ARREST was approved by 
the Medical Ethics Committee of the Academic Medical Centre (AMC) in Amsterdam and 
OPPEC by the Medical Ethics Committee of the University Medical Centre Utrecht (UMC). 
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In ARREST, written informed consent was obtained from all survivors of VT/VF and the use 
of observational data from non-survivors was allowed by the Medical Ethics Committee. In 
OPPEC, all participants provided written informed consent (Appendix 3, 4). 
ARREST registry 
The methodology of ARREST has been explained in detail in the methods section of study 1 
(Blom et al., 2014).  
OPPEC database 
OPPEC is a cross-sectional, community-based study, designed to assess the clinical, 
demographic, genetic, and pharmacological determinants of AED treatment response in an 
out-patient cohort with epilepsy in a (sub)urban region in the centre of the Netherlands (het 
Gooi-Utrecht) (Wassenaar et al., 2013; Wassenaar et al., 2014): appendix 5, 6. Subjects were 
recruited during an 18-month period (July 2010 to December 2011) from the databases of 30 
pharmacies, covering a population of about 250,000 inhabitants. Those who had at least two 
prescriptions for any AED dispensed in the previous two years (indicating long-term use) 
were asked to participate (Appendix 5): response rate 30% (Wassenaar et al., 2013).   
Cases 
People with SCA due to VT/VF and a presumed diagnosis of epilepsy based on the terms 
“epilepsy” or “epileptic seizure” listed in their GP or hospital records were extracted from all 
subjects enrolled in ARREST with complete GP and hospital records during a 7-year period 
(July 1st 2005 to July 31st 2012). Only those individuals with a confirmed diagnosis of active 
epilepsy were subsequently included in the study as cases (Appendix 6). To determine 
whether those with a confirmed diagnosis of active epilepsy could be classified as SUDEP, 
patient and event characteristics were evaluated by two neurologists with a special interest in 
epilepsy (JW Sander, RD Thijs) and one cardiologist (HL Tan). 
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In cases of disagreement, the reviewers discussed to reach consensus. SUDEP was defined as 
sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death, 
occurring in benign circumstances, in an individual with epilepsy, with or without evidence 
for a seizure and excluding documented status epilepticus (seizure duration ≥30 min or 
seizures without recovery in between), in which postmortem examination does not reveal a 
cause of death (Nashef et al., 2012). Cases without autopsy results were classified as either 
probable or possible SUDEP depending on whether a potentially competing cause of death 
was found after cardiac evaluation. Near-SUDEP was defined as “an individual with epilepsy 
who survived resuscitation for more than 1 hour after a cardiorespiratory arrest that has no 
structural cause identified after investigation” (Nashef et al., 2012). 
Controls 
The VT/VF control group consisted of all those with VT/VF without a history of epilepsy in 
ARREST in 2007-2008 with complete GP and hospital records. Each case was also matched 
by age (±5 years) and gender to three epilepsy controls from OPPEC. 
Definition of active epilepsy 
The data of all people with a presumed diagnosis of epilepsy in ARREST and of all 
participants in OPPEC was reviewed by two members of the OPPEC diagnostic confirmation 
team who are neurologists with a special interest in epilepsy (F Leijten and GJ de Haan), who 
independently rated the likelihood of this diagnosis on a scale of 0-100% (Wassenaar et al., 
2013; Wassenaar et al., 2014). People with an average score of ≥80% were considered to have 
epilepsy. Only individuals with active epilepsy, which was defined as current treatment with 
AEDs or a seizure within the previous two years were included as having active epilepsy 
(Fisher et al., 2005). 
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Collection of clinical information 
The following clinical data were obtained from GP, pharmacy and hospital records in 
ARREST and OPPEC: epilepsy characteristics (aetiology, seizure freedom in the last two 
years, age of onset and duration of epilepsy), intellectual disability (yes/no), cardiovascular 
risk factors (hypertension, hypercholesterolaemia, diabetes mellitus, and stroke/TIA), and 
clinically relevant heart disease (yes/no). Cardiac pathologies included ischaemic (myocardial 
infarction, heart failure), valvular, or congenital/inherited heart disease (aortic coarctation, 
hypertrophic obstructive cardiomyopathy) with or without cardiac arrhythmia (atrial 
fibrillation, atrioventricular block). Complete medication histories of the year before VT/VF 
(ARREST) or inclusion in the study (OPPEC) were obtained from community pharmacies. 
We defined three drug categories: 1) QT-prolonging medication (www.azcert.org) including 
the AEDs phenytoin and felbamate (Feldman & Gidal, 2013), 2) depolarization-blocking 
drugs (www.brugadadrugs.org) including the AEDs carbamazepine, oxcarbazepine, 
phenytoin, and lamotrigine (Rogawski & Löscher, 2004), and 3) cardiovascular drugs (β-
adrenoreceptor blockers, calcium channel antagonists, angiotensin-converting enzyme 
inhibitors, diuretics, angiotensin-II receptor blockers, nitrates, platelet aggregation inhibitors, 
and/or statins). Drugs may belong to more than one category. 
Statistical analysis  
Patient and event characteristics were described and compared between cases and VT/VF 
controls using χ2 statistics (Pearson/Fisher’s Exact where appropriate) for categorical data and 
the Student’s t-test/Mann Whitney U test for continuous data. Variables found significant in 
univariable analysis were included in a logistic regression model to determine whether the 
characteristics of VT/VF in cases and VT/VF controls differed. 
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To identify risk factors for VT/VF (cases vs. epilepsy controls), univariable and multivariable 
conditional logistic regression was employed, thereby accounting for matched data. In this 
model, Firth correction for rare events was used for seldom occurring variables (intellectual 
disability). P-values of <0.05 were considered to be significant. Statistics were performed in 
SPSS (cases vs. VT/VF controls; version 17.0 for Windows, Chicago IL, USA) and in R 
(cases vs. epilepsy controls 2; R statistical package, version 3.10, package clogit and logistf, 
version 1.10).  
 
3.3 Retrospective assessment of PGES >20s in people with multiple CSs recorded on video-
EEG in two epilepsy referral centres 
Sample selection 
We reviewed reports of digital video-EEGs from two tertiary epilepsy referral centres (Bonn 
and Heemstede) from the period 2003 to 2011 and selected people ≥15 years old who had two 
or more CSs recorded on long-term monitoring. The study size was determined by the number 
of available video-EEGs. This study was approved by the ethics committees at both sites; 
because of its observational nature, informed consent was not required at either site 
(Appendix 7). 
Collection of variables 
We collected data on: gender, age, presence of intellectual disability (yes/no), epilepsy 
classification (structural/metabolic vs. unknown), lesion on MRI (yes/no), age of onset, 
duration of epilepsy, frequency of CSs, AED regimen (prior to admission and for each 
subsequent monitoring day), state of wakefulness prior to seizure onset (awake/asleep), sleep 
stage prior to seizure onset (REM, NREM I-III), localization of EEG seizure onset 
(temporal/extratemporal), duration of the tonic and tonic-clonic phase as well as entire seizure 
duration.  
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Tapering was defined as any reduction of the total AED drug load during the recording 
period, compared with the regimen prior to admission. The overall drug load (prior to 
admission and each subsequent monitoring day) was estimated as the sum of the prescribed 
daily dose (PDD)/defined daily dose (DDD) ratios for each AED (Canevini et al., 2010). HR 
was measured during the last minute before seizure onset and the first minute after seizure 
end. This study was approved by the ethics committees at both sites; due to its observational 
nature informed consent was not required at either site.  Conventional scalp EEG recordings 
(International 10–20 System) (Stellate Harmonie, Stellate Systems, Montreal, QC, Canada; 
Schwarzer GmbH/Natus, Germany) were performed at a sampling rate of 200 Hz. A modified 
lead-I electrocardiogram (ECG) (Stellate Harmonie; Schwarzer GmbH/Natus) (adhesive 
electrode(s) placed below the clavicle) was simultaneously recorded. Random numbers were 
assigned to all individual seizures in order to blind patient status. Two board-certified clinical 
neurophysiologists (A Gaitatzis, RD Thijs) independently analysed the presence or absence of 
PGES>20s and duration of the tonic phase in all CSs. PGES was defined as the immediate 
postictal (within 30s), generalized absence of EEG activity >10 µV in amplitude, allowing for 
muscle, movement, breathing, and electrode artefacts (Lhatoo et al., 2010). 
 
Only PGES of >20s after CSs were scored as these were previously associated with increased 
SUDEP risk (Lhatoo et al., 2010). Due to privacy rules, video-recordings from Bonn could 
not be evaluated off-site, thus PGES was assessed using only EEG recordings in this site. In 
Heemstede both EEG and video were assessed. The onset of the tonic phase was defined as 
the occurrence of bilateral, symmetrical or asymmetrical, continuous muscle activity 
obscuring EEG background activity. Muscle activity was evaluated in the frontotemporal 
regions using a bipolar montage. The end of the tonic and onset of the clonic phase was 
defined by a sustained pattern of bilateral and synchronous bursts of muscle artefact with 
burst intervals ≥150 ms, and absence of muscle activity between bursts.   
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Statistical analysis 
The proportion of people in whom PGES consistently occurred (presence or absence of PGES 
>20s in all CSs) was calculated and related to the number of recorded CSs. Associations 
between PGES >20s and person- or seizure-specific variables were assessed with Fisher’s 
exact probability test, chi-square, or Mann-Whitney U tests, where appropriate. A mixed 
linear regression model was used to determine which variables were independently associated 
with PGES >20s after correction for individual effects and the varying number of seizures 
contributed by each person. Only those variables with p<0.05 at univariable analysis were 
entered and adjustments for multiple comparisons were made using the Holms-Bonferroni 
method. Statistical analysis was performed with SPSS (version 17 Chicago, IL, U.S.A.), and 
STATA 12 software (StataCorp LP, TX, USA).  
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4. Results 
 
4.1 Prospective, community-based case-control study of epilepsy as a risk factor for sudden 
cardiac arrest due to ECG-confirmed VT/VF    
 
We identified 1019 cases with VT/VF with an available medical and/or medication use 
history prior to the event; these cases were matched with 2834 controls. Mean age was 63.5 
years in cases (76.5% male), and 58.3 years in controls (68.5% male). We confirmed that the 
established risk factors for VT/VF were also associated with VT/VF in our study: table 6. 
Twelve cases (1.2%) and 12 controls (0.4%) had a diagnosis of active epilepsy at index date. 
Epilepsy was associated with an almost three-fold increased risk for VT/VF (adjusted OR 2.9 
[95%CI 1.1, 8.0], p= 0.034, model 2, table 7). Sub-analyses suggested that the adjusted 
VT/VF odds are higher in people with epilepsy aged <50 years (N=4, adjusted ORyoung 4.6, 
p=0.210) compared with people aged ≥50 years (N=8, adjusted ORold 2.4, p=0.128), and in 
females (N=5, adjusted ORfemales 4.6, p=0.044) compared with males (N=7, adjusted ORmales 
2.0, p=0.309). Epilepsy characteristics of cases and controls are listed in table 8.  
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Table 6: demographics and distribution of covariates in cases with sudden cardiac arrest, controls without sudden 
cardiac arrest, and cases with sudden cardiac arrest and epilepsy  
 
 Cases 
n=1019 
Controls 
n=2834 
Cases with epilepsy 
n=12 
Gender    
Male 780 (76.5) 1855 (68.5) 7 (58.3) 
Female 239 (23.5) 979 (31.5) 5 (41.7) 
Mean age, years (SD) 63.5 (13.7) 58.3 (14.5) 60.0 (16.0) 
Covariates    
Ischaemic CVD 443 (43.5) 141 (5.0) 3 (25 ) 
Stroke/TIA 49 (4.8) 71 (2.5) 1 (8.3) 
Hypertension 529 (51.9) 433 (15.3) 7 (58.3) 
Diabetes mellitus 219 (21.5) 294 (10.4) 1 (8.3) 
Heart failure 199 (19.5) 29 (1.0) 4 (33.3) 
Hypercholesterolemia 290 (28.5) 170 (6.0) 5 (27.8) 
Data are expressed as number (%) unless otherwise indicated. CVD = cardiovascular disease. TIA = transient 
ischaemic attack. SD, Standard deviation. 
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Table 7: multivariable analysis of risk factors for ECG-confirmed sudden cardiac arrest  
Abbreviations as in table 6.  
*Odds Ratios estimated with conditional logistic regression, matched by age, gender, and index date. 
** Model 1: Odds Ratios estimated with conditional logistic regression, matched by age, gender, and index date. 
All covariates that were significantly associated with ventricular tachycardia/fibrillation (at a p<0.1 level) were 
included in the regression analyses (ischaemic cardiovascular disease, stroke/transient ischaemic attack, 
hypertension, diabetes mellitus, heart failure and hypercholesterolemia). 
*** Model 2: Odds Ratios estimated with conditional logistic regression, matched by age, gender, and index 
date. All covariates that were significantly associated with ventricular tachycardia/fibrillation (at a p<0.1 level) 
were included in the regression analyses if they changed the point estimate of the association between epilepsy 
and sudden cardiac arrest due to ventricular tachycardia/fibrillation by >5%; the only such covariates were 
ischaemic cardiovascular disease, diabetes, and heart failure. 
  
 OR*(95% CI) 
p-value 
Model 1 OR** 
(95% CI) 
p-value 
Model 2 OR*** 
(95% CI) 
p-value 
Univariable 
analysis 
p-value 
Epilepsy 3.3 (1.4-7.5) 
 
2.8 (0.9-9.0) 
p=0.076 
2.9 (1.1-8.0) 
p=0.034 
p=0.005 
Ischaemic CVD 11.2 (8.8-14.3) 6.7 (5.0-8.8)  
p<0.001 
9 (7-11.7) 
p<0.001 
p<0.001 
Stroke/TIA 1.7 (1.1-2.5) 0.8 (0.4-1.6) 
p=0.53 
Not applicable p=0.012 
Hypertension 5.8 (4.8-7.0) 3.7 (2.9-4.7)  
p<0.001 
Not applicable p<0.001 
Diabetes mellitus 2.0 (1.6-2.4) 0.8 (0.6-1.1)  
p=0.1 
1.2 (0.9-1.5)  
p=0.2 
p<0.001 
Heart failure 20.5 (13.1-32.1) 9.9 (5.8-17)  
p<0.001 
12.9 (7.9-21.1) 
p<0.001 
p<0.001 
Hypercholesterolemia 5.6 (4.5-7.0) 2.9 (2.2-3.9) 
p<0.001 
Not applicable p<0.001 
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Table 8: distribution of epilepsy and cardiovascular characteristics in cases with sudden cardiac arrest and 
epilepsy and controls with epilepsy  
 
 Cases (n=12) Controls (n=12) 
Epilepsy aetiology 
    Structural/metabolic 
    Unknown¶  
    Genetic   
 
8 (67%)  
4 (33%) 
0 (0%) 
 
5 (42%) 
5 (42%) 
2 (17%) 
Seizure type
1
 
   Convulsive seizures 
   Focal seizures with alteration of awareness  
   Focal seizures without loss of awareness 
   Absence seizures 
 
9 
3 
1 
1 
 
10 
4 
1 
0 
Age at onset of epilepsy, yr (Median, Range) 46.5 (9-79) 42 (6-63) 
Duration of epilepsy, yr (Median, Range) 11 (0-52) 17.5 (2-33) 
Polytherapy (>1 antiepileptic drug) 
   Yes 
   No 
 
4 (33%)  
8 (67%)  
 
3 (25%) 
9 (75%) 
Antiepileptic drug use
1
 
    Valproic acid 
    Carbamazepine 
    Phenytoin 
    Phenobarbital 
    Topiramate 
    Clobazam 
    Lamotrigine 
 
7 
4 
3 
1 
1 
1 
0 
 
4 
5 
2 
1 
1 
0 
2 
History of underlying heart disease 
    Ischaemic heart disease 
    Heart failure 
    Structural heart disease
2
 
 
3 (25%) 
4 (25%) 
3 (25%) 
 
2 (17%) 
0 (0%) 
1 (8%) 
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    No history 4 (33%) 9 (75%) 
Cardiac medication use 
   Platelet aggregation inhibitors 
   Antihypertensives
3
 
   Antiarrhythmic agents
4
 
   Statins 
 
5 
8 
1 
5 
 
1 
2 
0 
0 
Evidence of acute myocardial infarction
5 
    Postmortem
6
  
    Clinical
7 
    Not Available 
 
3  
8 
4  
 
Deceased before hospital discharge 
    Yes 
    No 
 
12 (100%) 
0 (0%) 
 
 
1
Some patients had more than one type of seizure/antiepileptic drug/cardiac drug, therefore the number of 
seizure types/ antiepileptic drug used exceeds the total number of patients. 
2
Valve abnormalities and/or aortic 
coarctation. 
3
Diuretics, β-adrenoceptor blockers, calcium channel blockers, angiotensin converting enzyme 
inhibitors, angiotensin II receptor antagonists. 
4 
Amiodarone. 
5
 Patients may fall in more than one category. 
6
Evidence of acute myocardial infarction found during autopsy. 
7
Evidence of acute myocardial infarction found 
during clinical diagnosis and treatment of ventricular tachycardia/fibrillation (ECG, cardiac enzymes, coronary 
angiography). 
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4.2 Prospective, community-based case-control study of the circumstances and risk factors of 
VT/VF in epilepsy  
Cases 
During the study period 2584 people with VT/VF were enrolled, 39 of whom had a presumed 
diagnosis of epilepsy: figure 2. After exclusions due to inaccurate diagnosis (n=13), 
insufficient information to validate a diagnosis (n=6), or inactive epilepsy (n=2), 18 cases 
(mean age 57 years, 67% male) with VT/VF and active epilepsy were included in the final 
analysis: tables 9-11. The majority of cases from my first thesis study (10/12; 83%) were also 
included in this cohort.  
 
An underlying cardiovascular cause of VT/VF was found in 10 cases (56%): acute myocardial 
infarction, hypertrophic obstructive cardiomyopathy, and co-incidence of transient cardiac 
ischaemia and drug-induced QTc-prolongation. In five other cases (28%) an underlying 
cardiovascular cause was presumed: they had recent-onset cardiac symptoms (severe 
recurrent chest pains <1 week before VT/VF) or clinically relevant pre-existing heart disease. 
These suspicions could, however, not be confirmed as all died before hospital admission and 
autopsy was not performed. In the three remaining individuals (16%) no definite 
cardiovascular cause of VT/VF could be established after further investigations. In the first 
case, VT/VF was attributed to a high fever (42°C) secondary to autopsy-confirmed bilateral 
pneumonia. It did, therefore, not fulfil SUDEP criteria. The remaining two individuals died a 
few days later in the hospital after initial successful resuscitation and did not have autopsy: 
one of these, an apparently seizure-related case was classified as probable near-SUDEP in 
view of a normal comprehensive diagnostic work-up. In this case prolonged convulsive 
movements were reported by witnesses and rectal diazepam was administered. 
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The second case, apparently non-seizure-related, was classified as having possible near-
SUDEP case: slight ECG abnormalities without cardiac enzyme changes were found, and 
these were considered insufficient evidence for a diagnosis of myocardial infarction. 
 
Figure 2: Selection of cases with ventricular tachycardia/fibrillation and epilepsy 
 
 
2584 individuals of ≥12 years of age with ventricular tachycardia/fibrillation and complete GP or hospital 
records were enrolled in ARREST in the period from July 1st 2005- July 31st 2012. From this cohort 18 cases 
with active epilepsy were selected for this study after exclusions for various reasons. In 13 individuals a 
diagnosis of epilepsy was ruled out: data entry errors (n=3), alcohol-induced seizures (n=3), non-epileptic 
transient loss of consciousness (n=3), single seizure (n=3), revision of epilepsy diagnosis (n=1). In some 
individuals (n=6) there was insufficient information either to confirm or to rule out a diagnosis of epilepsy. In 
these cases, either the attending general practitioner and/or neurologist could not be located (n=4), or the 
diagnosis was established ≥20 years ago and full medical records were no longer available (n=2). 
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Table 9: characteristics of people with ventricular tachycardia/fibrillation and epilepsy (n=18)  
  
Male gender 12 (67%) 
Age, years  
0-20  1 (5.5%) 
21-40  2 (11%) 
41-60  7 (39%) 
61-80  7 (39%) 
>80  1 (5.5%) 
History of brain dysfunction or injury¶  
Intellectual disability 5 
Traumatic brain injury 3 
Stroke 4 
Cerebral asphyxia 2 
Cerebral abscess 1 
None  7 
Witnessed onset of SCA 13 (72%) 
Prolonged convulsive movements 2 (11%) 
Clinically relevant pre-existent heart disease ¶#  
Ischaemic 4 
Valvular 2 
Congenital 3 
Atrial fibrillation 2 
3
rd
 degree atrioventricular block 1 
Underlying cause of sudden cardiac arrest  
Acute myocardial infarction 8 (44%) 
Other cardiovascular cause* 2 (11%) 
Presumed cardiovascular cause  5 (28%) 
No cardiovascular cause established after further 
investigations**  
3 (17%) 
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Diagnostic work-up¶  
Ancillary tests  13 
Autopsy 4  
No ancillary tests or autopsy 5 
Evidence of acute myocardial infarction¶  
Ischaemic ECG 5 
Elevated cardiac enzymes 4 
Regional wall motion abnormalities on echocardiogram 1 
Percutaneous coronary intervention 3 
Coronary artery bypass graft 1 
Autopsy 3 
Deceased before hospital discharge 
Yes 
No 
 
14 (78%) 
4 (22%) 
¶People may fall under more than one category.  
#Clinically relevant heart disease was defined as ischaemic (myocardial infarction, heart failure), valvular, or 
congenital heart disease (aortic coarctation, hypertrophic obstructive cardiomyopathy) with or without cardiac 
arrhythmia (atrial fibrillation, 3
rd
 degree atrioventricular block). *Hypertrophic obstructive cardiomyopathy, 
transient cardiac ischaemia and drug-induced QTc-prolongation. **Fever-associated ventricular 
tachycardia/fibrillation secondary to bilateral pneumonia, probable near-SUDEP, possible near-SUDEP.  
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VT/VF characteristics in people with and without epilepsy 
In the 18 cases and 470 VT/VF controls general and event characteristics were analysed: table 
10. Acute myocardial infarction was the most common cause of VT/VF in both groups. In 
cases, events generally occurred at younger age (mean age 57 vs. 64 yr, p=0.023), and SCA 
onset was less likely to be witnessed (72 vs. 89%, p=0.048) and more likely to occur at/near 
home (89 vs. 58%, p=0.009) than in controls. In addition, the prevalence of congenital heart 
disease was higher in cases (17 vs. 1%, p=0.002). In multivariable analysis, these four 
variables were independently associated with SCA due to VT/VF in epilepsy: table 10. 
Epilepsy and other characteristics in people with and without VT/VF  
General and epilepsy characteristics were compared in 18 cases and 54 epilepsy controls: 
table 11. Cases were more likely to have clinically relevant heart disease (50 vs. 15%, 
p=0.005) and intellectual disability (28 vs. 2%, p<0.001). In multivariable analysis, these 
variables were independently associated with VT/VF in epilepsy: table 11. 
 
Table 10: Comparison of people with ventricular tachycardia/fibrillation and epilepsy and controls with 
ventricular tachycardia/fibrillation  
 Cases 
 (n=18) 
VT/VF controls 
(n=470) 
Crude OR (95% CI) Adjusted OR (95% CI) 
Demographics:     
Male gender 12 (67%) 376 (80%) 0.500 (0.183-1.367)  
Mean age, yr (SD) 57 (16.9) 64 (14.0) 0.965 (0.936-0.995) 0.961 (0.931-0.993) 
Cardiac risk factors:     
History of myocardial infarction 4 (22%) 136 (29%) 0.702 (0.227-2.170)  
Congenital heart disease 3 (17%) 5 (1%)# 18.560 (4.056-84.937) 19.806 (3.461-113.343) 
Stroke/transient ischaemic 
attack 
4 (22%) 48 (10%)# 2.506 (0.793-7.919)  
Hypertension 10 (56%) 207 (44%)  1.588 (0.616-4.096)  
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Hypercholesterolaemia 5 (28%) 156 (33%)# 0.772 (0.270-2.203)  
Diabetes mellitus 1 (6%) 99 (21%) 0.220 (0.029-1.677)  
Circumstances of event:     
Witnessed onset 13 (72%) 415 (89%)# 0.326 (0.112-0.951) 0.303 (0.096-0.954) 
Event during night-time¶  2 (11%) 83 (18%) 0.583 (0.131-2.583)  
Event at/near home 16 (89%) 272 (58%) 5.824 (1.324-25.617) 6.620 (1.420-30.868) 
Underlying cause of event:      
Acute myocardial infarction 8 (62%)□ 247 (57%)□ 1.192 (0.384-3.703)  
Deceased before  hospital 
discharge 
    
All SCA 14 (78%) 264 (56%)  2.731 (0.886-8.421)  
SCA¶  
(onset before EMS arrival )  
13 (76%) 255 (60%) 2.179 (0.699-6.796)  
Dichotomous data are expressed as n (%) and continuous data as mean (standard deviation). #These variables 
were unknown in 1-3 people with ventricular tachycardia/fibrillation without epilepsy: congenital heart disease 
(1), stroke/transient ischaemic attack (1), hypercholesterolaemia (1), and presence of witnesses (3). □The 
underlying cause of ventricular tachycardia/fibrillation was undetermined in 5 people with epilepsy and 39 
individuals without epilepsy. In 17 individuals with epilepsy and 426 people without epilepsy SCA onset 
occurred in the absence of EMS personnel. Night-time was defined as the period between 23:00 and 07:00. 
Associations were expressed as odds ratios with 95% confidence intervals. Significant associations are in bold. 
All covariates that significantly differed between cases and VT/VF controls (p<0.05) (age, presence of 
congenital heart disease, presence of witnesses, and occurrence of VT/VF at home) were entered in a logistic 
regression model to calculate adjusted odds ratios. 
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Table 11: Comparison of people with epilepsy and ventricular tachycardia/fibrillation and controls with epilepsy 
 Cases 
(n=18) 
Epilepsy 
controls 
(n=54) 
Univariable OR 
(95% CI) 
Multivariable OR 
(95% CI) 
Demographics:     
Male gender 12 (67%) 36 (67%) n.a n.a 
Mean age, yr (SD) 57 (16.9) 57.3 (15.9) n.a n.a 
Intellectual disability# 5 (28%) 1 (2%) 43.31 (2.07-908.26) 41.35 (1.35-1264.8) 
Epilepsy characteristics     
Structural/metabolic aetiology  11 (61%) 24 (44%) 1.87 (0.65-5.42) n.a 
Recent seizure 8 (44%) 31 (57%) 0.56 (0.18-1.75) n.a 
Age of onset, years 38 (1-79) 39.5 (1-79) 0.99 (0.96-1.02) n.a 
Duration of epilepsy, years 13 (0-67) 11.5 (0-76) 1.01 (0.98-1.04) n.a 
Cardiac risk factors:      
Clinically relevant heart disease  9 (50%) 8 (15%) 6.84 (1.79-26.18) 6.87 (1.29-36.56) 
Stroke/transient ischaemic attack 4 (22%) 7 (13%) 1.88 (0.49-7.24) n.a 
Hypertension 10 (56%) 25 (46%) 1.54 (0.48-4.98) n.a 
Hypercholesterolemia 5 (28%) 14 (26%) 1.10 (0.34-3.58) n.a 
Diabetes mellitus 1 (6%) 4 (7%) 0.72 (0.07-7.36) n.a 
Medication use:     
Polytherapy (>1 antiepileptic drug ) 5 (28%) 22 (41%) 0.62 (0.22-1.80) n.a 
QT-prolonging drugs 5 (28%) 13 (24%) 1.20 (0.37-3.92) n.a 
Depolarization-blocking drugs 10 (56%) 27 (50%) 1.25 (0.43-3.61) n.a 
Cardiovascular drugs 13 (72%) 27 (50%) 3.65 (0.90-14.73) n.a 
 
Dichotomous data are expressed as n (%), and continuous data as mean (standard deviation) or median (range). 
OR: Odds Ratio, CI: confidence interval. Odds ratios with 95% confidence intervals were calculated using 
conditional logistic regression matched by age and gender. Significant associations are in bold. All covariates 
that significantly differed between cases and epilepsy controls (p<0.05) (intellectual disability, presence of 
clinically relevant heart disease) were entered in multivariable analysis to calculate adjusted odds ratios. 
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4.3 Retrospective assessment of PGES >20s in people with multiple CSs recorded on video-
EEG in two epilepsy referral centres 
 
Prevalence and intraindividual consistency of PGES >20s 
We identified 170 CSs in 64 individuals. EEG recordings with less than one minute postictal 
recording time (n=13) and those of insufficient quality due to lead disconnection (n=3) were 
discarded, leaving 59 people with 154 CSs (19 with 47 seizures from Heemstede and 40 with 
107 seizures from Bonn). All these seizures were classified as focal seizures evolving into a 
bilateral convulsive seizure with tonic and/or clonic components. The median number of 
monitoring days was 5 (range 1 to 13). In two CSs from Bonn, PGES based on EEG alone 
could not be scored due to uncertainty about the presence of movement artefacts, so a local 
clinical neurophysiologist (R Surges) analysed both EEG and video for a final decision. In the 
remaining 152 CSs PGES was evaluated by two examiners (R Thijs, A Gaitatzis); in case of 
disagreement the examiners discussed to reach consensus. Interobserver agreement on 
PGES>20s was good: κ=0.77 (Cohen’s kappa). 
 
PGES >20s occurred in (37/59) 63% of individuals and in (57/154) 37% of CSs: tables 12-13. 
In figures 3 and 4 an example of a prolonged period of PGES is shown, whereas figure 5 
displays a postictal period without PGES. Presence or absence of PGES >20s was a consistent 
finding in (34/59) people (presence 12/59; absence 22/59), whereas 25/59 people had a 
mixture of CSs with and without PGES >20s: figure 6. The number of people with 
‘consistent’ results decreased as the number of CSs recorded increased: table 12, figure 6. 
None of the individuals described in this study had died at the time of data collection (July 
2012). 
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Figure 3: Start of PGES of 95s immediately after seizure end  
 
Flattening of EEG-activity in all channels is observed immediately after the end of a convulsive seizure barring 
muscle artefacts. The low frequency filter is set at 0.3 Hz and the high frequency filter at 35 Hz. 
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Figure 4: Continuation of PGES of 95s shown 50s after seizure end 
 
The low frequency filter is set at 0.3 Hz and the high frequency filter at 35 Hz. 
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Figure 5: The start of a postictal period without PGES  
 
No generalized flattening of EEG-activity is observed after the end of a convulsive seizure. The low frequency 
filter is set at 0.3 Hz and the high frequency filter at 35 Hz. 
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Table 12: Characteristics of people with a mixture of CSs with and without PGES >20s (n=25), and those in 
whom PGES >20s was either consistently present (n=12) or absent (n=22).  
Variables CSs +/-PGES>20s 
(n=25) 
All CSs + PGES>20s 
(n=12)  
All CSs - PGES>20s 
(n=22) 
No. of recorded 
CSs (%) 
      2 
    >2 
 
 
11 (44%) 
14 (56%) 
 
 
9 (75%) 
3 (25%) 
 
 
15 (68%)  
7 (32%) 
Gender (%)    
    Male 
    Female 
17 (68%) 
8 (32%) 
6 (50%) 
6 (50%) 
11 (50%) 
11 (50%) 
Age at time of EEG,  
yr (Median; Range) 
29 (16-63)  29 (15-49) 26 (16-57) 
Duration of epilepsy, 
yr (Median; Range) 
16 (1-44) 14 (1-47)      17 (0-53) 
 
Epilepsy aetiology (%)    
   Structural/metabolic  
   Unknown  
11 (44%) 
14 (56%) 
8 (67%) 
4 (33%) 
16 (73%) 
6 (27%) 
Lesion on MRI (%)*     
    Yes 
    No 
 
11 (44%) 
14 (56%) 
 
7 (64%) 
4 (36%) 
 
16 (73%) 
6 (27%) 
Frequency of CSs (%) 
   1-2 CSs/year 
   ≥3 CSs/year 
 
7 (28%) 
18 (72%) 
 
6 (50%) 
6 (50%) 
 
13 (59%) 
9 (41%) 
Mental retardation (%) 
    Yes 
    No 
 
2 (8%) 
23 (92%) 
 
1 (8%)  
11 (92%) 
 
2 (9%) 
20 (91%) 
*In one person with symptomatic generalised epilepsy no MRI was performed.  
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Table 13: Characteristics of CSs with PGES>20s versus CSs without PGES>20s 
Variables CSs with PGES>20s 
n=57 
CSs without PGES>20s 
n=97 
Test 
Age at onset of epilepsy  
yr (Median; Range) 
14 (0-55) 12 (0-55) MW=0.09 
State of wakefulness (%) 
    Asleep 
    Awake 
 
40 (70%) 
17 (30%) 
 
47 (48%) 
50 (52%) 
χ2, p=0.009 
Sleeping stage (%) 
    NREM1 
    NREM2 
    NREM3 
 
6 (15%) 
25 (63%) 
9 (22%) 
 
6 (13%) 
31 (66%) 
10 (21%) 
NA 
AED reduction (%) 
    Yes 
    No 
 
51 (89%) 
6 (11%) 
 
66 (68%) 
29 (32%) 
χ2, p=0.005 
Location (%) 
    SEIN 
    Bonn 
 
20 (35%) 
37 (65%) 
 
27 (28%) 
70 (72%) 
χ2, p=0.35 
Ictal EEG onset (%)* 
    Temporal 
    Extratemporal 
 
32 (56%) 
25 (44%) 
 
52 (53%) 
45 (47%) 
χ2, p=0.76 
Time from seizure onset to 
generalization, s  
(Median; Range)  
28 (2-367) 28 (0-121) MW, p=0.69 
Duration of tonic phase, s 
(Median; Range) 
32.5 (16-58) 31.5 (0-75) MW, p=0.59 
Duration of tonic-clonic 
phase, s  
(Median; Range) 
58 (22-118) 58.5 (11-138) MW, p=0.95 
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Total seizure duration, s 
(Median; Range) 
92 (25-430) 91.5 (29-486) MW, p=0.85 
Pre-ictal HR, bpm 
(Median; Range) 
73 (49-137)               73 (50-140)                    MW, p=0.91 
Postictal HR, bpm 
(Median; Range) 
132 (71-159)            136 (83-177)                   MW, p=0.16 
NREM=non-rapid eye movement 
AED= anti-epileptic drug 
HR= heart rate 
NA=not applicable 
*all people with symptomatic generalized epilepsy (n=3) had focal seizures evolving into a bilateral convulsive 
seizure with tonic and/or clonic components. 
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Figure 6: Intraindividual variability of PGES>20s in people with multiple recorded CSs. 
Most people (25/59) had a mixture of CSs with and without PGES >20s (grey bars). In 22/59 persons PGES 
>20s was consistently absent (white bars), whereas in 12/59 persons it was consistently present (black bars). 
Consistency of PGES >20s seemed dependent on the number of recorded CSs. 
 
Factors that facilitate the occurrence of PGES >20s 
In univariable analysis, PGES >20s was more frequently found after CSs that started from 
sleep (OR 2.5, 95% CI 1.3-5.0) and in CSs where medication was tapered (OR 3.7, 95% CI 
1.4-9.7). Other person or seizure-related variables did not differ between groups: tables 12-13. 
In multivariable analysis the variables “sleep” and “AED reduction” remained independent 
risk factors for PGES >20s after introduction into a mixed linear regression model: sleep OR 
3.29, 95% CI 1.21-8.96; AED reduction OR 4.80, 95% CI 1.27-18.14. 
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5. Discussion 
 
5.1 Prospective, community-based case-control study of epilepsy as a risk factor for sudden 
cardiac arrest due to ECG-confirmed VT/VF 
Strengths & weaknesses  
In this study, we provide first evidence that people with epilepsy may have a higher risk of 
VT/VF than the population without epilepsy. A major strength was the community-based 
design which ensured that selection bias was minimal. The inclusion of people with epilepsy 
and those with VT/VF was systematic. All individuals with the terms “epilepsy” or “epileptic 
seizure” in the GP diagnosis list were reviewed by a panel of experts to avoid overdiagnosis. 
The point prevalence of active epilepsy in controls was 0.4%. This agrees well with previous 
estimates in the general population and suggests that we included all people with active 
epilepsy (Forsgren et al., 2005). The mandatory multiple source notification system ensured 
that we included data from all potential resuscitations, so that no cases of ECG-documented 
VT/VF were missed. The study design and access to GP and hospital records enabled us to 
collect extensive information on the circumstances surrounding VT/VF, comorbidity, and 
potential confounders. We limited our analysis to cases of VT/VF with known medical and/or 
medication use history in order to have sufficient information to confirm or reject a diagnosis 
of active epilepsy. Selection bias can, therefore, not be entirely excluded. There is no reason 
to assume, however, that the proportion of people with epilepsy would differ in people with 
VT/VF with or without known medical and/or medication use history. We believe, therefore, 
that our results are still valid.  
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Comparison with literature 
SCA is a difficult condition to study in the general population given its unpredictability, the 
short time period before death occurs, and its low survival rate. In ECG-documented SCA, 
one of three presenting rhythms is generally found: bradycardia/asystole, pulseless electrical 
activity, or VT/VF. The first two conditions are the final common outcome of every SCA due 
to cardiac or non-cardiac causes (e.g. respiratory failure), precluding establishment of the 
causative mechanism. ECG-documentation of VT/VF is probably the best way in a 
community-based study to ensure that SCA is due to cardiac causes. People with epilepsy had 
an increased risk of VT/VF, which was even higher in women and the young. Cardiac disease, 
by far the most common cause of VT/VF (Huikuri et al., 2001), is less prevalent in these two 
groups, further supporting an important role for epilepsy in VT/VF risk.  
VT/VF risk & SUDEP 
The association between epilepsy and increased VT/VF risk may suggest that cardiac causes 
contribute to SUDEP in the community. It should be stressed, however, that VT/VF in 
epilepsy, and not SUDEP, was the subject of this study. We do not exclude the possibility that 
other proposed pathomechanisms (PGES followed by cardiorespiratory arrest, 
central/obstructive apnoea) also contribute to SUDEP in the community. Excess VT/VF risk 
may also extend to people with epilepsy beyond those with SUDEP: the higher risk was 
documented in a community-based sample of individuals with less severe epilepsy who are 
expected to have a lower SUDEP risk. The role of epilepsy as a risk factor for VT/VF may be 
underestimated under the traditional definition of SUDEP: those who die suddenly with 
evidence of acute ischaemic heart disease at autopsy would not be classified as SUDEP. In 
these individuals, epilepsy would be excluded as a contributing factor to sudden death.  
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Epilepsy or associated autonomic and cardiac (electrical) changes may, however, trigger a 
lethal cardiac arrhythmia after the threshold for VT/VF has been lowered by ischaemic heart 
disease (multiple-hit model). The similar prevalence of cardiovascular VT/VF risk factors in 
people with and without epilepsy who experienced VT/VF appears to support the multiple-hit 
model: cardiac comorbidity alone does not seem to explain the increased risk of VT/VF, but 
having epilepsy may lower the threshold for ventricular arrhythmia in those with cardiac 
conditions even further.  
Potential explanations for excess VT/VF risk in epilepsy 
As discussed previously, epilepsy and VT/VF share underlying pathophysiological changes 
that may facilitate ventricular arrhythmias in the presence or absence of seizures. In the 
majority of those with epilepsy who experienced VT/VF (92%) preceding seizure activity was 
not reported, suggesting that sudden death in epilepsy is not always seizure-related. Impaired 
cardiac autonomic function has been described in people with epilepsy and those who 
suffered VT/VF (Tsuji et al., 1996). Cardiac repolarization abnormalities (e.g. QTc-
lengthening and/or shortening) were reported in individuals with epilepsy. Mutations in ion 
channel genes that are expressed in heart and brain have been described in people with certain 
types of epilepsy, inherited cardiac arrhythmia syndromes, and SUDEP cases. Use of AEDs, 
particularly those with depolarization-blocking or QT-prolonging effects may also lower the 
threshold for ventricular arrhythmia. Lastly, epilepsy characteristics such as seizure 
frequency/type and epilepsy severity may modulate the risk of VT/VF in a similar way to that 
in SUDEP. Due to the small number of people with epilepsy who experienced VT/VF, the 
causes of excess VT/VF risk in this population could not be described further. In the second 
study of my thesis, therefore, our goal was to determine the underlying aetiologies of VT/VF 
in epilepsy.  
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5.2 Prospective, community-based case-control study of the circumstances and risk factors of 
sudden cardiac arrest due to VT/VF in epilepsy  
Main findings 
In this study, we collected a larger number of people with epilepsy who experienced VT/VF 
over a longer period of time from the same community-based registry in order to obtain in 
further detail the characteristics, aetiology, and risk factors of VT/VF in this population. An 
underlying (cardiovascular) aetiology, myocardial infarction, was the most common cause of 
VT/VF in those with and without epilepsy. General (age, prevalence of congenital heart 
disease) and event characteristics (presence of witnesses, location), however, differed 
significantly between both groups. Comorbidities (clinically relevant heart disease, 
intellectual disability) rather than epilepsy characteristics had the strongest associations with 
VT/VF in epilepsy compared with people with epilepsy without VT/VF.   
Study strengths 
The major strength of this study is its community-based approach that allowed me to analyse 
the full spectrum of SCA cases of definite cardiac origin in epilepsy: ECG-confirmed VT/VF. 
Each case was reviewed against (near-)SUDEP criteria. Due to this methodology, the 
contrasts and overlaps between SCA in epilepsy and (near-)SUDEP could be defined further. 
Ventricular arrhythmia may, therefore, be one of the underlying mechanisms of SUDEP not 
only in those with severe epilepsy, but also in community-dwelling people with epilepsy. Our 
approach is more rigorous than in two previous studies that analysed SCA in epilepsy in the 
community. In the first study conducted in Oregon only 26% (28/106) of SCA victims with 
epilepsy presented with VT/VF and the remaining individuals with bradycardia/asystole or 
pulseless electrical activity (Stecker et al., 2013). 
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In the second study set in Melbourne only 22% (185/841) of resuscitated young individuals 
(including those with epilepsy) presented with VT/VF (Deasy et al., 2011). No distinction 
between cardiac and non-cardiac SCA could be made due to the inclusion of all presenting 
rhythms, unlike in my study.  
Study limitations  
We found two near-SUDEP cases in this study that were categorized as probable/possible 
rather than definite SUDEP because autopsy was not performed. Those with epilepsy who 
experienced VT/VF and living controls with epilepsy were selected from two different 
community-based cohorts (ARREST & OPPEC). OPPEC was based on AED prescription 
records; this may have introduced bias since each control with epilepsy was by definition 
using AEDs unlike people with epilepsy who experienced VT/VF from ARREST. Controls 
could, therefore, potentially have had a higher prevalence of AED use and more severe 
epilepsy. In practice, however, every individual from both groups was taking AEDs, and the 
proportion of people with recent seizures (in the last two years) did not differ significantly.  
VT/VF in epilepsy & SUDEP 
In people both with and without epilepsy, the aetiology of VT/VF was mostly cardiovascular. 
In contrast, we found that general characteristics and event circumstances differed 
significantly between the two groups with VT/VF: people with epilepsy were younger and 
had a higher prevalence of congenital heart disease. In addition, the circumstances of SCA 
differed between those with and without epilepsy: The onset of VT/VF in epilepsy was less 
likely to be witnessed and more frequently occurred at/near home. Similar circumstances have 
been reported in most SUDEP cases. This further supports the notion that cases of VT/VF in 
epilepsy in the general population can present as SUDEP and may be diagnosed as such. 
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Taken together, our data suggest that cardiovascular events constitute the predominant cause 
of VT/VF in epilepsy, whereas in a minority with unexplained ventricular arrhythmia a 
diagnosis of (near) SUDEP may be established. This may explain why common SUDEP risk 
factors such as the presence of recent seizures were not associated with VT/VF risk in 
epilepsy in this study.  
Potential explanations for excess VT/VF risk in epilepsy  
Shared genetics, shared aetiology, or shared (cardiovascular) comorbidity are potential 
explanations for the increased risk of VT/VF in epilepsy. A single mutation in an ion channel 
gene such as SCN1A may confer intellectual disability, a propensity for epilepsy, and an 
innate vulnerability to lethal cardiac arrhythmia (especially in the presence of new-onset or 
pre-existent heart disease) (Johnson et al., 2009; Glasscock, 2014). Epilepsy, intellectual 
disability, and congenital heart disease may result from a multiple malformation syndrome: 
genetic defects may affect the development of both heart and brain or abnormal 
cardiovascular function may lead to poor (intrauterine) brain growth (Miller & Vogel, 1999). 
The incidence of lethal arrhythmia appears to be much higher in adults with (repaired) 
congenital heart disease than in the general population (Silka et al., 1998; Oechslin et al., 
2000), thus linking epilepsy, intellectual disability, and VT/VF. A higher prevalence of 
(occult) cardiovascular comorbidity in those with epilepsy may also explain excess VT/VF 
risk. There are several clues linking epilepsy, cardiac comorbidity, and VT/VF. Firstly, people 
with epilepsy appear to have a worse cardiovascular risk profile than the general population: 
large health interview surveys have shown that those with a “history of epilepsy” are more 
likely to be cigarette smokers (Kobau et al., 2004; Elliott et al., 2008a; Elliott et al., 2008b; 
Kobau et al. 2008; Hinnell et al., 2010; CDC, 2013), and tend to exercise less (Kobau et al., 
2004; Strine et al., 2005; Elliott et al., 2008 b; Kobau et al. 2008; Hinnell et al., 2010; CDC, 
2013).   
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In people with epilepsy, obesity appears to be more common (Kobau et al., 2004; Kobau et 
al., 2008; Hinnell et al., 2010; CDC, 2013), and a higher prevalence of high blood pressure, 
pre-diabetes and stroke has been reported (CDC, 2013). AED use may further worsen the 
cardiovascular risk profile: weight gain is a commonly reported side effect of frequently used 
AEDs such as carbamazepine, and valproic acid (Katsiki et al., 2014). As discussed 
previously, enzyme-inducing AEDs may also be arteriosclerogenic, since they have been 
associated with elevated levels of serological vascular risk markers. Secondly, people with 
epilepsy have been found to have a higher prevalence of a variety of heart diseases and heart 
disease in general than the general population: in health interviews surveys, the categories 
“previous myocardial infarction” or “any heart disease” were more frequently reported in 
those with a “history of epilepsy” (Strine et al., 2005; Elliott et al., 2008b; CDC et al., 2013). 
In one study comparing the prevalence of somatic comorbidity between a large, unselected 
cohort with epilepsy and the general population, several types of heart disease were found to 
be more common in people with epilepsy (Gaitatzis et al., 2004): table 14. In a nationwide 
cohort study from Denmark, AED-treated people with epilepsy without previous stroke had a 
higher risk of myocardial infarction and cardiovascular death than the general population 
(Olesen et al., 2013). 
 
Table 14: Prevalence ratios of different types of heart disease in people with epilepsy when compared to the 
general community without epilepsy 
 
Types of heart disease Prevalence ratios (95% CIs) 
Congenital cardiac abnormalities 7.34 (4.58-11.75) 
Heart failure 1.68 (1.45-1.95) 
Ischemic heart disease 1.34 (1.19-1.50) 
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In a long-term follow-up study of a cohort with convulsive epilepsy in rural China, the 
mortality risk due to myocardial infarction was increased three-fold compared with the 
general population (Ding et al., 2013). Thirdly, cardiac comorbidity may more easily trigger 
life-threatening arrhythmias or cardiac death in people with epilepsy. In SCA survivors who 
were implanted with a cardioverter-defibrillator device, people with epilepsy had a higher risk 
of recurrent life-threatening cardiac tachyarrhythmia and cardiac death (Badheka et al., 2010). 
In a prospective case-control study, the odds of incident acute myocardial infarction was 4.8 
times as high in people with epilepsy as in the general population (Janszky et al., 2009). 
Those with epilepsy also had a worse prognosis after suffering acute myocardial infarction 
after correction for traditional cardiovascular risk factors: a 3.5 times increased risk of cardiac 
death. Chronic inflammation (e.g. the inflammatory cytokine interleukin-6 (IL-6)) may be a 
link between epilepsy, intellectual disability, and cardiovascular comorbidity by promoting 
atherosclerosis or arrhythmogenesis (Hussein et al., 2013). The levels of IL-6 appear to be 
chronically elevated in people with epilepsy (Nowak et al., 2011), those with intellectual 
disability (Lehtimäki et al., 2011), and, to an even further extent, in individuals with both 
conditions (Lehtimäki et al., 2011). High concentrations of this cytokine were found to be 
associated with an increased risk of sudden cardiac death in a prospective community-based 
study after correction for traditional risk factors (Hussein et al., 2013).  
Recommendations 
In conclusion, our study proposes that VT/VF risk in epilepsy is mainly determined by 
comorbid conditions such as pre-existing heart disease. Careful attention to cardiovascular 
risk factors in people with epilepsy may reduce the rate of sudden death in this population.  
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5.3 Retrospective assessment of PGES >20s in people with multiple convulsive seizures 
recorded on video-EEG in two epilepsy referral centres 
Main findings  
We focused on the intraindividual variability of PGES >20s in people with multiple CSs and 
found that PGES consistency became progressively lower when more CSs were evaluated per 
individual. The prevalence of PGES >20s was higher after CSs arising from sleep or when 
medication had been reduced. PGES >20s had limited consistency in people with multiple 
CSs. High intraindividual variability may explain conflicting findings in previous studies 
regarding the value of PGES as a SUDEP risk marker (Lhatoo et al., 2010; Surges et al., 
2011). Interestingly, intraindividual variability of PGES was higher in the study that found no 
relationship between PGES and SUDEP risk (Surges et al., 2011). Overall, these findings 
stress that the occurrence of PGES is critically dependent on the number of seizures analysed 
and, therefore, unlikely to be a reliable SUDEP risk marker.  
Comparison with literature 
A potential association between duration of the tonic phase and PGES has been reported 
previously (Tao et al., 2013), but this was not found in our study. Differences in seizure 
selection may explain these conflicting results. In the former study, 18.5% of seizures had no 
tonic phase compared with 0% in our sample. Presence of a tonic phase was highly predictive 
of PGES: OR 180 (Tao et al., 2013). The reported association between tonic duration and 
PGES may predominantly rely on the contrast between seizures with and without a tonic 
phase. Differences in seizure type rather than in tonic duration may, therefore, be responsible 
for the proposed relation between tonic duration and PGES. 
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Peri-ictal HR changes were similar in CSs with and without PGES>20s confirming our 
previous findings (Lamberts et al., 2013 a). In other electroclinical studies, peri-ictal HR 
acceleration was found to be either higher (Moseley et al., 2013) or lower in CSs with PGES 
than in those without PGES (Tao et al., 2013). Unfortunately, our findings cannot be easily 
compared, since these latter studies used a different definition of tachycardia (Moseley et al., 
2013) or did not report the HR measurement periods (Tao et al., 2013).  
Strengths and limitations 
PGES was scored differently in Heemstede (EEG and video) and Bonn (EEG only), which 
may have introduced bias. This is unlikely, however, since the prevalence of PGES>20s was 
similar in both centres: table 13. All EEG studies were independently scored by two observers 
with good interobserver agreement. We could not analyse the effect of peri-ictal hypoxaemia 
on PGES due to the lack of concurrent oximetry measurements. The link between sleep and 
PGES may be explained by underlying peri-ictal hypoxaemia. Currently, it is unclear whether 
more severe hypoxaemia occurs during CSs arising from sleep. In a previous study 
hypoxaemia was equally frequent during nocturnal and daytime seizures, but mostly focal 
seizures were analysed (Bateman et al., 2008). Similarly, underlying hypoxaemia may explain 
the association between AED reduction and PGES. This appears unlikely, however, since no 
relationship between AED withdrawal and ictal hypoxaemia was found in a systematic 
analysis of seizure-related respiratory dysfunction (Bateman et al., 2008). Ideally, an analysis 
of the association between AED withdrawal and PGES would take into account the amount 
and speed of AED reduction. Unfortunately, such an analysis could not be performed in this 
study due to its retrospective nature and the great variety in AEDs and reduction schedules. 
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Aetiology of PGES 
As discussed previously, there are several theories regarding the aetiology of PGES. In this 
study, we did not see an association between seizure duration and PGES, thus confirming the 
findings of all previous electroclinical studies on PGES.  It is unlikely, therefore, that PGES is 
the result of neuronal exhaustion. The second hypothesis states that PGES may be due to 
preceding cardiovascular or respiratory dysfunction. Concurrent oximetry and blood pressure 
measurements were not available in this study, and our findings, therefore, neither support nor 
disprove this theory. It has been proposed that PGES results from the increased activity of 
inhibitory neuronal networks in response to ongoing seizure activity (Lhatoo et al., 2010). 
This theory may explain the association between sleep and PGES, since inhibitory neuronal 
network activation is also involved in the process of sleep (Steriade et al., 1993). Similarly, 
AED use may modulate seizure-related inhibitory neuronal network activation (Tilz et al., 
2006), as AED reduction in the EMU can lead to an increase in seizure intensity and 
frequency (Zhou et al., 2002; Wang-Tilz et al., 2005). It may be speculated that changes in 
these seizure characteristics can trigger an exaggerated termination response by inhibitory 
neuronal networks. A further elucidation of the link between different AED withdrawal 
schedules, changes in seizure characteristics, and PGES may be of interest.  
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6. My findings in context 
6.1 General aim of thesis 
The general aim of my thesis was to elucidate further the role of the heart in sudden death in 
epilepsy. To accomplish this goal, I investigated the association between VT/VF and epilepsy 
from various angles: a community-based approach was used to determine the association 
between VT/VF and epilepsy, and to assess the potential overlap between this condition and 
SUDEP. Our search yielded several new clues favouring a link between VT/VF, epilepsy and 
SUDEP, which are summarized in figure 7.  
 
Figure 7: Links between epilepsy, sudden cardiac arrest due to ventricular tachycardia/fibrillation, and sudden 
unexpected death in epilepsy 
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I found that people with epilepsy had a three times higher odds of VT/VF than the general 
population irrespective of traditional cardiac risk factors using a prospective community-
based registry of resuscitation efforts. In a recent study I took a different approach and 
analysed the prevalence of three ECG risk markers for SCA in the ECGs of 185 people with 
refractory epilepsy and 178 controls without epilepsy (Lamberts et al., 2015):  
1. severe QTc-prolongation: >450ms in males, >470ms in females (Algra et al., 1991; Straus 
et al., 2006; Soliman et al., 2011) 
2. ERP or early repolarization pattern: figure 8 (Tikkanen et al., 2009; Sinner et al., 2010; 
Haruta et al., 2011; Rollin et al., 2012) 
3. Brugada ECG-pattern (Matsuo et al., 2001) 
People with epilepsy were found to have a longer mean QTc-interval (405 vs 394 ms, 
p<0.001) than controls without epilepsy and were more likely to display severe QTc-
prolongation (5% vs 0%, p=0.002). Those with epilepsy also more frequently displayed ERP 
(34% vs. 13%, p<0.001), whereas the prevalence of the Brugada ECG pattern was similar in 
both groups (2% vs. 1%, p>0.999). The results in this study thus appear to further support a 
link between epilepsy and SCA. To further explore this link, I analysed the effect of three 
potential risk factors of VT/VF in epilepsy in a larger group of 18 cases with epilepsy and 
VT/VF: use of AEDs with depolarization-blocking or QT-prolonging properties, epilepsy 
severity, cardiovascular comorbidity.  
 
 
Figure 8: Person with epilepsy and early repolarization pattern in the inferior leads. J-point elevation of ≥ 0.1 
mV with slurring morphology in two adjacent leads (III and aVF). 
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Depolarization-blocking and QT-prolonging AEDs 
I did not find an association between the use of potentially arrhythmogenic AEDs (with 
depolarization-blocking or QT-prolonging properties) and VT/VF in epilepsy. My study was, 
however, neither powered nor designed to exclude every possibly negative effect of these 
AEDs. In another recently published community-based study, AED use was reported to give a 
higher risk of sudden cardiac death in people with and without epilepsy in another recently 
published community-based study (Bardai et al., 2015). There were, however, a number of 
possible methodological flaws: the authors used an epidemiological definition of sudden 
cardiac death in which all sudden natural deaths were attributed to cardiac causes in the 
absence of a competing cause. In people with epilepsy, however, SUDEP of a non-cardiac 
origin is a major diagnostic alternative in such cases. Sudden unexplained deaths (i.e. without 
a definite anatomical or toxicological cause) in this population, therefore, cannot be assumed 
to be of cardiac origin without additional ECG-documentation, a proof that was present in the 
first two studies of this thesis. The reported association between AED use and sudden cardiac 
death may thus have been confounded by epilepsy and its association with both AED use and 
SUDEP. Carbamazepine and gabapentin were the only AEDs that were individually 
associated with an increased risk of sudden cardiac death, which the authors attributed to their 
purported depolarization-blocking properties.  
 
It is unclear, however, to what extent indication bias might have played role. Carbamazepine 
is a drug of first choice in people with focal epilepsy, and stroke is a leading cause of this type 
of epilepsy, particularly in the elderly (Ryvlin et al., 2006). Gabapentin is rarely used in 
refractory epilepsy, but in controls without epilepsy chronic diabetic neuropathic pain is an 
important indication (Moore et al., 2014). It is, therefore, possible that the excess risk of 
sudden cardiac death in carbamazepine and gabapentin users was caused by a worse baseline 
cardiovascular status rather than depolarization-blocking properties.  
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In conclusion, more research is needed to determine whether the use of potentially 
antiarrhythmic AEDs may trigger SCA. My recently conducted ECG-study may provide a 
starting point for addressing this issue, as it raises the question whether those individuals with 
epilepsy and severe QTc-prolongation or ERP may be at highest risk for the potentially 
negative effects of these AEDs.  
Epilepsy severity  
Epilepsy severity was not found to be a major determinant of VT/VF risk. Most people with 
epilepsy (56%; 10/18) had been seizure free for the last two years before SCA. Only 28% 
(5/18) of cases was on polytherapy, thus further suggesting that the seizure burden was 
relatively mild in our sample. Correspondingly, VT/VF in epilepsy rarely appeared to be 
seizure-related: 11%, 2/18. I cannot exclude the possibility, however, that our sample of SCA 
cases with epilepsy may have been biased towards those with less severe forms of epilepsy.  
In individuals with severe refractory epilepsy living in specialized institutions the presentation 
of VT/VF may be more likely to be mistaken for seizure-like movements and emergency 
medical services may, therefore, not be contacted or only contacted after a delay.  
This would reduce the odds of ECG-confirmation of VT/VF in these individuals and, 
therefore, of their entering into the ARREST database. Nevertheless, my findings of an excess 
risk of life-threatening ventricular arrhythmia in people with epilepsy that is not associated 
with epilepsy severity appear to correspond with data on overall mortality in epilepsy. In the 
National General Practice Study of Epilepsy (NGPSE), the first prospective population-based 
cohort study of children and adults with epilepsy from the time of diagnosis, seizure 
recurrence did not affect the mortality rate after a median follow-up of 11.8 years (Lhatoo et 
al., 2001). After a median follow-up of 22.8 years, the standardized mortality ratio was still 
elevated in the remaining people in the cohort, even though 80% were in 5-year terminal 
remission, and 60% were off AEDs for ≥5 years (Neligan et al., 2011).  
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In other recent studies where mortality in community-dwelling people with epilepsy was 
investigated, the association between seizure frequency and risk of death was not addressed, 
presumably because this data was unavailable (Berg et al., 2013; Ding et al., 2013; Fazel et 
al., 2013; Holst et al., 2013; Nevalainen et al., 2013). In contrast, in selected cohorts with 
more severe epilepsy a high seizure frequency was found to be predictive of mortality 
(Sillanpää & Shinnar, 2010; Nevalainen et al., 2012; Trinka et al., 2013; Novy et al., 2013). In 
the latter study, this variable was found to be an independent risk factor of premature 
mortality even in non-seizure-related deaths due to, for example, cardiovascular disease 
(Novy et al., 2013). Overall, there appears to be an increased risk of non-seizure-related 
mortality (and life-threatening arrhythmia) in community-based samples with epilepsy. High 
seizure frequency may further aggravate this risk, but this will presumably only become 
apparent in selected cohorts with severe epilepsy.   
Cardiovascular comorbidity 
I found that cardiovascular comorbidity was the strongest determinant of VT/VF in people 
with epilepsy. Intellectual disability was also associated with an increased risk of VT/VF in 
epilepsy, but should probably be interpreted as a proxy for cardiovascular comorbidity rather 
than as a cause. As discussed previously, intellectual disability may be linked with 
cardiovascular comorbidity in several ways: e.g. a multiple malformation syndrome of both 
brain and heart or enhanced vasculosclerogenesis due to chronic inflammation. In people with 
intellectual disability, cardiovascular disease may also be more likely to go unrecognized and 
untreated because of the inability to express symptoms clearly (van den Akker et al., 2006).  
 
In the first study of this thesis, I established that people with epilepsy had a higher risk of 
VT/VF than the general population. In the second study, it was found that cardiovascular 
comorbidity was the strongest determinant of VT/VF in epilepsy.  
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The excess VT/VF risk in this population may, therefore, either be explained by 1) a higher 
prevalence of (occult) cardiovascular comorbidity or 2) an increased vulnerability to the 
proarrhythmic effects of cardiovascular disease (multiple hit model). People with epilepsy 
may have a worse cardiovascular baseline status than the general population at the time of 
diagnosis due to underlying causes of epilepsy such as stroke. The effects of an unhealthier 
life-style or epilepsy-associated changes such as genetic modifiers, (progressive) autonomic 
dysfunction, cardiac electrical properties, and AED treatment may further accelerate the 
development of cardiovascular disease. For example, genetic modifiers affecting the function 
of ion channels in the brain and heart may increase the likelihood of developing epilepsy, 
severe QTc-prolongation, ERP, and fatal cardiac arrhythmias and thus potentially explain the 
findings of my recent ECG-study (Hirose et al., 2005; Johnson et al., 2009; Watanabe et al., 
2011). Alternatively, an increased vulnerability in people with epilepsy to the (proarrhythmic) 
effects of cardiovascular disease may be suggested by the fact that this population had a 
higher recurrence of life-threatening cardiac arrhythmias (Badheka et al., 2010) and a worse 
prognosis after acute myocardial infarction than controls without epilepsy (Janszky et al., 
2009). My main goals in the first two studies of this thesis were to assess whether people with 
epilepsy had an increased risk of VT/VF and to identify the underlying determinants. The 
question why cardiovascular disease leads to an excess risk of VT/VF in people with epilepsy 
should be addressed in future studies. 
VT/VF in epilepsy  
In the majority of cases of VT/VF in epilepsy (89%; 16/18), an underlying cardiac cause was 
found or suspected. In two remaining individuals (11%; 2/18) VT/VF remained unexplained 
after additional investigations and they were, therefore, classified as near-SUDEP. 
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As expected, the most important cause of VT/VF in people with and without epilepsy was 
acute myocardial infarction. Those with epilepsy had different patient characteristics, 
however, as they were significantly younger (57 vs. 64 years of age) and more likely to have 
congenital heart disease at the time of SCA (17 vs 1%). This may suggest that VT/VF in 
epilepsy has a different underlying aetiology. In people with epilepsy the prevalence of 
congenital heart abnormalities was found to be 7x higher than in those without epilepsy 
(Gaitatzis et al., 2004). Conversely, people with congenital heart disease were reported to be 
at increased risk of developing epilepsy when compared to age- and sex-matched controls 
without congenital heart disease (Billett et al., 2008). Congenital heart disease appears to be a 
more important cause of sudden cardiac death in the young (<40 years of age), whereas 
coronary artery disease accounts for the majority of cases over 40 (Van der Werf, 2010). The 
link between epilepsy and congenital heart disease may, therefore, partially explain why those 
with epilepsy experienced SCA at a younger age. The circumstances surrounding SCA in 
people with and without epilepsy also differed: The onset of SCA in epilepsy more frequently 
occurred at or near home (89 vs. 58%) and unwitnessed (28 vs 11%). The negative 
socioeconomic impact of having epilepsy may be a possible explanation: people with epilepsy 
are less likely to be married or to be employed (mcCagh et al., 2009), which may cause them 
to spend a greater portion of their time in or around the house and alone. Interestingly, the 
tendency to occur at/near home and unwitnessed has been described in most SUDEP cases, 
suggesting that a proportion of cases of VT/VF in epilepsy in the general population can 
present as probable SUDEP and may be diagnosed as such.  
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SUDEP 
It is nigh impossible to study the pathomechanisms of SUDEP in the community for the 
following reasons: SUDEP predominantly occurs unwitnessed at night, and there is only a 
short time frame before death ensues. Cause of death can only be determined ad hoc and not 
retrospectively by postmortem investigations. A portable device providing continuous 
monitoring of multiple body systems (EEG, HR, O2 saturation, blood pressure) would, 
therefore, be required to “catch” SUDEP cases in the community and accurately determine the 
underlying pathophysiological cascade. This is not feasible in view of the invasiveness 
together with the required number needed to monitor over a long period of time. In the first 
two studies of this thesis I, therefore, took advantage of the infrastructure of ARREST, a 
prospective community-based database of ECG-confirmed VT/VF aimed at establishing the 
genetic and clinical determinants of SCA. The great advantage of focusing on ventricular 
arrhythmia as a potential underlying mechanism of SUDEP is its unquestionable cardiac 
origin. Simultaneous measurements of multiple body systems to determine the underlying 
pathophysiological cascade could, therefore, be dispensed with. My studies were, 
unavoidably, limited to one specific potential underlying mechanism of SUDEP. Presumably, 
some unwitnessed cases where emergency medical services were either not alerted or arrived 
too late to detect VT/VF were missed as well as those SUDEP cases due to non-cardiac 
mechanisms. It is impossible, therefore, to indicate what proportion of all SUDEP cases is 
caused by VT/VF. Non-cardiac mechanisms may be responsible for a majority of SUDEP 
cases in the community: in a previous study of out-of-hospital SCA, 93% of autopsy-
confirmed SUDEP cases presented with asystole, which may suggest a cardiac but also a non-
cardiac origin (Deasy et al., 2011). Overall, my work is a first attempt to characterize the 
importance of VT/VF in premature sudden death in epilepsy in a community-based sample. 
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6.2 The mechanisms of premature sudden death in epilepsy  
Ventricular arrhythmia: a contributor to premature mortality in epilepsy? 
The increased risk of VT/VF in people with epilepsy cannot be explained by SUDEP alone, as 
only 2/18 cases of SCA in epilepsy were classified as (near)-SUDEP. VT/VF in epilepsy was, 
generally, not seizure-related and tended to occur in middle age in the presence of pre-existing 
heart disease. In the community-based NGPSE cohort with epilepsy the premature mortality 
rate remained two-fold increased after 22.8 years of follow-up even though the majority of 
individuals were seizure-free by then and off AED treatment (Neligan et al., 2011). At this 
point in time, the risk of death due to ischaemic heart disease also became significantly 
elevated. A mortality survey in residents of a tertiary epilepsy referral centre confirmed that 
early mortality in epilepsy (defined as occurring at ~45–50 years) was not always a 
consequence of seizures, but also due to other causes such as cardiovascular disease (Novy et 
al., 2013). My findings of an increased VT/VF risk in people with epilepsy may partly explain 
non-seizure-related excess mortality in the general population with epilepsy. The contribution 
of life-threatening ventricular arrhythmias to premature death in epilepsy may first become 
apparent in middle age, when the prevalence of cardiovascular disease in the population 
increases. Little is known about the aetiology and risk factors of VT/VF in epilepsy in the 
community. My work is a first step to better understanding of this important issue.  
Sudden unexpected vs. sudden cardiac death in epilepsy 
People with SUDEP typically have a different profile from those with VT/VF and epilepsy: 
young (20-40) versus middle-aged, refractory vs. well-controlled epilepsy, absence vs. 
presence of additional cardiovascular comorbidity.  
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These conditions, however, are likely to present both ends of a continuum rather than two 
sharply delineated entities: in SUDEP seizures appear to be the dominant trigger, whereas in 
VT/VF in epilepsy a combination of epilepsy-related effects and cardiovascular disease may 
be involved. Sudden death cases with pre-existing conditions that could have contributed to 
death such as coronary insufficiency are generally excluded from SUDEP research studies 
under current definitions (Nashef et al., 2012). If excess sudden death mortality in people with 
epilepsy is, therefore, exclusively considered through the lens of SUDEP, the effects of both 
epilepsy and of co-existing disease as risk factors are probably underestimated. Under the new 
unified SUDEP criteria, the category of “SUDEP Plus” has been created in order to 
investigate the role that epilepsy and/or co-existing disease may have in causing SUDEP. If I 
had used the category of SUDEP plus in the second study of this thesis, the overlap between 
SUDEP and VT/VF in epilepsy would have probably been larger. In one case of VT/VF in 
epilepsy who had a history of hypertrophic obstructive cardiomyopathy, ventricular 
arrhythmia appeared to be triggered by a seizure-like episode for which diazepam was 
administered. This case was not classified as SUDEP due to the presence of pre-existing 
cardiac comorbidity, but would presumably have fulfilled the criteria for SUDEP plus (Nashef 
et al., 2012). It may be exceedingly difficult in a community-based setting, however, to 
determine reliably whether VT/VF is caused by the effects of cardiac comorbidity, epilepsy, 
or both. For instance, sudden death cases with a pre-existing heart condition (e.g. long-QT-
syndrome) and an ECG-documented fatal arrhythmia can only be classified as SUDEP plus if 
there is a preceding seizure trigger (Nashef et al., 2012). In a community-based setting, 
however, reports of seizure-like events occurring just before ECG-documentation of VT/VF 
may represent either genuine epileptic activity or epilepsy mimics such as hypoxaemia-
induced seizures due to SCA. My co-authors and I, therefore, decided not to use SUDEP plus 
criteria.  
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To appreciate fully the role of epilepsy and accompanying comorbidity in causing premature 
sudden death mortality, the following approach may be better: an analysis of all sudden deaths 
in people with epilepsy regardless of the underlying cause of death. 
PGES: SUDEP risk factor? 
The value of a new potential risk marker for SUDEP, PGES>20s, was assessed in the last 
study of this thesis. The intraindividual variability of this EEG characteristic was critically 
dependent on the number of CSs recorded per person and is, therefore, unlikely to be a 
reliable predictor of SUDEP risk. Sleep and AED reduction were found to be facilitating co-
factors of PGES>20s.  
Aetiology of PGES 
The relationship between sleep, AED reduction, and PGES may suggest that these postictal 
EEG changes reflect the enhanced activity of inhibitory neuronal networks responding to 
ongoing seizure activity: neuronal inhibition also plays a role in the sleep process and may be 
modulated by AED use. Interestingly, a recent study has documented enhanced inhibitory 
neuronal activity towards the end of focal seizures. In intracerebral recordings of guinea pig 
and human brains the final stage of focal seizures was characterized by recurring, 
synchronous bursts of increasing amplitude (excitatory activity) and progressively longer 
interburst intervals: inhibitory activity (Boido et al., 2014). To test neuronal excitability 
during bursts the dentate gyrus of the guinea pig brains was stimulated using a fork electrode: 
it became progressively more difficult to elicit a field response with the fork electrode in the 
late interburst intervals towards the end of a seizure. Together, these findings suggest that 
seizure termination is caused by the simultaneous and opposite enhancement of excitation 
(during bursts) and inhibition (between bursts).  
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Another study assessing EMG signals in CSs, further supports the concept that active neural 
inhibition plays a role in seizure termination (Conradsen et al., 2013). There was an increase 
in EMG frequency which reached its peak in the late tonic phase. During the clonic phase the 
energy of clonic discharges progressively decreased, whereas the silent period between 
discharges progressively increased. The energy in the last clonic discharge was extinguished 
in some seizures but not in others, suggesting that neuronal exhaustion was not the only 
mechanism involved in seizure termination. In seizures with a higher peak EMG frequency 
longer silent periods were found. The progressive changes in these periods might, therefore, at 
least partially be explained by neural inhibitory mechanisms.  
 
Next to the theory that PGES may be caused by excessive activation of inhibitory neuronal 
networks, a second hypothesis suggests that it results from preceding hypoxia, hypotension, or 
asystole. In this context, I have mentioned a few studies where PGES was preceded by peri-
ictal hypoxaemia (Seyal et al., 2012; Seyal et al., 2013) or hypotension (Borzorgi et al., 2013), 
but have not yet detailed the relationship between PGES and peri-ictal HR(V) change. In an 
electroclinical study, I compared peri-ictal HR(V) changes between CSs with and without 
PGES at 1 minute before seizure onset and 1, 3, 5, 15 and 30 minutes after seizure end in a 
group of 50 people with epilepsy (Lamberts et al., 2013 a): changes in HR and HRV were 
associated with neither presence nor duration of PGES. In other studies, peri-ictal HR 
acceleration was found to be either higher (Moseley et al., 2013) or lower (Tao et al., 2013) in 
CSs with PGES than in those without PGES. Longer PGES duration was associated with 
measures of higher postictal sympathetic (Poh et al., 2012) and lower parasympathetic activity 
(Poh et al., 2012; Freitas et al., 2013).  
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These contradictory results highlight the probable heterogeneity of PGES, as its presence is 
not associated with definite abnormalities that are known to trigger fatal cardiac disturbances. 
These findings also underscore the fact that PGES is not likely to be predictive of SUDEP, as 
SUDEP is a multifactorial process: figure 1. A CS followed by PGES may be prerequisite for 
most cases of SUDEP, but death will presumably only ensue when the perfect combination of 
predisposing factors, a seizure trigger, and unfavourable peri-ictal circumstances occurs.  
Sleep, PGES, and SUDEP 
The link between PGES, an EEG hallmark of SUDEP, and sleep is intriguing because most 
SUDEP cases also occur during sleep. In fact, in a reanalysis of the data from the largest 
SUDEP case-control study (154 SUDEP victims, 616 living controls with epilepsy) to date, I 
found that SUDEP risk may not only be determined by CS frequency, but also by CS timing 
(Lamberts et al., 2012). Sleep-related SUDEP cases were four times more likely to be 
unwitnessed than SUDEP cases that occurred during the day. In addition, those with sleep-
related SUDEP more frequently had a history of nocturnal seizures: OR 3.6, 95% CI 1.4, 9.4. 
After correction for CS frequency and other covariates, a history of nocturnal seizures 
remained a significant risk factor for SUDEP: OR 2.6, 95% CI 1.3, 5.0. Nocturnal CSs may, 
therefore, not only increase the risk of PGES, but also of SUDEP.  
 
Nocturnal CSs may be associated with less favourable circumstances than daytime CSs, thus 
explaining the higher risk of PGES and SUDEP. Nocturnal CSs are more likely to go 
unwitnessed. Early intervention by nursing staff, however, (e.g. oxygen administration) may 
shorten the duration of subsequent PGES (Seyal et al., 2013). The presence of a family 
member or caregiver in the immediate aftermath of a CS may also reduce the risk of SUDEP 
(Langan et al., 2005; Ryvlin et al., 2013 a).  
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In conclusion, there appears to be a link between sleep, PGES, and SUDEP. This highlights 
the importance of further studies to determine the effectiveness of preventive measures 
including night supervision (Lamberts et al., 2012).  
6.3 SUDEP prevention: current perspectives 
Demonstrating the effectiveness of preventive measures 
Inaccurate individual risk assessment and an insufficient understanding of the underlying 
pathophysiological mechanisms of SUDEP are currently the two major problems that impede 
the implementation and development of preventive measures. Before such measures can be 
used in routine clinical care, their value should be demonstrated in a high risk population. 
 
Unfortunately, we still cannot characterize those at high-risk accurately enough to make such 
studies feasible. The highest incidence of SUDEP to date was reported in those undergoing 
presurgical evaluation or individuals who failed epilepsy surgery: 9.3/1,000 (Dasheiff, 1991). 
To demonstrate a reduction of SUDEP incidence by 50% during a 6-month preventive 
intervention, would require the enrolment of approximately 12,000 participants with epilepsy 
(Ryvlin et al., 2013 b). This would present considerable (and perhaps insurmountable) 
financial and logistical efforts. Alternatively, the effectiveness of preventive measures could 
be tested in high risk populations using surrogate endpoints for SUDEP. SUDEP can 
generally be considered to be the fatal result of a CS. Other, more frequently occurring, 
consequences of such seizures e.g. severe fractures, traffic accidents may, therefore, have 
value as potential substitute endpoints (Persson et al., 2002). A strong association between 
such variables and SUDEP should first be established in epidemiological studies before they 
can be used as alternative endpoints in smaller, more feasible clinical trials. 
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Analysing the effect of preventive interventions in well-defined high-risk communities with 
validated SUDEP registers (e.g. residents of tertiary epilepsy referral centres) would be 
another option. People with Dravet syndrome constitute another promising group for clinical 
intervention trials, because they appear to have a very high risk of SUDEP: 12.5% may die 
before age 50. In addition, the underlying cause of this syndrome, mutations in the neuro-
cardiac ion channel gene SCN1A, has been identified. This population may, therefore, be a 
more obvious target for cardiac preventive interventions. The value of postictal interventions 
may also be assessed in the EMU using biological surrogate markers of SUDEP such as 
PGES or the depth and duration of postictal coma. 
Current targets for intervention 
A better understanding of SUDEP pathophysiology may lead to improved risk profiling, and 
thus enable us to select those individuals with a sufficiently high SUDEP risk for clinical 
intervention trials. SUDEP pathomechanisms could also be targeted more directly, thus 
opening new avenues for prevention. At this point in time, we know that in most SUDEP 
cases peri-ictal cardiorespiratory dysfunction appears to play a role. In addition, the 
surrounding circumstances may adversely affect both conscious and autonomous breathing 
efforts in the postictal phase. Minimizing the CS burden and reducing postictal respiratory 
distress, therefore, currently constitute our most promising preventive options.  
Minimizing CS burden 
When confronted with an individual with epilepsy who continues to have seizures despite 
AED treatment, reassessment of the diagnosis of epilepsy should be the first point of concern 
(Lamberts et al., 2013 b): figure 9.  
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Unfortunately, misdiagnosis of epilepsy is not rare. Of 94 people who presented at a tertiary 
epilepsy referral centre because of “refractory epilepsy”, 13% (12/94) eventually received an 
alternative diagnosis (Smith et al., 1999). Of the remaining 82 individuals, 16 (19%) 
eventually became seizure-free. Only 44% (7/16) of the seizure-free group had genuine 
refractory epilepsy. The most important cause of “pseudo-refractoriness” was misclassified 
IGE treated with aggravating narrow spectrum AEDs. If misdiagnosis or misclassification of 
epilepsy is ruled out, avoidance of seizure-precipitating factors such as alcohol and drug 
abuse or sleep-deprivation should be discussed (Lamberts et al., 2013 b). Confirming AED 
adherence may be in order considering that 40% of people with epilepsy take fewer AEDs 
than prescribed (Davis et al., 2008), which is associated with a three times higher mortality 
risk (Faught et al., 2008). When all these factors have been addressed, dose adjustment or 
expansion of the number of AEDs should be considered. Unfortunately, approximately 30% 
of the population with epilepsy will ultimately remain refractory for treatment despite these 
measures (Kwan & Sander, 2004). Timely referral for presurgical evaluation or other 
alternative treatment options such as vagal nerve stimulation should then become a priority. 
Successful surgical treatment of refractory epilepsy may be one of the most effective options 
currently available to achieve seizure freedom and reduce the risk of SUDEP. As discussed 
previously, people who achieved seizure freedom after epilepsy surgery were found to have a 
lower risk of SUDEP than those who failed surgery: table 4. It remains unclear, however, if 
this can be ascribed to the effect of epilepsy surgery or to pre-existing biological differences 
between the two groups (Ryvlin et al., 2005).  
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Vagal nerve stimulation (VNS) is most frequently used in people with refractory epilepsy who 
do not qualify for epilepsy surgery. Those who start VNS may sporadically become seizure 
free (El Tahry et al., 2010). The SUDEP incidence rate in cohorts treated with VNS, however, 
appears to be similar to other populations with severe epilepsy (Annegers et al., 2000; 
Schachter, 2006; Granbichler et al., 2015). New treatment modalities involving 
neurostimulation such as stimulation of the anterior nuclei of the thalamus and responsive 
neurostimulation have recently become available (Liu et al., 2013). It remains to be seen 
whether these future treatment options will have additional beneficial effects on seizure 
frequency and SUDEP incidence compared to optimal AED treatment.  
 
Figure 9: Strategy when confronted with “refractory epilepsy” 
 
Step Question Action 
1 Has AED treatment really failed? Check: 
1) Diagnosis 
2) Classification 
3) Treatment adherence 
4) Precipitating factors 
2 Can the current AED regime be 
improved? 
Dosage adjustment or AED 
switch/addition  
3 Other therapies possible? Referral to epilepsy centre for: 
1) Presurgical evaluation 
2) Vagal nerve stimulation 
3) Other treatment options 
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Reducing postictal respiratory distress  
Sleeping materials and an unfavourable postictal body position, may exacerbate seizure-
related postictal respiratory distress and should be corrected, if possible. Most SUDEP cases 
are found in bed, at night, while lying prone, whereas in the general population only ~3% of 
males and 6% females prefer a prone sleeping posture (Gordon et al., 2007). This position, 
therefore, appears to be conspicuously common in SUDEP cases. It has been suggested that a 
prone posture may increase postictal respiratory distress especially when lying face-down and 
rebreathing into a pillow. Body repositioning may not automatically occur at this time, if there 
is profound postictal depression of consciousness.  
 
Low airflow resistance lattice foam pillows have, therefore, been developed to reduce the risk 
of postictal asphyxia. Simulated rebreathing tests using a ventilator suggested that the risk of 
reaching a clinically relevant inspiratory CO2 concentration of 10% was lower when using 
lattice pillows as opposed to standard pillows (Catcheside et al., 2014). The effect of lattice 
pillows on postictal respiratory parameters such as O2 saturation has, however, not yet been 
investigated in humans. If a caregiver or family member is present during the immediate 
postictal period, turning a person with epilepsy onto his side may further reduce seizure-
related respiratory distress and prevent SUDEP: analogous to the effect of sleeping posture on 
the incidence of SIDS (Kinney & Thach, 2009). In addition, physical stimulation of people 
with epilepsy during the immediate postictal phase may reduce central hypoventilation 
(Ryvlin et al., 2013 b).  
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Nocturnal supervision can increase the likelihood of bystander presence during the time 
period when those with epilepsy may be at highest risk of SUDEP. Definitive evidence of its 
effectiveness, however, is still lacking. Abnormalities in the serotonergic 5-HT arousal system 
(Tupal & Faingold, 2006) and respiratory depression due to enhanced secretion of the 
anticonvulsant adenosine (Shen et al., 2010), may also play a role in seizure-related 
respiratory dysfunction, thus presenting targets for SUDEP prevention. It has been suggested 
that the use of selective serotonin reuptake inhibitors (SSRIs) may activate the 5-HT arousal 
system, thus reducing peri-ictal respiratory abnormalities. In mice with defects in the 5-HT 
system exhibiting postictal respiratory arrests (Tupall & Faingold, 2006), the subsequent 
introduction of the SSRI fluoxetine was found to abolish these symptoms. In a retrospective 
study, peri-ictal hypoxaemia (<85% O2 desaturation) was less frequently seen after focal 
seizures in people with epilepsy on SSRIs than in those without these medications (Bateman 
et al., 2010 b). In the same study SSRI treatment had no significant effect, however, on peri-
ictal hypoxaemia resulting from CSs. In CSs central hypoventilation may not be the only 
cause of hypoxaemia, as a ventilation/perfusion mismatch due to pulmonary oedema may also 
occur. This may explain why SSRI treatment appears to be less effective in CSs than in focal 
seizures with alteration of awareness. It remains unclear whether SSRIs may be of value in 
preventing death, considering that CSs are the seizure type most commonly associated with 
SUDEP. High peri-ictal levels of adenosine may not only suppress ongoing seizure activity 
but also impede respiratory function (Shen et al., 2010). When mice with impaired adenosine 
clearance were pretreated with either caffeine (an adenosine receptor inhibitor) or saline, the 
caffeine group’s survival after seizure onset was significantly longer (Shen et al., 2010). 
Caffeine may, therefore, reduce seizure-related breathing abnormalities. Use of this drug is 
not likely to become a measure to prevent SUDEP, however, due to its proconvulsant effects 
(Shapira et al., 1985).  
Lamberts114 
 
Ambulatory SUDEP prevention devices 
The use of pacemakers and implantable cardioverter defibrillators to prevent sudden cardiac 
death in high risk individuals with heart disease has been very rewarding. Similarly, the use of 
ambulatory devices to prevent SUDEP in the remaining population at risk would be 
conceivable. In contrast to sudden cardiac death, however, there appears to be simultaneous 
involvement of multiple body systems (brain, lungs, cardiovascular system) in most cases of 
SUDEP. It remains unclear, therefore, which specific abnormality should trigger an 
intervention by the preventive device. A device that would react to PGES or an equivalent 
(e.g. a sharp decrease in spectral energy of the EEG) may become a viable option with the 
advent of responsive neurostimulation. In addition, the type of intervention that should be 
administered remains unclear. An implantable cardioverter defibrillator can correct the 
underlying problem in one system (ventricular arrhythmia), thus preventing sudden cardiac 
death. In most impending SUDEP cases, however, simultaneous interventions in multiple 
systems (respiration, heart rhythm, blood pressure) is likely to be required as VT/VF only 
plays a role in minority of cases. At this point in time, therefore, there is no place for SUDEP 
devices as high risk individuals cannot yet be identified. Devices detecting seizures in general, 
irrespective of potential effects on cardiorespiratory control, are currently the most effective 
preventive measure as they can notify bystanders or caregivers.  
6.4 SUDEP and the future   
SUDEP awareness and documentation 
Substantial deficiencies in the documentation of epilepsy-related deaths were reported in the 
National Sentinel Clinical Audit of Epilepsy-related Deaths in the UK, suggesting that a 
considerable proportion of SUDEP cases may have been misdiagnosed (Hanna et al., 2002).  
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Between September 1999 and August 2000 2412 deaths (1023 with post-mortem records, 
1389 without post-mortem records) were registered with epilepsy mentioned somewhere on 
the death certificate. Of these deaths, 43% (439/1023) of cases with post-mortem records and 
11% (156/1389) of cases without post-mortem records were audited. The investigation of 
cause of death was found to be inadequate in 87% (383/439) of audited cases with post-
mortem records: requisite post-mortem investigations such as a toxicological analysis for 
alcohol and drugs, a histological examination of major organs, and a neuropathological 
examination of the brain were not always performed. In addition, variable phrasings of a 
single cause of death were frequently used or a cause of death was cited despite a lack of 
pathological evidence. Of audited cases without post-mortem records, 25% (39/156) were 
specifically certified as due to epilepsy. Of these deaths, 38% (15/39) were sudden and/or 
unwitnessed and should, therefore, have been subject to post-mortem. The term SUDEP, 
defined in 1997 (Annegers, 1997; Nashef, 1997), was cited in 9% (54/595) of all audited 
cases (with and without post-mortem records). To summarize, post-mortem investigations 
were not standardized nor always performed, a number of death certificates listed the 
incorrect cause of death, and autopsy was withheld in a number of sudden and/or unwitnessed 
deaths thus precluding a diagnosis of definite SUDEP.  
 
The documentation of epilepsy-related deaths and diagnosing of SUDEP cases may be 
equally deficient in the Netherlands, where the main studies described in my thesis were 
performed. Recently, Dutch investigative journalists reported that the standard procedures for 
“schouwartsen” (forensically trained physicians) when assessing a possible unnatural death 
(many of which may be sudden) vary considerably across the Netherlands: during the external 
examination routine procurement of blood and urine samples was carried out only in the most 
urbanized regions of the Netherlands (KRO Brandpunt, 2014).  
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SUDEP awareness and the registration of epilepsy-related deaths may improve in the future as 
SUDEP is steadily gaining more attention in both medical and layman’s circles (Brigo et al., 
2014). Accordingly, a number of interdisciplinary SUDEP meetings for epilepsy care 
professionals have recently been organized in the Netherlands and the first steps were taken to 
establish a national registry and develop educational material. 
 
Greater recognition and better documentation of SUDEP may enable the comparison of 
incidence data in the community between different countries. Across European nations 
epilepsy care is organized very differently and this may, therefore, give us more insight into 
the effect of health care availability on SUDEP incidence. For example, the number of board-
certified neurologists per 100.000 inhabitants is much higher in the Netherlands than in the 
UK: 4.7 vs. 0.9/100.000 (Struhal et al., 2011). A negative trend that may hinder accurate 
SUDEP diagnosing is the progressive decline in clinically indicated autopsy rates in most 
developed countries: from 42.7% in 1979 to 15.3% in 2001 in the UK (Burton & Underwood, 
2007). An important differential diagnosis of SUDEP is suicide, which is also likely to be 
sudden, unexpected, and unwitnessed and 3x more common in people with epilepsy than in 
the general population (Bell et al., 2009) or in siblings without epilepsy (Fazel et al., 2013). 
In the absence of autopsy, suicides in people with epilepsy may be misdiagnosed as probable 
SUDEP (Kapusta et al., 2011). In addition, in 40% (14/35) of sudden deaths in a tertiary 
epilepsy referral centre that might have been classified as probable SUDEP, autopsy results 
suggested a different (usually cardiovascular) diagnosis (Novy et al., 2013): this further 
underscores the importance of this procedure for correct classification. Definite SUDEP can, 
therefore, only be established when alternative causes of death have been ruled out by post-
mortem investigations (Annegers, 1997; Nashef, 1997). 
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To (partially) compensate for the growing lack of autopsies, the additional collection of health 
information regarding the deceased through interviews with family members (i.e. verbal 
autopsy) may become more important in determining whether epilepsy-related deaths are due 
to SUDEP. Future research may yield more clues as to which data should be collected to most 
accurately predict autopsy-negative epilepsy-related sudden deaths, so that a reliable 
diagnosis of SUDEP will remain possible.  
SUDEP: subdivisions by underlying mechanism 
Over the last few decades it has time and again been re-iterated that epilepsy is a disorder or a 
family of disorders rather than a uniform disease (Fisher et al., 2014). In fact, "Epilepsy is not 
a disease, but a collection of diverse syndromes, some of which are secondary to other 
derangements, and some of which are seemingly primary" (Fisher, 1989). If the epilepsies can 
be considered a heterogeneous group, it is reasonable to assume that SUDEP, a definition by 
exclusion of a type of sudden death in people suffering from the epilepsies may include a 
heterogeneous set of conditions as well. This view appears to be supported by the analysis of 
ictal video-EEG-recordings of SUDEP, which has yielded multiple potential 
pathomechanisms rather than a single all-encompassing cause of death (Dasheiff & 
Dickinson, 1986; Purves et al., 1992; Thomas et al., 1996; Bird et al., 1997; Lee, 1998; So et 
al., 2000; Tavee & Morris III, 2008; Espinosa et al., 2009; Lhatoo et al., 2010; Bateman et al., 
2010 a; Tao et al., 2010; Lanz et al., 2011; Ryvlin et al., 2013 a; Jeppesen et al., 2014). Partly 
to re-emphasize this heterogeneity, I chose to focus mostly on (peri-ictal) cardiac arrhythmia 
as a less prevalent potential underlying mechanism of SUDEP in my thesis, as opposed to 
“the early, centrally mediated, severe alteration of both respiratory and cardiac functions after 
CSs” (PGES followed by gradual cardiorespiratory arrest) which has recently been proposed 
as the predominant underlying pathomechanism (Ryvlin et al., 2013 a).  
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Each condition under the umbrella term SUDEP may have its own distinctive risk factors, 
pathophysiological mechanisms, and may require unique preventive measures, thus 
explaining why individual risk assessment nor scientifically proven prevention have yet been 
achieved. By pooling resources of epilepsy research centres across the globe the identification 
and definition of SUDEP’s subordinate conditions along with their associated risk factors, 
pathomechanisms, and preventive strategies may be accelerated. The MORTEMUS study  in 
which the SUDEP incidence in EMUs was estimated by collecting data from centres in 
Europe, Israel, Australia, and New Zealand serves as a successful example of this strategy 
(Ryvlin et al., 2013 a). Recently, the National Institutes of Health have awarded a large grant 
to a consortium of epilepsy research centres that have pledged such a far-reaching 
collaboration in the field of SUDEP research (NIH, 2014; The Lancet Neurology, 2015). 
Regardless of future breakthroughs, however, there exists a current, urgent need for effective 
preventive strategies. 
SUDEP: genetic screening  
As I have explained earlier, genetic modifiers may play a role as predisposing factors in the 
pathophysiology of SUDEP: figure 1. Screening for such modifiers in those at highest risk of 
SUDEP (people with refractory epilepsy) may, therefore, contribute to improved individual 
risk assessment. Suitable screening target(s) may be found among the mutations that have 
previously been reported in SUDEP victims: see section 1.7. Some of the implicated genes are 
associated with epileptic encephalopathies (SCN1A, SCN8A), and others with the inherited 
cardiac arrhythmogenic disease long QT-syndrome (SCN5A, KCNH2). HCN2 and HCN4 are 
involved in generating spontaneous rhythmic activity in cardiac pacemaker and neuronal 
cells, but are not associated with a specific disease.  
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Genetic testing in SUDEP victims has, thus far, focussed predominantly on those genes that 
may facilitate fatal cardiac arrhythmia (e.g. SCN5A). The findings I have presented in this 
thesis, however, and in particular the MORTEMUS study, suggest that the commonest 
SUDEP pathomechanism is not (seizure-related) cardiac arrhythmia but rather the sequence of 
PGES and cardiorespiratory arrest. It is currently unfeasible to identify genetic modifiers that 
facilitate this sequence as its underlying cause is incompletely understood.  
 
In a recent study, generalized seizures were evoked in anaesthetized mice carrying mutations 
in the KCNQ1 gene (involved in long QT syndrome) or the SCN1A gene and wild-type mice, 
while electrophysiological signals in the cortex and brain stem as well as heart and respiratory 
parameters were recorded (Aiba & Noebels, 2015). In mutant but not in wild-type mice, the 
electrophysiological hyperactivity caused by generalized seizures was found to trigger 
spreading depression, a self-propagating wave of inhibition that depolarizes neuronal 
membranes in such a way that action potentials can no longer be generated (Bernard, 2015).  
Spreading depression was then followed by PGES, respiratory arrest, asystole, and death. The 
same manifestations could also be evoked by directly triggering spreading depression in the 
brain stem of mutant mice (i.e. without a preceding seizure), thereby proving causality. These 
results suggest that genetic modifiers may facilitate seizure-triggered spreading depression, 
and thereby, the sequence of PGES and cardiorespiratory arrest. Interestingly, spreading 
depression is also thought to be the underlying cause of migraine aura (Tolner et al., 2015). 
Genes associated with familial hemiplegic migraine (CACNA1A, ATP1A2, and SCN1A), a 
rare monogenic migraine with aura subtype (Tolner et al., 2015), may, therefore, be promising 
targets for genetic testing in SUDEP victims. If the search for genetic modifiers of spreading 
depression in SUDEP victims is successful, genetic screening in high-risk groups to improve 
individual SUDEP risk assessment may come within reach.   
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Nocturnal supervision and seizure detection 
As explained previously, achieving seizure freedom may be the best way to reduce SUDEP 
risk, but this can only be achieved in approximately 70% of people with epilepsy despite 
optimal treatment. In addition, a considerable number of individuals with epilepsy may have a 
relapsing-remitting course, thus hindering early identification of drug-refractory epilepsy, 
timely referral, and institution of appropriate treatment until it might be too late (Shorvon, 
1984; Shorvon & Luciano 2007). Every (convulsive) seizure can kill, and people may, 
therefore, still die suddenly even after years of seizure freedom. In hospital settings, seizure-
surveillance systems may be used to promote the timely arrival of medical personnel in the 
(post)ictal period.  
 
In the community, SUDEP cases were predominantly nocturnal and unwitnessed, and most 
likely to be triggered by nightly CSs (Lamberts et al., 2012). Supervision at night, i.e. by a 
family member sleeping in the same room or alerted by a listening device, has so far been the 
only documented preventive factor (Langan et al., 2005). For these reasons, and given the 
relatively smaller impact of surveillance at night on everyday life, it is likely that nocturnal 
supervision in a home environment using seizure monitoring devices will become more 
commonplace in the future. Unfortunately, many currently available seizure-surveillance 
systems that use a combination of multiple factors to detect seizures are unsuitable for long-
term monitoring at home due to a high rate of false-positive alerts (Carlson et al., 2009; 
Beniczky et al., 2013; Narechania et al., 2013; van de Vel et al., 2013).  
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The best scientific evidence of the preventive value of nocturnal supervision using a particular 
seizure monitoring device would be a randomized controlled trial comparing the effects of 
this measure versus no intervention on SUDEP incidence in a cohort of people with refractory 
epilepsy. As explained previously, SUDEP incidence is too low even in high-risk groups to 
make such a trial financially and logistically feasible. In addition, depriving the control group 
of a potentially life-saving intervention raises severe ethical concerns. I, therefore, do not 
foresee the emergence of evidence-based SUDEP prevention measures. Alternative 
approaches could be considered, however, including retrospective case-control studies 
comparing seizure monitoring devices and nocturnal supervision measures in SUDEP cases 
and living controls with epilepsy. This may be most rewarding in the residential population of 
a tertiary epilepsy referral centre as these are well-defined high-risk cohorts where valid 
SUDEP registers are likely to be in place and a variety of (nocturnal) seizure-monitoring 
devices has come into use over the last few decades. 
 
When seizure detection devices become more accurate and widely used in the home 
environment, family members will more frequently encounter patients during the early 
postictal period at the brink of dying from SUDEP. “What is to be done?” is then the crucial 
question. In practice, a number of actions will be taken simultaneously such as patient 
repositioning from the prone to the side, physical stimulation, or even cardiopulmonary 
resuscitation. In all likelihood, it will remain impossible to separate the effects of each 
measure and determine which have preventive value and which do not. I believe, therefore, 
that a protocol detailing the steps to be taken once called by the bedside by a seizure alarm 
should be developed based on expert consensus. This information may then be divulged to the 
patient and his/her family members by the treating neurologist, once they have expressed an 
interest in implementing nocturnal supervision. 
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In this thesis I have drawn a number of analogies between SUDEP and SIDS, another 
autopsy-negative sudden death syndrome predominantly occurring during sleep, which may 
also be seizure-related in some cases. In SIDS, a single measure, i.e. putting children to sleep 
in the supine position, was eventually found to be a major preventive factor (Kinney & Thach, 
2009), seemingly belying my scepticism regarding the discovery of a similar preventive 
magic bullet in SUDEP. The major difference between SIDS and SUDEP, however, is that 
there was a major (iatrogenic) rise in the incidence of SIDS in the 1970 and 1980s due to the 
medical recommendation to put children to sleep in the prone position (to prevent 
regurgitation) (Högberg & Bergström, 2000). Sleeping position, therefore, became an obvious 
focus of subsequent studies designed to explain this SIDS epidemic. In the post “back-to-
sleep” era the analogy between SIDS and SUDEP has become even stronger, as both are 
syndromes with a complex, multifactorial aetiology including putative genetic factors and 
preventive measures are lacking (Tomson et al., 2008; Kinney & Thach, 2009). 
Seizure-related & non-seizure-related cardiac arrhythmia 
In this thesis I discussed various potentially negative effects of epilepsy on the heart: genetic 
modifiers of ion channel genes expressed in heart and brain may convey a tendency to 
develop epilepsy and an increased vulnerability to cardiac arrhythmia. Progressive autonomic 
dysfunction, i.e. decreasing HRV measures, was reported in people with refractory temporal 
lobe epilepsy (Suorsa et al., 2011), and was associated with a higher risk of cardiac mortality 
and sudden cardiac death (Tsuji et al., 1996; Stein & Kleiger 1999). ECG risk markers of 
SCA (severe QTc-prolongation and ERP) were found to be more common in people with 
refractory epilepsy than in controls without epilepsy (Lamberts et al., 2015).  
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In the first study of my thesis, I provided evidence that people with epilepsy in the community 
had a 3x higher risk of ECG-confirmed VT/VF than those without epilepsy. In the second 
study, it was established that most cases of VT/VF with epilepsy in the community were non-
seizure-related and that pre-existing cardiac comorbidity was the strongest associated risk 
factor. I suggested various theories for the higher risk of non-seizure-related VT/VF in people 
with epilepsy such as the possible arteriosclerogenic or arrhythmogenic properties of AEDs, a 
worse cardiovascular risk profile and higher prevalence of cardiac comorbidity, or an innate 
vulnerability for life-threatening cardiac arrhythmia. Unfortunately, the relatively modest 
number of cases with VT/VF in epilepsy precluded a deeper analysis of its aetiology and risk 
factors. Continuing efforts to identify prospectively and fully characterize all cases with 
epilepsy and ECG-confirmed VT/VF in the community-based ARREST-database may help to 
further elucidate the underlying causes of non-seizure-related VT/VF and sudden death in 
epilepsy. Research on premature mortality in the middle-aged with comorbidity should not be 
neglected in favour of understanding sudden death in the young and healthy.  
 
Apart from peri-ictal VT/VF which does not appear to be common, asystole is a far more 
frequent seizure-related arrhythmia thought to be implicated in SUDEP. The point prevalence 
of ictal asystole in hospital-based studies of EEG-recordings was reported to be 0.3-0.4% 
(Rocamora et al., 2003; Schuele et al., 2007; Lanz et al., 2011), but much higher figures (6-
19%) were found in long-term monitoring studies using a Reveal, an implantable loop 
recorder (Rugg-Gunn et al., 2004; Nei et al., 2012). The asystolic responses in these latter 
studies were not captured in the hospital, which suggests that the majority of these 
arrhythmias may go unnoticed in routine clinical practice. 
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The unexpectedly high prevalence of clinically relevant ictal asystole in both Reveal studies 
(i.e. resulting in pacemaker implantation) have not yet lead to the adoption of new standards 
of epilepsy care such as preventive cardiac screening in people with severe epilepsy. This may 
be due to the small numbers of individuals with only the severest forms of epilepsy who were 
analysed. The results, therefore, could not be translated to the larger and clinically more 
important group of people with drug-refractory epilepsy representing 30% of the entire 
population with epilepsy. The unresolved pathophysiology of ictal asystole, particularly 
regarding its lethality, may be a second reason why preventive cardiac screening in people 
with drug-refractory epilepsy has not yet been adopted. As discussed in the introduction to 
this thesis, ictal asystole may have similar characteristics to those seen in cardioinhibitory 
vasovagal syncope (Schuele et al., 2008). As such, it may constitute a self-limiting seizure 
termination mechanism: a seizure triggers ictal asystole causing brain ischemia, thus 
terminating seizure activity which resolves the cardiac arrhythmia (Schuele et al., 2010). 
 
A long-term ECG monitoring study in a larger representative group of people with drug-
refractory focal epilepsy after performing initial autonomic function tests (e.g. tilt table) in 
each individual may resolve these two issues: the prevalence of ictal asystole in a larger, 
representative group of people with drug-refractory focal epilepsy can be determined. 
 In addition, a better insight of the underlying mechanism of ictal asystole may be gained: 
those with ictal asystole may be more prone to VVS and have a higher proportion of positive 
tilt table tests. The findings of such a study may have the potential to launch a wider debate on 
the necessity of preventive cardiac screening and treatment (e.g. pacemaker implantation) in 
people with drug-refractory focal epilepsy to decrease the incidence of SUDEP in this high-
risk population. 
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As explained previously, people with Dravet syndrome may be another promising target for 
preventive cardiac screening, as this population appears to have an extremely high risk of 
SUDEP and the underlying cause of this epilepsy syndrome is known: mutations in the neuro-
cardiac ion channel SCN1A (Genton et al., 2011). In an animal model of Dravet syndrome, 
mice in which SCN1A was knocked out in the brain developed prolonged atropine-sensitive 
ictal bradycardia at the end of a CS culminating in terminal asystole (Kalume et al., 2013). 
This suggests that in this population (seizure-related) cardiac arrhythmia, particularly 
asystole, may play a more prominent role in the pathophysiology of SUDEP than in others 
with epilepsy. Currently, the prevalence of ictal cardiac arrhythmia in people with Dravet 
syndrome is unknown. Performing long-term ECG monitoring in this population using an 
implantable loop recorder is unfeasible, however, as most people with Dravet syndrome suffer 
from intellectual disability. Alternatively, such a study may be performed using cotton T-
shirts containing recently developed wireless wearable ECG sensors for long-term monitoring 
(Nemati et al., 2012). 
Seizure termination, PGES, and SUDEP 
Individual SUDEP risk assessment remains out of reach, thus hindering attempts to institute 
targeted preventive measures. In 2010 the EEG characteristic PGES was proposed as a 
promising new risk marker for SUDEP in a retrospective electroclinical study, in which those 
with PGES>20s after CSs had a 13x higher risk of dying of SUDEP in the future than living 
controls with epilepsy (Lhatoo et al., 2010). This association between PGES and SUDEP 
could not be replicated in a second, larger study (Surges et al., 2011). 
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In the last main study of this thesis, I demonstrated that the intraindividual variability of 
PGES>20s was very high, thus explaining these contrasting results. My findings implied that 
PGES>20s after CSs may have little clinical usability as a SUDEP risk marker. This does not 
at all mean, however, that the concept of PGES is useless. Individual video-EEG case reports 
of SUDEP showed and the MORTEMUS study confirmed that PGES represents the first step 
in a pathophysiological cascade followed by gradual cardiorespiratory cessation in the 
majority of recorded SUDEP cases (Dasheiff & Dickinson, 1986; Purves et al., 1992; Thomas 
et al., 1996; Bird et al., 1997; Lee, 1998; So et al., 2000; Tavee & Morris III, 2008; Espinosa 
et al., 2009; Lhatoo et al., 2010; Bateman et al., 2010 a; Tao et al., 2010; Lanz et al., 2011; 
Ryvlin et al., 2013 a; Jeppesen et al., 2014). The aetiology of PGES remains unclear, but 
requires elucidation as this may also improve our understanding of SUDEP. In my thesis I 
have tried to take a first step in this direction. I found significant associations between sleep, 
AED reduction, and PGES, suggesting that this EEG characteristic may result from an 
increased activity of inhibitory neuronal networks. As discussed previously, progressive 
lengthening of interburst intervals (EEG) or interclonic intervals (EMG) may represent 
increasing inhibitory activity before seizure offset (Conradsen et al., 2013; Boido et al., 2014), 
and the speed of lengthening of successive intervals may be a measure for the strength of 
seizure inhibition (Conradsen et al., 2013). It would be interesting to determine whether the 
rate of increase in interburst/interclonic interval durations during CSs is associated with the 
presence or duration of ensuing PGES. If so, this would provide further evidence that this 
EEG characteristic may result from the increased activation of inhibitory neuronal networks 
in response to ongoing seizure activity. The next step may then be to compare electroclinical 
characteristics in fatal CSs (ending in SUDEP) and non-fatal CSs. Such a study should be 
feasible due to the collection of video-EEG-recordings of SUDEP in the recent systematic 
retrospective survey of EMUs (MORTEMUS) (Ryvlin et al., 2013 a).  
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Earlier in the discussion of this thesis, I posited the question as to what extent PGES in fatal 
and non-fatal CSs represented the same process. Unfortunately, this EEG characteristic cannot 
be directly compared in fatal and non-fatal CSs, as it is of infinite duration in fatal CSs. An 
analysis of interburst/interclonic interval frequency in video-EEG-recordings of fatal and non-
fatal CSs may clarify whether and how the process of seizure termination differs between 
these groups. This may potentially improve our understanding of SUDEP pathophysiology. In 
addition, if a cut-off point for interburst/interclonic interval frequency can be determined to 
distinguish between fatal and non-fatal CSs, this may become a valuable trigger for a future 
ambulatory SUDEP prevention device.  
 
In conclusion, I have briefly outlined some developments that are expected to take place 
within the next decade in epilepsy care and SUDEP research and have suggested several 
research approaches to further stimulate those developments: a growing awareness and more 
accurate diagnosing of SUDEP, the founding of new international networks in the scientific 
community (centre without walls) dedicated to further elucidating the pathophysiology of 
SUDEP including the role of seizure inhibition mechanisms, risk profiling tailored to separate 
SUDEP pathomechanisms e.g. those at risk for lethal arrhythmias as this may require specific 
interventions (implantable cardioverter defibrillator, pacemaker), screening for genetic 
modifiers in high risk groups, and improving the accuracy of seizure detection devices. It is 
my expectation that due to these developments we will be able to reduce the incidence of 
SUDEP in the coming decade. 
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7. Conclusions  
 
I analyzed ventricular arrhythmia, a presumed pathomechanism in ictal recordings of 
SUDEP,in people with epilepsy in the community. Those with epilepsy in the community 
were found to have a 3x higher risk of ECG-documented VT/VF than the general population 
irrespective of traditional cardiac risk factors. The most common cause of VT/VF in epilepsy 
was acute myocardial infarction. Comorbidity such as clinically relevant pre-existent heart 
disease rather than epilepsy characteristics were the strongest risk factors for VT/VF in 
epilepsy. In two persons with epilepsy who were successfully resuscitated, VT/VF remained 
unexplained after additional investigations and a diagnosis of near-SUDEP could be 
established. Ventricular arrhythmia may, therefore, also be an underlying SUDEP mechanism 
in the community. My findings may partly explain long-term non-seizure-related excess 
mortality in people with epilepsy in the community, as has been documented in the NGPSE 
study. Little is known is known about the aetiology and risk factors of VT/VF in epilepsy in 
the community. My work represents a first step to better understanding this important issue.  
 
PGES occurs in the majority of fatal CSs and appears to be an EEG hallmark of SUDEP. A 
better understanding of the process underlying PGES is, therefore, important. PGES >20s 
after non-fatal CSs has been proposed as a new SUDEP risk marker, but its clinical value 
remains unclear. Conflicting findings between studies may be explained by the varying 
number of seizures per individual that was analyzed. I found that the intraindividual 
variability of PGES >20s in people with multiple recorded CSs was high, suggesting that the 
clinical usability of this potential SUDEP risk marker is limited. 
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Sleep and AED reduction before CS onset appeared to facilitate the occurrence of PGES 
>20s, suggesting that PGES may result from the increased activity of inhibitory neuronal 
networks in response to ongoing seizure activity. Other electroclinical characteristics such as 
progressive lengthening of interburst intervals (EEG) or interclonic intervals (EMG) may also 
result from the increased activity of inhibitory neuronal networks in response to ongoing 
seizure activity, and the speed of lengthening of successive intervals may be a measure for the 
strength of seizure inhibition. If the rate of increase in interburst/interclonic interval durations 
during CSs is associated with the presence or duration of ensuing PGES, this would provide 
further evidence that PGES results from this seizure termination mechanism. A further 
comparison of electroclinical seizure characteristics in fatal CSs (ending in SUDEP) and non-
fatal CSs may then clarify whether and how seizure termination differs between these two 
groups. This may potentially improve our understanding of SUDEP pathophysiology.  
 
I have briefly outlined some developments that are expected to take place within the next 
decade in epilepsy care and SUDEP research and have suggested several research approaches 
to further stimulate those developments: a growing awareness and more accurate diagnosing 
of SUDEP, the founding of new international networks in the scientific community (centre 
without walls) dedicated to further elucidating the pathophysiology of SUDEP including the 
role of seizure inhibition mechanisms, risk profiling tailored to separate SUDEP 
pathomechanisms e.g. those at risk for lethal arrhythmias as this may require specific 
interventions (implantable cardioverter defibrillator, pacemaker), and improving the accuracy 
of seizure detection devices. It is my hope that due to these developments we will be able to 
reduce the incidence of SUDEP in the future. 
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TOESTEMMINGSFORMULIER 
 
OPPECstudie: OutPatient Population based Epilepsy Cohort to study genetic, 
etiologic, clinical and pharmacological factors in treatment response 
 
Studie naar de oorzaken voor het wel of niet werken van medicijnen bij epilepsie.  
 
Onderzoeksnummer:  
 
Naam:     ______________________________________ _____ 
Adres (straat, huisnummer, toevoegingen): ___________________________________________ 
Postcode:     ___________________________________________ 
Woonplaats:     ___________________________________________ 
 
Geboortedatum:  ____ / ____ / ______ 
Geslacht:   
o man 
o vrouw 
 
Wij zouden het waarderen als u de uitgebreide vragenlijst online zou willen invullen. Dit kunt u al gelijk 
doen door te gaan naar onze website: : http://www.epilepsieonderzoek.nl 
Indien u dit op een later tijdstip wilt doen kan dat natuurlijk ook, wij zouden dan graag uw e-mail adres 
willen gebruiken om u de vragenlijst online toe te sturen.  
 
e-mailadres:     __________________________________________ 
 
Als u graag op de hoogte blijft van nieuws over de OPPEC studie kunnen wij uw e-mail adres ook 
gebruiken voor toesturen van de nieuwsbrief.  
Wilt u 2x per jaar een digitale nieuwsbrief ontvangen: 
o ja 
o nee 
 
Ik heb de informatiebrief voor de proefpersoon gelezen. Ik heb al dan niet gebruik gemaakt van de 
mogelijkheid vragen te stellen. Ik heb genoeg tijd gehad om te beslissen of ik meedoe.  
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Onderzoeksnummer:  
 
Ik weet dat sommige mensen mijn gegevens kunnen zien. Die mensen staan vermeld in de Algemene 
brochure. 
 
Ik weet dat meedoen helemaal vrijwillig is. Ik weet dat ik op ieder moment kan beslissen om niet meer 
mee te doen. Daarvoor hoef ik geen reden te geven. 
 
Graag bij elk van onderstaande punten doorstrepen wat niet van toepassing is: 
 
• Ik geef wel/ geen* toestemming om mijn gegevens te gebruiken, voor de doelen die in de 
informatiebrief staan. 
 
• Ik geef wel/ geen* toestemming voor deelname aan onderzoek naar genetische factoren die 
verantwoordelijk zijn voor de werking van medicijnen, d.m.v. bloed onderzoek.  
 
• Ik geef wel/ geen* toestemming om mijn lichaamsmateriaal (DNA) nog maximaal 15 jaar na 
afloop van dit onderzoek te bewaren, zodat dit in de toekomst gebruikt kan worden voor nieuw 
onderzoek.  
 
• Ik geef wel/ geen* toestemming om in de toekomst opnieuw benaderd te worden voor 
nader onderzoek of follow- up onderzoek.  
 
• Ik geef wel/ geen* toestemming om mijn medische gegevens over mijn epilepsie op te 
vragen bij mijn huisarts of specialist(en). Ik besef dat mijn huisarts of specialist dan ook weet 
dat ik meedoe aan dit onderzoek.  
 
Gegevens huisarts en/ of behandelend specialist, bij wie gegevens mogen worden opgevraagd: 
Naam huisarts:_________________________________________________________ 
Adres: _______________________________________________________________ 
_____________________________________________________________________ 
Naam specialist:________________________________________________________ 
Adres: _______________________________________________________________ 
_____________________________________________________________________ 
 
Ik wil WEL/ NIET* deelnemen aan dit onderzoek 
 
Naam proefpersoon: _________________________________________________ 
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Handtekening: _______________________________ Datum : ____ / ____ / ________ 
Appendix 5: introductory questionnaire OPPEC 
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 VRAGENLIJST  
 
Onderzoeksnummer:  
 
 
U krijgt deze brief omdat u onderstaand(e) geneesmiddel(en) gebruikt: 
 
 
______(Sticker met merknaam voorgeschreven anti epilepticum of anti epileptica)________ 
 
 
 
 
1) Gebruikt u een of meerdere van bovenstaande medicijnen voor epilepsie (epileptische 
aanvallen/ insulten/ wegrakingen/ absences)?  
o Ja 
o Nee 
 
2) Gebruikt u een of meerdere van bovenstaande medicijnen voor migraine, pijn of depressie?  
o Ja 
o Nee  
 
U hoeft de volgende vragen alleen te beantwoorden indien u bij vraag 1 ja heeft ingevuld.  
3) Hoeveel epileptische aanvallen heeft u de afgelopen 2 jaar gehad?  
(Eén antwoord aankruisen) 
o een of meer keer per dag 
o een of meer keer per week 
o een of meer keer per maand 
o een of meer keer per jaar 
o minder dan een keer per jaar 
o geen aanvallen 
 
4) Wanneer was uw laatste epileptische aanval?  (Eén antwoord aankruisen) 
o vandaag 
o deze week 
o deze maand 
o het afgelopen half jaar 
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o meer dan een half jaar geleden 
o meer dan 1 jaar geleden 
o meer dan 2 jaar geleden 
 
5) Wie schrijft uw medicijnen tegen epilepsie voor?  
o huisarts 
o neuroloog in een algemeen ziekenhuis 
o neuroloog in een universitair ziekenhuis 
o neuroloog in een speciale epilepsiepolikliniek 
o kinderarts 
o anders namelijk; ___________________________________________ 
 
6) Hoe vaak ziet u de arts die u medicijnen voorschrijft?  
o Nooit (herhalingsrecepten via de doktersassistente) 
o ______ keer per jaar 
 
7) Wanneer was uw laatste bezoek aan de arts die uw epilepsie behandelt?  
o 1 maand geleden 
o 3 maanden geleden 
o 6 maanden geleden 
o 12 maanden geleden 
o meer dan 12 maanden geleden 
 
8) Heeft u het laatste jaar over uw epilepsie gesproken met uw behandelend arts?  
o ja 
o nee 
 
 
DANK VOOR UW MEDEWERKING! 
 
Indien u gelijk ook de uitgebreide vragenlijst wilt invullen dan kunt u deze vinden via de website: 
http://www.epilepsieonderzoek.nl  
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VRAGENLIJST 
 
Onderzoeksnummer:  
 
U heeft aangegeven mee te willen werken aan het OPPEC onderzoek.  
Dit is een groot nationaal onderzoek naar de oorzaken voor het wel of niet werken van 
medicijnen tegen epilepsie. 
Wij zouden het erg op prijs stellen als u deze vragenlijst zou willen invullen. Let op deze 
vragenlijst is dubbelzijdig geprint, dus vergeet niet ook de achterkant in te vullen. 
Eventueel kunt u deze vragenlijst ook online invullen via: www.epilepsieonderzoek.nl 
 
Vult u hier de datum in waarop u deze vragenlijst invult (dd/ mm/ jjjj):  ____/____/ 20___ 
 
1. Wat is uw geslacht? (kies een van de volgende mogelijkheden) 
o vrouw 
o man 
 
2. Wat is uw geboortedatum? (dd/ mm/ jjjj)   ____/____/19____ 
 
3. Wat is uw hoogst genoten opleiding?(kies een van de volgende mogelijkheden) 
o geen opleiding 
o lagere school/ basisonderwijs 
o middelbare school of lager beroepsonderwijs (LBO) 
o middelbaar beroepsonderwijs (MBO) of vakopleiding 
o hoger beroepsonderwijs (HBO) of universiteit 
o anders nl: ______________________________ 
 
4. Hoe is uw arbeidssituatie? Ik heb: (kies een van de volgende mogelijkheden) 
o een betaalde baan 
o geen betaalde baan 
o ik studeer of zit op school 
o anders nl: ______________________________ 
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5. Hoe woont u?  (kies een van de volgende mogelijkheden) 
o alleen  
o ik woon samen of ben getrouwd 
o bij mijn ouders 
o in een woongroep, begeleid of beschermd wonen 
o anders nl: ______________________________ 
 
6. Wat is uw lengte:  _____________ (cm)  
 
7. Wat is uw gewicht: ______________ (kg) 
 
8. Rookt u? (kies een van de volgende mogelijkheden) 
o ja 
o nee 
o ik heb vroeger gerookt 
 
9. Gebruikt u wel eens alcoholhoudende drank? (kies een van de volgende mogelijkheden) 
o vaak (dagelijks) 
o regelmatig (een/ meer keer per week)  
o af en toe (een/ meer keer per maand) 
o zelden (een/ meer keer per jaar) 
o nooit 
  
10. Gebruikt u wel eens drugs/ verslavende middelen? (kies een van de volgende mogelijkheden) 
o vaak (dagelijks) 
o regelmatig (een/ meer keer per week)  
o af en toe (een/ meer keer per maand) 
o zelden (een/ meer keer per jaar) 
o nooit 
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De volgende vragen gaan over uw familie 
 
11. Heeft u kinderen?  (kies een van de volgende mogelijkheden) 
o ja;  ik heb (graag aantal invullen)  ______ zoons 
       ______ dochters  
o nee  ga naar vraag 13 
 
12. Indien u kinderen heeft: (kies een van de volgende mogelijkheden) 
Heeft een of meer van uw kinderen epilepsie of epileptische aanvallen? 
o ja:   
Zo ja, hoeveel van uw kinderen hebben epilepsie/ epileptische aanvallen 
(graag aantal invullen)  ______ van mijn kinderen 
o nee 
o weet ik niet  
 
13. Heeft u broers en/ of zussen?  (kies een van de volgende mogelijkheden) 
o ja;  ik heb (graag aantal invullen)  ______ broers 
       ______ zussen  
o nee  ga naar vraag 15 
 
14. Indien u broers en/ of zussen heeft: 
Heeft een of meer van uw broers en/ of zussen epilepsie of epileptische aanvallen? 
o ja:   
Zo ja, hoeveel van uw broers en/of zussen hebben epilepsie/ epileptische 
aanvallen (graag aantal invullen)         ______ van mijn broers/zussen 
o nee 
o weet ik niet  
 
15. Komt er in uw gezin of familie epilepsie voor?(kies per vraag een van de mogelijkheden) 
 ja nee weet ik niet 
Vader o  o  o  
Moeder o  o  o  
Grootouders of verdere familie 
(ooms/ tantes/ neven/ nichten) 
o  o  o  
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16. Indien u heeft aangegeven dat een of meer van uw grootouders of verdere 
familieleden epilepsie of epileptische aanvallen hebben,  
Kunt u aangeven bij hoeveel van deze familieleden epilepsie (of epileptische 
aanvallen) voorkomt? (graag aantal invullen) 
♦ bij ______ van mijn grootouders (opa’s en oma’s)   
♦ bij ______ van mijn verdere familie (ooms/ tantes/ neven/ nichten) 
 
17. Zijn al uw grootouders (opa’s en oma’s) geboren in Nederland? (kies een van de volgende 
mogelijkheden) 
o ja 
o nee  
o weet ik niet  
 
18. Bent u in de afgelopen 2 jaar zwanger geweest? (kies een van de volgende mogelijkheden) 
o ja 
o ja; maar dit leidde tot een miskraam  
o nee  ga naar vraag 21 
o niet van toepassing  ga naar vraag 21 
 
19. Bent u op dit moment zwanger? (kies een van de volgende mogelijkheden) 
o ja 
o nee  
 
20. Is de behandeling van uw epilepsie veranderd tijdens uw laatste zwangerschap? (kies 
een van de volgende mogelijkheden) 
o ja, ik moest meer anti-epileptica innemen 
o ja, ik moest minder anti-epileptica innemen 
o ja, het soort anti-epilepticum werd gewijzigd 
o ja, ik ben gestopt met de anti-epileptica 
o nee 
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De volgende vragen gaan over uw huidige of eerdere medicatie gebruik 
 
21. Gebruikt u op dit moment anti-epileptische medicijnen? (kies een van de volgende 
mogelijkheden) 
o ja 
o nee  ga naar vraag 23 
 
22. Vindt u dat uw huidige medicijnen tegen epilepsie voldoende helpen tegen uw 
aanvallen? (kies een van de volgende mogelijkheden) 
o ja 
o nee 
o weet ik niet 
 
23. Hoeveel verschillende medicijnen tegen epilepsie heeft u sinds uw eerste epileptische 
aanval gehad? (kies een van de volgende mogelijkheden) 
o ik heb nog steeds hetzelfde medicijn als in het begin  ga naar vraag 25 
o ik heb 2 verschillende medicijnen geprobeerd 
o ik heb 3 verschillende medicijnen geprobeerd 
o ik heb meer dan 3 verschillende medicijnen tegen epilepsie gehad 
o weet ik niet  ga naar vraag 25 
o niet van toepassing  ga naar vraag 25 
 
24. Indien u ooit veranderd bent van medicijnen tegen epilepsie, wat was hiervoor de 
reden? (u mag meerdere antwoorden aankruisen) 
o medicijn was niet (voldoende) effectief of de aanvallen namen toe  ga naar 
vraag 26 
o ik had last van bijwerkingen  
o zwangerschap  ga naar vraag 26 
o weet ik niet  ga naar vraag 26 
o anders namelijk: _________________________  ga naar vraag 26 
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25. Indien u last heeft of had van bijwerkingen van uw anti-epileptica, wat waren uw 
klachten? (u mag meerdere antwoorden aankruisen) 
o geheugen problemen of vergeetachtigheid 
o concentratie problemen 
o moeite met spreken of het vinden van woorden 
o suf, slaperig of extra moe 
o rusteloos gejaagd, agressief of geïrriteerd 
o piekeren, terneergeslagen, droevig of depressief 
o duizelig, trillerig, coördinatie problemen  
o dubbel of wazig zien 
o hoofdpijn 
o gewichtsverandering (toename/ afname), weinig eetlust of maag/ 
darmproblemen 
o huiduitslag, huidproblemen, haaruitval of allergische reactie 
o weet ik niet 
o anders nl: _________________________________ 
 
26. Hebt u ooit, zelf of met hulp van uw arts, geprobeerd om uw medicijnen tegen 
epilepsie helemaal te stoppen? (kies een van de volgende mogelijkheden) 
o ja   
o nee  ga naar vraag 28 
o niet van toepassing  ga naar vraag 28 
 
27. Indien u heeft geprobeerd te stoppen bleef u aanvalsvrij? (kies een van de volgende 
mogelijkheden) 
o ja   
o nee 
 
28. Vergeet u wel eens om uw medicijnen in te nemen? (kies een van de volgende 
mogelijkheden) 
o nooit 
o heel soms  
o regelmatig (een of meer keer per maand) 
o vaak (een of meer keer per week) 
o zeer vaak  
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De volgende vragen gaan over uw gezondheid en uw epilepsie. 
 
29. Hoe oud was u toen u uw eerste epileptische aanval kreeg?  ______ jaar 
 
30. Heeft u “grote” aanvallen?  (kies een van de volgende mogelijkheden) 
o Ja; 
zo ja, hoeveel grote aanvallen heeft u in het afgelopen jaar gehad? (graag 
aantal invullen) ________ aanvallen  
o nee  
o weet ik niet 
 
31. Heeft u “kleine” aanvallen?  (kies een van de volgende mogelijkheden) 
o Ja; 
zo ja, hoeveel kleine aanvallen heeft u in het afgelopen jaar gehad? (graag 
aantal invullen; een schatting voldoet) ________ aanvallen 
o nee  
o weet ik niet 
 
32. Indien u nog epileptische aanvallen heeft, zijn deze voor u ‘acceptabel’? dat wil 
zeggen: vindt u het niet noodzakelijk dat er wat aan gedaan wordt als dat mogelijk 
zou zijn?  (kies een van de volgende mogelijkheden) 
o ja 
o nee  
 
33. Hoeveel invloed heeft uw epilepsie op uw dagelijks leven? (omcirkel één cijfer op de 
schaal hieronder)  
 
 
 
 
 
  
Veel invloed 
 
Weinig tot geen invloed 
1 2 3 4 5 6 7 8 9 10 
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34. Heeft u voor uw 6e jaar koortsstuipen gehad? (kies een van de volgende mogelijkheden) 
o ja 
o nee 
o weet ik niet 
 
35. Komen koortsstuipen, voor de leeftijd van 6 jaar, in uw familie voor? (kies een van de 
volgende mogelijkheden) 
o ja 
o nee 
o weet ik niet 
 
36. Heeft u ooit een status epilepticus (een aanval die langer dan een half uur duurde en 
waarvoor de meeste mensen naar het ziekenhuis worden gebracht) gehad? (kies een 
van de volgende mogelijkheden) 
o ja 
o nee 
o weet ik niet 
 
37. Bent u ooit voor een aanval acuut in het ziekenhuis opgenomen of heeft u hiervoor 
de eerste hulp/spoedeisende hulp bezocht? (u mag meerdere antwoorden aankruisen) 
o ja, bij de 1e aanval 
o ja, bij een latere aanval 
o nee 
o weet ik niet 
 
38. Heeft u ooit een hersenoperatie gehad? (kies een van de volgende mogelijkheden) 
o ja 
o nee  ga naar vraag 40 
o weet ik niet  ga naar vraag 40 
 
39. Was deze operatie voor epilepsie? (kies een van de volgende mogelijkheden) 
o ja 
o nee; deze was voor: _______________________________________ 
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40. Heeft u ooit een zware hersenschudding gehad? (kies een van de volgende mogelijkheden) 
o ja 
o nee  ga naar vraag 42 
o weet ik niet  ga naar vraag 42 
 
41. Was deze hersenschudding voor of na het begin van uw epilepsie? (kies een van de 
volgende mogelijkheden) 
o voor 
o na 
 
42. Heeft u naast uw epilepsie, nog andere ziekten/ aandoeningen? (u mag meerdere 
antwoorden aankruisen) 
o Ja; namelijk: 
o Suikerziekte 
o Beroerte/ hart en vaatziekten 
o Leverziekte 
o Nierziekte 
o Darmziekte 
o Anders namelijk: _____________________________________ 
o Nee 
 
43. Zijn er, voor uw epilepsie, behalve medicijnen, ook andere behandelingen 
geprobeerd?(u mag meerdere antwoorden aankruisen) 
o Ja; een hersenoperatie 
o Ja; een nervus vagus stimulatie 
o Ja, een ketogeen dieet 
o Anders, namelijk: _________________________________________ 
o Nee  ga naar vraag 45 
 
44.  Zo ja was/ waren deze behandeling(en) effectief? (kies een van de volgende 
mogelijkheden) 
o ja 
o nee 
o weet ik niet 
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De volgende vragen gaan over de epileptische aanvallen die u heeft of heeft gehad. 
Vult u onderstaande vragen, indien mogelijk, samen of in overleg met uw partner of 
huisgenoten in.  
 
45. Heeft u in de afgelopen 2 jaar aanvallen gehad? (kies een van de volgende mogelijkheden) 
o ja 
o nee 
 
46. Wanneer was uw laatste aanval?  
o ______ jaar geleden 
o ______ maanden geleden 
o ______ weken geleden 
o ______ dagen geleden 
 
47. Beginnen uw epileptische aanvallen altijd hetzelfde? (kies een van de volgende 
mogelijkheden) 
o ja 
o nee 
o weet ik niet 
 
48. Zijn er bepaalde omstandigheden/ prikkels die uw aanvallen meestal uitlokken? (u 
mag meerdere antwoorden aankruisen) 
o ja; namelijk: 
o slaaptekort 
o stress 
o flikkerend zonlicht 
o tv 
o videogames 
o disco 
o geluiden/ muziek 
o menstruatie 
o alcohol 
o koort 
o Anders namelijk: _____________________________________ 
o nee 
o weet ik niet 
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49. Voelt u soms een epileptische aanval heel kort (seconden) van tevoren aankomen? 
(u mag meerdere antwoorden aankruisen) 
o ja; namelijk door: 
o een beeld of geluid 
o een geur, smaak of opstijgend gevoel vanuit de buik 
o een plotseling angstig gevoel 
o een gevoel iets al eerder gezien of meegemaakt te hebben 
o hoofdpijn 
o duizeligheid 
o een gevoel dat ik herken, maar moeilijk kan beschrijven  
o anders namelijk: _____________________________________ 
o nee 
o weet ik niet 
 
50. Heeft u aanvallen tijdens de slaap? (kies een van de volgende mogelijkheden) 
o ja, de meeste aanvallen zijn tijdens slaap 
o ja, sommige aanvallen zijn tijdens slaap 
o ja, vooral bij het ontwaken 
o nee 
o weet ik niet 
 
51. Valt u wel eens bij een aanval? (kies een van de volgende mogelijkheden) 
o ja, altijd 
o ja, soms 
o nee 
o weet ik niet 
 
52. Heeft u aanvallen die bestaan uit een korte spierschok (of myoclonieen) van ca. 1 
seconde? (kies een van de volgende mogelijkheden) 
o ja, dat kan op ieder tijdstip van de dag 
o ja, vooral ’s ochtends na het ontwaken 
o ja, bij het inslapen 
o nee 
o weet ik niet 
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53. Heeft u wel eens een tonisch-clonische aanval gehad? Dat is een grote aanval of 
insult met verlies van bewustzijn en trekkingen van armen en benen. (kies een van de 
volgende mogelijkheden) 
o ja 
o nee 
o weet ik niet 
 
54. Heeft u absences? Dat zijn aanvallen met kortdurende afwezigheid, waarin u niet op 
anderen reageert. (kies een van de volgende mogelijkheden) 
o ja 
o nee 
o weet ik niet 
 
55. Heeft u verschillende soorten epileptische aanvallen? (kies een van de volgende 
mogelijkheden) 
o ja, ik heb geheel verschillende aanvallen 
o ja, de aanvallen lijken erg op elkaar (zelfde begin) maar verschillen in 
zwaarte, of ze lijken op elkaar maar sommige aanvallen zijn groot en andere 
aanvallen klein 
o nee 
o weet ik niet 
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De volgende vragen hebben alleen betrekking op uw meest voorkomende type 
aanvallen. Het is goed mogelijk dat u meerdere typen aanvallen heeft. Beantwoordt u 
echter de volgende vragen alleen voor het meest voorkomende soort aanvallen.  
 
56. Hoe oud was u toen u uw eerste epileptische (meest voorkomende type) aanval 
kreeg?  _________ jaar 
 
57.  Hoeveel van deze epileptische aanvallen heeft u in uw leven (ongeveer) gehad? 
(kies een van de volgende mogelijkheden) 
o 1 aanval 
o minder dan 5 
o tussen de 5 en 10 
o meer dan 10 
o meer dan 100 
 
58. Voelt u soms deze (meest voorkomende type) epileptische aanvallen heel kort 
(seconden) van tevoren aankomen? (u mag meerdere antwoorden aankruisen) 
o ja; namelijk door: 
o een beeld of geluid 
o een geur, smaak of opstijgend gevoel vanuit de buik 
o een plotseling angstig gevoel 
o een gevoel iets al eerder gezien of meegemaakt te hebben 
o hoofdpijn 
o duizeligheid 
o een gevoel dat ik herken, maar moeilijk kan beschrijven  
o anders namelijk: _____________________________________ 
o nee 
o weet ik niet 
 
59. Kunt u tijdens deze aanval praten? (kies een van de volgende mogelijkheden) 
o ja 
o soms wel, soms niet 
o nee 
o weet ik niet 
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60. Hoeveel van deze epileptische aanvallen heeft u de afgelopen 2 jaar gehad? (kies een 
van de volgende mogelijkheden) 
o een of meer keer per dag 
o een of meer keer per week 
o een of meer keer per maand 
o een of meer keer per jaar 
o minder dan een keer per jaar 
o geen aanvallen 
 
61. Hoelang duren deze aanvallen meestal? (kies een van de volgende mogelijkheden) 
o een paar seconden 
o een paar minuten 
o een paar uren 
o wisselend 
o weet ik niet 
 
62. Wat geldt voor deze epileptische aanvallen? (kies een van de volgende mogelijkheden) 
o ik kan me niets van de aanval herinneren, het zijn altijd anderen die vertellen 
dat ik er een gehad heb 
o ik kan me iets van de aanval herinneren, maar het meeste ben ik kwijt 
o ik maak het grootste deel van mijn aanval gewoon mee 
o ik weet zelf precies wat er tijdens mijn aanval gebeurt 
 
63. Heeft u bij deze aanvallen wel eens? (u mag meerdere antwoorden aankruisen) 
 ja nee weet ik niet 
Wilde bewegingen in de slaap o  o  o  
Een tongbeet o  o  o  
In de broek geplast o  o  o  
Veel speeksel verloren o  o  o  
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64. Moet u na een epileptische aanval herstellen? (kies een van de volgende mogelijkheden) 
o Ja; na deze aanval geldt meestal: 
o ik ben verward 
o ik kan niet goed uit mijn woorden komen 
o ik herken mensen niet 
o ik weet niet goed waar ik ben 
o anders nl: _________________________________ 
o nee 
 
65. Weet u hoe uw type epilepsie of deze aanvallen genoemd worden? (kies een van de 
volgende mogelijkheden) 
o focale epilepsie of partiële epilepsie o.a. temporaalkwab epilepsie, 
frontaalkwab epilepsie  
o gegeneraliseerde epilepsie o.a. absences, myoclonieen, tonische (clonische) 
aanvallen, clonische aanvallen, atonische aanvallen, juveniele myoclonus 
epilepsie (JME) 
o anders o.a. syndroom van West, syndroom van Lennox-Gastaut 
o weet ik niet 
o anders nl: ____________________________________________ 
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De volgende5 vragen gaan over de hierboven gestelde vragen. Deze zijn niet verplicht 
maar we zouden het fijn vinden als u deze toch wilt invullen, zodat we, indien nodig, 
de vragenlijst nog beter kunnen maken.  
 
Hierna kunt u verder gaan met het 2e deel van de vragenlijst . 
 
1. Door wie is deze vragenlijst ingevuld? (kies een van de volgende mogelijkheden) 
o mijzelf (degene die de epileptische aanvallen heeft) 
o anders nl: ___________________________________ 
 
2. Hoeveel tijd heeft het invullen van de vragenlijst tot nu toe ongeveer gekost? 
 ______ minuten  
 
3. Hoe duidelijk vond u de gestelde vragen over het algemeen?  
o zeer helder/ zeer begrijpelijk 
o begrijpelijk/ duidelijk 
o onbegrijpelijk/ onduidelijk 
o zeer onbegrijpelijk/ vaag 
o anders nl: ___________________________________ 
 
4. Hoe moeilijk vond u de vragen over het algemeen? 
o zeer ingewikkeld 
o moeilijk 
o makkelijk 
o zeer eenvoudig 
o anders nl: ___________________________________ 
 
5.  Heeft u verdere vragen of opmerkingen over dit eerste deel van de vragenlijst? 
 _________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
______________________________________________________________ 
 
 
 
  Vragenlijst OPPEC studie- oktober 2010 
pagina 17 van 21 
Deel 2 van de vragenlijst:  
Dit deel gaat over de kwaliteit van uw leven (uw gezondheid en uw dagelijkse bezigheden) bij 
epilepsie als ook over eventuele bijwerkingen die u zou kunnen ondervinden door het 
gebruik van anti-epileptica. 
 
Deze vragen gaan over hoe u zich VOELT en hoe het met u ging in de afgelopen 4 weken. Wilt u a.u.b. 
bij elke vraag het antwoord geven dat het best benadert hoe u zich voelde. Hoe vaak gedurende de 
afgelopen 4 weken. (omcirkel één cijfer) 
  Altijd Meestal Vaak Soms Zelden Nooit 
1. Had u veel energie? 1 2 3 4 5 6 
2. Voelde u zich somber en 
neerslachtig? 
1 2 3 4 5 6 
 
De volgende vraag gaat over problemen die u misschien heeft bij bepaalde ACTIVITEITEN. Hoe veel 
problemen hebben uw epilepsie of anti-epileptische medicijnen gedurende de afgelopen 4 weken 
veroorzaakt bij… (omcirkel één cijfer) 
  Heel 
veel 
Veel Enigszins Maar 
weinig 
Helemaal 
niet 
3. Autorijden, motorfiets rijden, etc. 1 2 3 4 5 
 
De volgende vraag gaat over hoe u zich VOELT over uw epileptische aanvallen. (omcirkel één cijfer) 
  Heel bang Enigszins 
bang 
Niet erg bang Helemaal niet 
bang 
4. Hoe bang bent u ervoor in de komende 4 weken een epileptische aanval te hebben? 1 2 3 4 
 
Omcirkel één cijfer bij elk van deze PROBLEMEN om aan te geven hoe veel last u ervan heeft op een 
schaal van 1 tot 5, waarbij 1 = Helemaal geen last van, en 5 = Heel veel last van. 
  Helemaal 
geen last 
van 
   Heel veel 
last van 
5. Geheugenproblemen 1 2 3 4 5 
6. Beperkingen wat betreft werk 1 2 3 4 5 
   7. Beperkingen in uw sociale contacten 1 2 3 4 5 
8. Lichamelijke bijwerkingen van anti-
epileptische medicijnen 
1 2 3 4 5 
9. Psychische bijwerkingen van anti-
epileptische medicijnen 1 2 3 4 5 
 
10. Hoe was de KWALITEIT VAN UW LEVEN gedurende de afgelopen 4 weken (dat wil zeggen: hoe 
ging het met u)? 
  Heel goed 
kon 
nauwelijks 
beter 
Vrij goed Ongeveer 
even goed 
als slecht 
Vrij slecht Heel slecht 
kon 
nauwelijks 
slechter 
 Kwaliteit van leven 1 2 3 4 5 
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11. Hoe zou u, over het geheel genomen, de kwaliteit van uw leven beoordelen? (Omcirkel één cijfer op de 
schaal hieronder) 
                                                       
 
  0    1      2         3           4  5   6     7        8          9           10           
                                               
Deze vragen gaan over hoe u zich VOELT en hoe het met u ging in de afgelopen 4 weken. Wilt u a.u.b. 
bij elke vraag het antwoord geven dat het best benadert hoe u zich voelde. 
Hoe vaak gedurende de afgelopen 4 weken…(omcirkel één cijfer) 
  Altijd Meestal Vaak Soms Zelden Nooit 
12. Voelde u zich levenslustig? 1 2 3 4 5 6 
13. Was u erg zenuwachtig? 1 2 3 4 5 6 
14. Zat u zo in de put dat niets u kon 
opvrolijken? 
1 2 3 4 5 6 
15. Voelde u zich rustig en tevreden? 1 2 3 4 5 6 
16. Voelde u zich uitgeput? 1 2 3 4 5 6 
17. Was u een gelukkig mens? 1 2 3 4 5 6 
18. Voelde u zich moe? 1 2 3 4 5 6 
19. Maakte u zich er zorgen over weer 
een epileptische aanval te krijgen? 1 2 3 4 5 6 
20. Had u moeite met redeneren en het 
oplossen van problemen (bijvoorbeeld 
plannen maken, besluiten nemen, 
nieuwe dingen leren)? 
1 2 3 4 5 6 
21. Heeft uw gezondheid u beperkt bij uw 
sociale activiteiten (zoals vrienden of 
familie bezoeken)? 1 2 3 4 5 6 
 
De volgende vraag gaat over het GEHEUGEN…(omcirkel één cijfer) 
  Ja, 
veel 
Ja, enigszins Maar weinig Nee, helemaal 
niet 
22. Heeft u in de afgelopen 4 weken 
problemen gehad met uw geheugen? 
1 2 3 4 
 
Met de volgende vraag willen we te weten komen hoe vaak u in de afgelopen 4 weken moeite had 
om iets te onthouden of hoe vaak dit geheugenprobleem u gehinderd heeft bij uw normale werk of 
dagelijkse leven. …(omcirkel één cijfer) 
  Altijd Meestal Vaak Soms Zelden Nooit 
23. Moeite om dingen te onthouden die 
mensen u vertelden 
1 2 3 4 5 6 
 
Slechtst mogelijke 
Kwaliteit van Leven (zo slecht als, 
of erger dan, dood zijn) 
Best mogelijke Kwaliteit van 
Leven  
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De volgende vragen gaan over CONCENTRATIE problemen die u misschien heeft. Hoe vaak heeft u in 
de afgelopen 4 weken moeite gehad om u te concentreren of hoe vaak hinderden deze problemen u bij 
uw normale werk of dagelijkse leven? …(omcirkel één cijfer) 
  Altijd Meestal Vaak Soms Zelden Nooit 
24. Moeite met concentreren bij het lezen 1 2 3 4 5 6 
25. Moeite om u op één ding tegelijk te 
concentreren 
1 2 3 4 5 6 
 
De volgende vraag gaan over problemen die u misschien heeft bij bepaalde ACTIVITEITEN. Hoe veel 
problemen hebben uw epilepsie of anti-epileptische medicijnen gedurende de afgelopen 4 weken 
veroorzaakt bij... …(omcirkel één cijfer) 
  Heel 
veel 
Veel Enigszins Maar 
weinig 
Helemaal 
niet 
26. Activiteiten in uw vrije tijd (zoals 
hobbies, uitgaan) 
1 2 3 4 5 
 
De volgende vragen gaan over hoe u zich VOELT over uw epileptische aanvallen. …(omcirkel één cijfer) 
  Veel zorgen Een beetje 
zorgen 
Helemaal 
geen zorgen 
27. Maakt u zich zorgen dat u zichzelf bezeert tijdens 
een epileptische aanval? 1 2 3 
  Heel bezorgd Enigszins 
bezorgd 
Niet zo erg 
bezorgd 
Helemaal 
niet bezorgd 
28. Hoe bezorgd bent u dat u in de komende 4 
weken in verlegenheid gebracht zal worden 
of dat u andere problemen in uw sociale 
contacten zal hebben tengevolge van een 
epileptische aanval? 
1 2 3 4 
29. Hoe bezorgd bent u dat de medicijnen die u 
inneemt slecht voor u kunnen zijn als u ze 
langdurig inneemt? 
1 2 3 4 
 
Omcirkel één cijfer bij onderstaand PROBLEEM om aan te geven hoe veel last u ervan heeft op een 
schaal van 1 tot 5, waarbij 1 = Helemaal geen last van, en 5 = Heel veel last van. 
  Helemaal 
geen last 
van 
   Heel veel 
last van 
30. Epileptische aanvallen 1 2 3 4 5 
 
31.  Hoe goed of slecht denkt u dat uw gezondheid is? Op de thermometer-schaal hieronder staat 100 
voor de best denkbare gezondheidstoestand en 0 voor de slechtst denkbare gezondheidstoestand. Geef 
a.u.b. aan wat u van uw gezondheid vindt door een cijfer op de schaal te omcirkelen Beschouw bij het 
beantwoorden van deze vraag uw epilepsie als onderdeel van uw algehele gezondheid. 
 
0 10 20 30 40 50 60 70 80 90 100 
Slechts denkbare 
gezondheidstoestand 
Best denkbare 
gezondheidstoestand 
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De volgende vragen gaan over mogelijke bijwerkingen van anti-epileptische medicatie. 
Kunt u hieronder aangeven of u last heeft van deze problemen en zo ja, hoe lang u al last 
heeft van deze klachten? 
 
 
Geen 
probleem 
Een mild 
probleem 
Matig 
probleem 
Ernstig 
probleem 
Sinds 
enkele 
weken 
Enkele 
maanden 
Een half 
jaar of 
langer 
1 Mijn tandvlees geeft problemen ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
2 Mijn gewicht is afgenomen (ik val af) ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
3 Ik heb problemen bij het onthouden van namen ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
4 Ik voel me vaak suf en slaperig ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
5 Ik moet me soms vasthouden anders val ik ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
6 Ik vergeet van alles zoals afspraken ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
7 Ik vind het moeilijk me te concentreren ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
8 Ik word snel moe en heb weinig energie ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
9 Ik word snel agressief ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
10 Ik kan me maar een korte tijd concentreren op iets ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
11 Ik stoot me voortdurend tegen tafels, deurposten etc ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
12 Ik voel me gejaagd en rusteloos ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
13 Ik merk dat ik traag reageer op anderen ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
14 Ik kan niet lang achter elkaar met iets bezig zijn ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
15 Ik merk dat ik traag spreek ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
16 Ik voel me de hele tijd druk en opgewonden ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
17 Ik voel me vaak duizelig ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
18 Ik heb weinig eetlust ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
19 Mijn menstruatie begint soms later of eerder ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
20 Ik merk dat ik af en toe moeilijk uit mijn woorden kom ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
21 Ik voel me vaak misselijk ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
22 Ik ben de hele dag aan het piekeren ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
23 Ik heb vaak last van diarree ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
24 Mijn handen trillen voortdurend ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
25 Ik heb last van veel speeksel ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
26 Ik zie regelmatig dubbel ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
27 Ik heb huiduitslag of andere huidproblemen ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
28 Mijn gewicht is toegenomen (ik word dikker) ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
29 Ik denk trager dan ik gewend was ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
30 Ik ben snel geïrriteerd ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
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Geen 
probleem 
Een mild 
probleem 
Matig 
probleem 
Ernstig 
probleem 
Sinds 
enkele 
weken 
Enkele 
maanden 
Een half 
jaar of 
langer 
31 Ik voel me teneergeslagen en droevig ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
32 Ik heb vaak moeizame ontlasting ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
33 Ik heb moeilijkheden met het vinden van woorden ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
34 Ik kom tot minder en ben minder aktief ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
35 Ik kan niet in slaap komen en lig vaak wakker ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
36 Ik heb minder zin in sex ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
37 Er zijn dagen dat ik niets kan doen door de hoofdpijn ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
38 Mijn haren vallen uit ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
39 Ik zie wazig ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
40 Ik heb veel meer beharing ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
41 Als ik iets wil pakken beginnen mijn handen te trillen ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
42 Ik voel me niet goed in staat de gewone dingen te 
doen 
∋ ∋ ∋ ∋ ∋ ∋ ∋ 
43 Ik heb veel last van hoofdpijn ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
44 Het vrijen is minder plezierig geworden ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
45 Ik heb last van mijn maag ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
46 Ik voel me licht in het hoofd ∋ ∋ ∋ ∋ ∋ ∋ ∋ 
 
 
Dank u voor het invullen van deze vragenlijst 
 
 
 
Appendix 7: medical ethical approval PGES study 

